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Attentional dysfunction in Parkinson’s disease: 
The role of central amygdala dopamine and possible treatment options 
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Supervisor:  Hongjoo J Lee 
 
While it is known that Parkinson’s disease (PD) results in motor dysfunction, 
there exist many cognitive symptoms including impairments in attention. PD patients 
demonstrate impaired ability to switch attention between tasks, rules, or stimuli, ignore 
irrelevant stimuli, and sustain attention to stimuli or tasks. Dysfunction of the 
mesocortical system is suggested to be responsible for these attentional deficits. 
However, attentional impairments surface in the early stages of the disease and cortical 
areas are among the last regions to show pathology. Further, it is not well understood 
how effective common dopamine replacement therapy (L-dopa) is in restoring attentional 
dysfunction. Recent work suggests that L-dopa may only improve some aspects of 
attentional function in PD, thus making further examination of the effects of L-dopa on 
attentional function important. And as L-dopa also has many other limitations (e.g. 
possible development of unwanted motor side effects), it is also necessary to investigate 
other possible treatments for these dysfunctions.  
In this dissertation, I first examined the role of dopaminergic function in the 
central amygdala (CeA) in the regulation of attentional processes in rodents. I found that 
dopaminergic input into the CeA mediated by D1 receptors is necessary for attention 
switching (i.e. disengagement behavior) and selective and sustained attention in rodents. 
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Then I investigated the effects of L-dopa on these two different types of attentional 
deficits in a rodent model of PD in which dopamine is depleted unilaterally using the 
neurotoxin, 6-hydroxydopamine. While L-dopa was able to recover basic attentional 
switching, more complex attentional processes (i.e. selective and sustained attention) 
were not recovered. In an attempt to find a better treatment for these deficits, I used 
methylene blue (MB), a metabolic enhancer and antioxidant, to target mitochondrial 
dysfunction, a characteristic of all compromised dopamine cells. While MB was able to 
provide moderate neuroprotection in this model of PD, it was unable to recover 
attentional function. Taken together, my dissertation work demonstrates that attentional 
function is partly regulated by sub-cortical CeA dopamine mechanisms and that PD-
related attentional dysfunction may require a multi-faceted treatment approach.  
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Chapter 1: Background 
Parkinson’s disease (PD) is a neurodegenerative disorder that results in 
progressive cell loss in many brain regions.  Most prominently, dopamine cells within the 
substantia nigra pars compacta (SNc) die, which is responsible for the hallmark motor 
dysfunctions including akinesia, rigidity, tremor, bradykinesia and postural instability 
(Fahn & Sulzer, 2004; Fahn, 2003). However, there are also a host of cognitive deficits in 
PD which include attentional impairments (Dubois & Pillon, 1997; Pfeiffer, Løkkegaard, 
Zoetmulder, Friberg, & Werdelin, 2014a; Weintraub et al., 2015; Wu et al., 2012). This 
attentional dysfunction can include difficulty in switching tasks or rules, sustaining 
attention, and selectively attending to relevant stimuli while ignoring irrelevant stimuli. It 
is not well understood how these problems with attention arise in PD. The 
neuropathological progression of the disease is such that areas commonly implicated in 
executive function (prefrontal cortex) do not show degeneration until the later stages of 
the disease while attentional impairments can occur very early on (Braak, Ghebremedhin, 
Rüb, Bratzke, & Del Tredici, 2004; Filoteo et al., 1997; Zhou et al., 2012). Therefore, it 
is logical to postulate that other areas affected in PD may cause these symptoms. In order 
to test this hypothesis, I first examined the potential involvement of the central amygdala 
dopamine system in attentional functions.  Then, I investigated the nature of attentional 
deficits in a rat model of PD and the efficacy of traditional dopamine replacement 
therapy. Finally, I evaluated a potential novel treatment using the compound, methylene 
blue to globally enhance neurological function. 
1.1 ATTENTIONAL DEFICITS IN PARKINSON’S DISEASE 
It is common for patients with PD to exhibit non-dementia-related cognitive 
dysfunction. Sixty-five percent of patients show difficulty with at least one of the 
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following: executive function, working memory, and attention (Wu et al., 2012). 
Furthermore, almost half of these patients experience more than one of these 
dysfunctions. Impairments in attentional function are common in PD patients and are 
usually one of the first cognitive impairments to arise (Chaudhuri, Healy, & Schapira, 
2006; Chaudhuri & Schapira, 2009). However, attention is usually impacted in several, 
specific ways. Patients most prominently display impairments in sustained attention, 
selective attention, and shifting attention (Wu et al., 2012). Anecdotally, patients with PD 
have reported difficulty in either stopping one task to start another or terminating 
attention to a stimulus to attend to another stimulus. This has been further corroborated 
by empirical work demonstrating that patients do indeed show impaired task switching 
behavior (Ravizza & Ciranni, 2002).  
Further work has been done to assess the ability of PD patients to shift implicitly 
learned rules or strategies. This ability to shift response strategy or ‘set’ (also known as 
set-shifting) is usually tested in humans using the Wisconsin Card Sorting Task or a 
related variant. In these tasks, the participant implicitly learns a response rule and once 
proficient in this response strategy, the rule is changed (unbeknownst to the participant) 
such that now the patient must either apply the same rule to a new set of stimuli (i.e. 
intradimensional shifting) or shift to a new response rule requiring attention to another 
aspect/dimension of the stimuli (i.e. extradimensional shifting). PD patients generally 
show impairments in extradimensional shifting (shifting to a new response rule) and 
commonly perseverate on a previously learned rule instead of shifting attention to another 
dimension of the stimuli (Lees & Smith, 1983; Cools, Barker, Sahakian, & Robbins, 
2001; Cools, Clark, Owen, & Robbins, 2002; Ravizza & Ciranni, 2002).  
Another common attentional dysfunction in PD is an inability to sustain attention. 
First empirically reported in 1989, PD patients demonstrated “increased distractibility” 
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and “difficulty holding attention” relative to healthy controls (Levin, Llabre & Weiner, 
1989). Others have expanded on these findings and have further shown that impairments 
in signal/stimulus detection increase relative to the length of the time delay from the 
beginning of the trial to the stimulus presentation (Zhou et al., 2012). In addition to 
sustaining attention to a stimulus, patients also show deficits in selective attention, that is 
attending only to specific stimuli while ignoring other irrelevant stimuli (Filoteo et al., 
1997; Yamaguchi & Kobayashi, 1998). Zhou et al. (2012) found dysfunction of the 
‘orienting network’ in which a person must orient or attend to stimuli before being able to 
respond but not in the ‘executive network’ (the ability to choose a response) in patients 
with mild PD. Others have shown similar findings of selective attention deficits and 
further note that these deficits can be seen in early-to-moderate PD especially when the 
attentional demands are high (Filoteo, et al., 1997; Yamaguchi & Kobayashi, 1998).  
Deficits in set-shifting, selective attention and sustained attention can also predict 
freezing of gait severity, gait speed, and falls in PD patients (Allcock et al., 2009; Lord, 
Rochester, Hetherington, Allcock, & Burn, 2010; Naismith, Shine, & Lewis, 2010; 
Rochester et al., 2004; Shine et al., 2013; Smulders, Esselink, Bloem, & Cools, 2015; 
Stefanova et al., 2014). This suggests that understanding the underlying cause of 
attentional dysfunction in PD will not only lead to improved cognitive outcomes but also 
better treatment of some motor aspects of this disease.  
1.2 MODELING ATTENTIONAL DEFICITS IN PD 
Several attempts have been made to model cognitive dysfunction in animal 
models of PD. Most commonly, rodents or non-human primates are exposed to 
neurotoxins to specifically deplete dopaminergic cells. The neurotoxins 1-methyl-4-
phenyl-1,2,3,6-tetrahydropiridine (MPTP) and 6-hyrodroxydopamine (6-OHDA) are 
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generally used for this purpose. Both aggregate in dopaminergic cells, inhibit 
mitochondrial respiration thus causing an increase in oxidative stress and subsequently 
apoptosis (Glinka, Tipton, & Youdim, 1996; Glinka, Tipton, & Youdim, 1998; Kupsch et 
al., 2014; Mizuno et al., 1998; Nicklas, Vyas, & Heikkila, 1985).  As expected, this 
model results in PD-like motor deficits (bradykinesia, akinesia, etc.) in both rodents and 
non-human primates. However, the extent to which this preparation impairs cognitive, 
and more specifically attentional dysfunction has been understudied.  
There has been wide range of work examining the role of dopamine in attentional 
processing and it has been demonstrated that dopamine, especially in the striatum is 
necessary for selective and sustained attention (Agnoli & Mainolfi, 2012; Chudasama & 
Robbins, 2004; Domenger & Schwarting, 2006; Granon et al., 2000; Rogers, Baunez, 
Everitt, & Robbins, 2001; Winstanley et al., 2010). However while these studies imply 
the incursion of attentional dysfunction in dopamine depletion models of PD, very few 
studies have actually been conducted to examine both the cognitive and attentional 
deficits in animal models of PD. Most prominently, the effects of MPTP administration 
in macaques on attention have been studied. Originally it was demonstrated that MPTP 
exposure leads to cognitive and attentional deficits and that these deficits onset before 
motor dysfunction when MPTP is slowly administered over weeks (Schneider, Sun, & 
Roeltgen, 1994; Schneider & Kovelowski, 1990). And when specifically studying 
attention using a cued reaction time task using the same model, Decamp & Schneider 
(2004) found that performance was markedly impaired in monkeys receiving MPTP 
compared to monkeys that had not received the neurotoxin. Furthermore, in these same 
macaques, MPTP treatment caused mild impairments in set-shifting similar to the pattern 
of deficits seen in patients with PD. Additionally, other aspects of cognitive function 
including spatial working memory have been studied, and it has been demonstrated that 
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neurotoxin models of PD in rats and macaques do indeed impair cognitive function 
similar to that of human PD after controlling for motor deficits (Decamp & Schneider, 
2004; Ramirez-Garcia et al., 2014).  
1.3 POTENTIAL ROLE OF THE CENTRAL NUCLEUS OF THE AMYGDALA IN PD-RELATED 
ATTENTIONAL DEFICITS 
Currently, the etiology of these attentional deficits in PD is not well understood. 
The prefrontal cortex (PFC), a structure important for higher cognition, executive 
function and some attentional functions, is generally considered to be responsible for the 
attentional dysfunction in PD (Cools et al., 2002; Ravizza & Ciranni, 2002). Even though 
the PFC plays an important role in attentional processing, compromised PFC function 
may not be the reason for all of the attentional deficits seen in PD. Attentional 
dysfunction in PD normally occurs early in the disease progression while pathological 
changes in the PFC do not occur until later stages of the disease (Alafuzoff et al., 2009; 
Braak et al., 1994; Braak et al., 2004). Furthermore, attempts to recover cognitive 
function in PD by targeting the PFC specifically have proven ineffective in improving 
attentional symptoms (Lewis, Slabosz, Robbins, Barker, & Owen, 2005; Owen et al., 
1993). For these reasons, another circuit impaired early in PD might be responsible for 
the attentional deficits in PD. One area that could be responsible for part of the attentional 
dysfunction in PD is a subnuclei of the amygdala, the central nucleus of the amygdala 
(CeA).  Pathological changes including an increase in the presence of Lewy bodies and 
Lewy neurites in the amygdala and specifically the CeA are seen early in the progression 
of PD, much earlier than PFC pathology (Braak et al., 1994). 
The CeA has been shown to be involved in several attentional processes in a rat 
model. Specifically, the CeA is necessary for conditioned orienting  (behavioral 
manifestation of enhanced attention to biologically relevant cues; Chachich & Powell, 
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1998; Gallagher, Graham, & Holland, 1990), and surprise-induced enhancement of 
learning  (Holland & Gallagher, 1993; Lee, Youn, Gallagher, & Holland, 2008;Lee, 
Youn, O, Gallagher, & Holland, 2006; Maddux, Kerfoot, Souvik, & Holland, 2007). 
Most relevantly, the CeA plays an important role in mediating selective and sustained 
attention (P C Holland, Han, & Gallagher, 2000; Maddux et al., 2007). To assess these 
aspects of attention, the five choice serial reaction time task is commonly used. In this 
task, the rat is required to attend to multiple locations in order to detect the stimulus. The 
rat is required to wait several seconds for the stimulus to appear (sustained attention) and 
must ignore irrelevant stimuli while waiting (selective attention). Lesions of the CeA in 
rats causes impairments in this selective and sustained attention task when the attentional 
load is high (Holland et al., 2000; Maddux et al., 2007). This pattern of deficits is similar 
to what is seen in PD. Patients with PD show some deficits in selective and sustained 
attention but these deficits are most pronounced when the attentional demand is high 
(Brown & Marsden, 1990; Maddox, Filoteo, Delis, & Salmon, 1996; Taylor, Saint-Cyr, 
& Lang, 1986).  
Also important to consider is that the CeA has a large reciprocal connection with 
the SNc (Fudge & Haber, 2000). It is widely known that dopaminergic denervation of the 
SNc is the hallmark pathology of PD but it is mainly discussed within the context of the 
nigrostriatal pathway responsible for motor function. However, it is important to consider 
that CeA-dependent attentional processes discussed earlier are also dependent on the 
connection with the SNc (El-amamy & Holland, 2010; Lee, Youn, Gallagher, & Holland, 
2008;  Lee, Youn, O, Gallagher, & Holland, 2006). So it would be expected that 
depletion of SNc dopamine would result in the altered CeA function possibly leading to 
impaired attentional processing. Therefore, understanding the role of CeA dopamine 
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mechanisms in attentional processing is crucial for understanding the attentional deficits 
seen in PD.  
 
1.4 USE OF L-DOPA FOR THE TREATMENT OF ATTENTIONAL DYSFUNCTION IN PD 
Patients with PD are most frequently treated with Levodopa (L-dopa), the 
chemical precursor to dopamine. L-dopa administration is highly effective at treating the 
hallmark motor dysfunctions of the disorder, but the efficacy of L-dopa in ameliorating 
cognitive/attentional deficits is not well understood.  Most consistently, improvement of 
set-shifting deficits is reported with L-dopa usage. Patients typically show improvement 
compared to counterparts off L-dopa as well as never-treated newly diagnosed patients 
(Hornykiewicz et al., 1974; Cools et al., 2001; Cools et al., 2002; Owens et al., 1993). It 
seems that working memory can also be improved by L-dopa however it is less 
consistently seen (Fuhrer et al., 2014; Lewis et al., 2005; Marini, Ramat, Ginestroni, & 
Paganini, 2003).  
While deficits in set-shifting can be restored with L-dopa, other new cognitive 
deficits emerge with the use of L-dopa. Namely, while L-dopa restores the ability to shift 
to a new response strategy in PD patients, the ability to reverse a rule (i.e. shift response 
strategy to a previously incorrect one) becomes impaired while on L-dopa (Owens et al., 
1993, Cools et al., 2002). To explain this enhancement of some function but decrements 
in others, an overdose hypothesis has been formulated. It postulates that impairments in 
reversal learning are caused by an overdose of dopamine to the not-yet-depleted ventral 
striatum of early-moderate PD (Cools et al., 2006). However recently it has also been 
shown that L-dopa can exacerbate sustained attentional deficits in a non-human primate 
model of PD. Schneider and colleagues (2012) found that the dose effective for treating 
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the motor symptoms further impaired performance in a sustained attention task. 
Therefore, while the overdose hypothesis may account for some L-dopa-decrements in 
attentional and cognition, it cannot account for all of them.   
Further, in some instances, no impact of L-dopa, either positive or negative, on 
attentional function has been observed. Specifically, selective attention remains impaired 
in patients on L-dopa compared to patients who have abstained from their L-dopa 
regimen (Lewis et al., 2005; Moustafa, Sherman, & Frank, 2008). Even more, these 
deficits remained unimproved while other working memory deficits improved 
considerably with L-dopa administration. Therefore, while some success is seen in using 
L-dopa to treat cognitive deficits, it may be that different domains of attention/cognitive 
impairments might require different therapies. For these reasons, it is imperative to study 
the nature of L-dopa’s influence specifically on attentional deficits associated with PD. 
While L-dopa may prove effective in treating attentional dysfunction seen in PD, 
it may still not be the ideal means for treating both the motor and cognitive deficits of PD 
simultaneously.  L-dopa has several shortcomings that greatly impact PD patients. Firstly, 
the dosage necessary to relieve motor symptoms increases over time due to a 
development of tolerance as well as receptor density changes, and at later stages of the 
disease L-dopa becomes less effective simply due to the severity of dopamine depletion 
(Lessner, Fahn, Snider, Cote, Isgreen, & Barrett, 1979). The enhancement of dopamine 
synthesis and transmission is global and not simply confined to the depleted nigrostriatal 
pathway, which has been shown to be problematic for other dopaminergic functions such 
as reward learning.  There is a significant incidence of impulse control disorders 
including gambling addiction in patients on L-dopa and dopamine agonists (Leeman & 
Potenza, 2011). Furthermore, L-dopa at large doses can cause severe adverse effects 
either after prolonged use or once a high dose of L-dopa is reached. Most commonly, 
 9 
extramotor side effects known as L-dopa induced dyskinesias (LIDs) are seen in PD 
patients and are defined as involuntary repetitive-like movements of the face or limbs 
(Rajput et al., 2002). LIDs can become very severe and can interfere with a patient’s 
ability to function (Ahlskog, 2011). Therefore, it could be problematic if a high dose is 
needed to remediate attentional dysfunction because of the possible development of these 
LIDs or other adverse outcomes. 
1.5 POTENTIAL USE OF METHYLENE BLUE FOR THE TREATMENT OF MULTIPLE CLASSES 
OF SYMPTOM IN PD 
Because of L-dopa’s adverse effects, investigating other treatment options is 
essential. Instead of targeting a specific neurotransmitter system (i.e. dopamine) it may be 
more efficacious to target the system as a whole. Neurodegenerative diseases (including 
PD) are commonly marked by mitochondrial dysfunction and oxidative stress (Banerjee 
et al., 2014; Barnham, Masters, & Bush, 2004; Fukae, Mizuno, & Hattori, 2007; 
Schapira, 2008). Therefore, treating the widespread cellular dysfunction may prove to 
enhance a wider range of symptoms. One potential way to enhance mitochondrial 
function is through the administration of methylene blue (MB). MB is a compound that 
acts by shuttling electrons to the electron transport chain, thus enhancing the activity of 
cytochrome c oxidase and subsequently enhancing metabolism of the cell (Visarius, 
Stucki, & Lauterburg, 1997). MB is also an antioxidant as a consequence of its rapid-
cycling redox properties. Therefore, MB is desirable for the treatment of PD because a 
hallmark pathological trait is oxidative stress, and apoptosis due to oxidative stress is the 
primary cause of dopaminergic cell loss in PD (Kanthsamy, Borowitz, G., & Isom, 1994; 
Pallanck & Greenamyre, 2006; Schapira, 2008; Visarius et al., 1997). Recently, 
Hochgräfe and colleagues (2015) demonstrated that MB can slow the rate of protein 
aggregation when given preventatively (i.e. prior to reaching symptom threshold) in a 
 10 
transgenic model of Alzheimer’s disease. Therefore, MB may be useful not only in 
enhancing function of a compromised cell via enhanced metabolism, but also in 
decreasing the presence of reactive oxidative species (oxidative stress) thereby increasing 
the likelihood of cell survival. 
Additionally, boosting metabolic function via methylene blue has been shown to 
be beneficial for cognition. In naive animals, MB has been shown to increase cognitive 
abilities specifically in learning and memory paradigms (Martinez et al., 1978, Riha, 
Bruchey, Echevarria, Gonzalez-Lima, 2005; Callaway, Riha, Wrubel, McCollum, 
Gonzalez-Lima, Callaway, Riha, Bruchey, Munchi, Gonzalez-Lima, 2004; Wrubel, 
Barret, Shumake, Johnson, Gonzalez-Limam 2006; Wrubel, Riha, Maldonado, 
McCollum, & Gonzalez-Lima; Rojas et al., 2012). And recently, MB has been studied in 
several neurodegenerative diseases and aging-related conditions. MB was shown to 
improve motor function and decrease tau aggregations in a pesticide model of PD (Wen, 
et al., 2011) and improve cognition and decrease pathological presence in a model of 
Alzheimer’s disease (Medina et al., 2011).  Most recently, discrimination learning was 
shown to be enhanced in a rat model of cerebral hypoperfusion with the administration of 
MB (Auchter, Williams, Barksdale, Monfils & Gonzalez-Lima, 2014). MB can also be 
used chronically without the induction of adverse side effects (Naylor et al., 1986).  In 
sum, MB has been shown to be effective in rat models of neurodegenerative disorders for 
treating cognitive function. Furthermore MB has the potential to be useful in treating 
multiple classes of deficits simultaneously because MB is activity dependent and 
aggregates in areas where the demand is high (Barrett, Shumake, Jones, & Gonzalez-
Lima, 2003; Quirk, Garcia, & González-Lima, 2006). However, no research has been 
conducted yet to investigate the use of MB to improve attentional function alone or in 
conjunction with motor function in a PD model.   
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Chapter 2: The role of the central amygdala dopamine in 
disengagement behavior 
2.1 ABSTRACT1 
Unilateral nigrostriatal dopamine depletion in animals induces contralateral 
sensorimotor deficits that are like symptoms associated with Parkinson's disease (PD). 
Unilateral nigrostriatal dopamine depletion also causes a contralateral deficit in 
disengagement behavior (e.g., ability to stop an ongoing activity to orient/attend to a new 
stimulus). This disengagement deficit has been shown to be resistant to treatments that 
rescued other motor and somatosensory deficits. Thus, disengagement behavior may 
involve unique sensorimotor information integration potentially important for attentional 
allocation and may rely strongly on a mechanism that includes extranigrostriatal circuitry. 
The central nucleus of the amygdala (CeA) and its connections with the nigral dopamine 
system have been reported to modulate cognitive processes dependent substantially on 
attentional allocation. CeA dopamine function might be also important for disengagement 
behavior. In Experiment 1, rats received microinfusions of 6-hydroxydopamine 
unilaterally to induce dopamine terminal loss in the CeA and were tested for 
disengagement behavior in addition to several sensorimotor functions. These rats showed 
deficits in contralateral disengagement behavior and an asymmetry in adhesive dot 
removal from the paws, but not in forelimb use in a cylinder or amphetamine rotation. In 
Experiment 2, rats received D1 or D2 antagonists into the CeA unilaterally prior to 
behavioral tests. The D1 antagonist disrupted disengagement behavior without affecting 
the other sensorimotor tests examined. The D2 antagonist had no effects on any of the 
                                                
This work was published as: ES Smith,  SA Geissler, T Schallert, & HJ Lee. (2013). The role of the central amygdala dopamine in 
disengagement behavior. Behavioral Neuroscience,  127(2), 164-174. Authors Smith and Lee contributed to the experimentation, data 
analyses, and writing of the manuscript. Dr. Schallert contributed to the development of the experimental design and the written 
manuscript. Dr. Geissler contributed to the experimentation done for this work.  
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behaviors tested. Our results suggest that CeA dopamine function is involved in 
modulation of disengagement behavior. 
 
2.2 INTRODUCTION 
Parkinson’s disease (PD) is best recognized as a movement disorder triggered by 
a significant loss of nigrostriatal dopamine input, but is accompanied by various non-
motor symptoms including cognitive related dysfunction (Marsh & Berk, 2003; 
McDowell & Chesselet, 2012). In particular, PD patients have difficulty shifting attention 
between two tasks (Cools et al., 2001; Naismith et al., 2010; Ravizza & Ciranni, 2002; 
Yamaguchi & Kobayashi, 1998).  Different prefrontal and parietal cortical subregions are 
known to be involved in attentional shifting (Corbetta & Shulman, 2002; Fox, Barense, & 
Baxter, 2003; Ng, Noblejas, Rodefer, Smith, & Poremba, 2007; T W Robbins, 2007).  
However, the prefrontal and parietal cortical regions show pathological changes in late 
stage of PD (Braak et al., 2004) while deficits in attentional shifting appear in early stage 
of PD and do not respond well to treatment targeted to improve frontal cortical function 
(Lewis et al., 2005; Owen, Roberts, Hodges et al., 1993).  Thus, other brain regions likely 
contribute to the difficulty that PD patients have in shifting attention between tasks. 
One of the cognitive operations involved in shifting attention is the ability to 
disengage from the currently focused event and orient to a different event (Posner, 
Walker, Friedrich, & Rafal, 1984).  Using an animal model for PD, Schallert and Hall 
(1988) first reported that nigral dopamine depletion resulted in impaired disengagement 
behavior.  Rats normally show orienting to tactile-perioral stimulation by disengaging 
from on-going activities such as eating and drinking.  However, rats with unilateral 
partial dopamine depletion due to infusion of 6-OHDA into the medial forebrain bundle 
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did not disengage from eating or drinking to orient to the tactile-perioral stimulation in 
the contralateral side.  This disruption in disengagement was not due to simple 
somatosensory deficit because the same rats showed robust orienting to the same 
stimulation in the absence of on-going activities. Interestingly, behavioral training or 
tissue grafting that aimed at restoring nigrostriatal-dependent sensory and motor deficits 
in the PD animal models did not rescue this disengagement deficit (Mandel, Brundin, & 
Björklund, 1990; Nikkhah, Duan, Knappe, Jo¨dicke, & Bjo¨rklund, 1993; Schallert & 
Hall, 1988). This suggests that disengagement behavior is likely to rely on a circuitry 
other than (or in addition to) the nigrostriatal one important for sensorimotor processing.  
The central nucleus of the amygdala (CeA) has reciprocal connections with the 
substantia nigra pars compacta, SNc, (Cheung, Ballew, Moore, & Lookingland, 1998; 
Fudge & Haber, 2000; Gonzales & Chesselet, 1990; Lee et al., 2005; Ottersen, 1981) and 
destroying nigral dopamine cells results in significantly reduced dopamine fibers in the 
CeA  (Schober, Hertel  & Unsicker, 2005). Several animal studies already showed that 
the CeA and its connections with the SNc were important for attentional allocation 
(Gallagher et al., 1990; Han, McMahan, Holland, & Gallagher, 1997; Holland et al., 
2000; Lee et al., 2008; Lee et al., 2005, 2006).  These studies do not necessarily address 
the exact nature of the information processing between the CeA and the SNc (i.e., from 
the CeA to the SNc, vice versa or both), but clearly support the idea that communication 
between these two structures is essential for some aspects of attentional processing.  It is 
then possible that CeA dopamine function might be involved in disengagement behavior. 
We addressed this possibility by depleting dopamine input more specifically to the CeA 
(experiment 1) and temporarily inactivating CeA D1 and D2 receptors (experiment 2).  
Additional tests were administered to examine whether the CeA dopamine system would 
affect other somatosensory and motor functions. 
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2.3 METHOD 
2.3.1 Subjects 
Long Evans male rats (Charles River, Wilmington, MA), weighing between 250-
275g at the beginning of the experiment were housed individually in a colony room on a 
reversed light-dark schedule with the lights off between 10 A.M. and 8 P.M. and the 
room was maintained at a constant temperature (72º F).  All animals were monitored 
daily and allowed ad libitum access to food.  Water was only restricted for the 24 hours 
directly preceding the behavioral tests. All experiments were conducted according to the 
National Institutes of Health’s Guide for the Care and Use of Laboratory Animals and all 
protocols were approved by the Institutional Animal Care and Use Committee at The 
University of Texas at Austin. 
2.3.2 Experiment 1 
2.3.2.1 Surgery.  
Six rats were anesthetized using 2-5% isoflurane gas (Abbott Laboratories, 
Abbott Park, IL) and were placed into the stereotaxic frame (Kopf Instruments, Tujunga, 
CA). Each animal then received unilateral infusion of 6-hydroxydopamine (6-OHDA; 
Sigma Aldrich, St. Louis, MO) into the central nucleus of the amygdala (CeA). A 28-
gauge needle (PlasticsOne, Roanoke, VA) was placed targeting the CeA (AP = -2.0mm 
and -2.4mm, ML = ± 4.2 mm, DV = -8.2mm) and 0.2-0.4 µl of 6 µg/µl 6-OHDA in PBS 
(i.e., 0.1 M phosphate buffer with 0.9 % saline) with 0.1% (w/v) ascorbic acid was 
infused at 0.1 µl/min rate. Each rat received two injections at two different AP 
coordinates.  The injected site was counterbalanced so that half of the animals received 
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the lesion on the right CeA and the other half received it on the left CeA. Once the 
infusion was completed, the needle was left in place for five more minutes to allow the 
solution to diffuse, so that there would be no solution taken up to the striatum when the 
needle was removed. All rats were allowed to recover for two weeks before testing.   
2.3.2.2 Behavioral Measures.  
The disengagement test, an adhesive removal test, forelimb use in a cylinder and 
an amphetamine-induced rotation test were conducted.  For all the tests, the experimenter 
was blind to the lesion condition.  For the 24 hours immediately prior the disengagement 
test, all rats were water deprived so that they would be motivated to drink when the 
testing began.  Individually, each animal was allowed to drink from the water spigot at 
the back of the home cage.  While engaged in drinking, each rat was stimulated periorally 
using a cotton swab. Three trials were conducted on each side, in which the order of 
stimulation was randomized.  The number of times the animal disengaged from drinking 
after the perioral stimulation was recorded for each side and percentages were calculated.  
Animals were also periorally stimulated when they were not engaged in drinking to 
measure baseline reaction to sensory stimulation.     
In the adhesive removal test, round adhesive dots (1.3 cm diameter, Office Depot, 
Austin, TX) were placed on each forepaw pad.  After being placed back in the home 
cage, the rat was allowed to remove the adhesive dots immediately without a limited hold 
(i.e., without having to wait for a certain time to initiate the response). The order (left vs. 
right forepaw) and latency in which the rat made contact with the dots and removed the 
dots were recorded over five trials.  Percentage of trials where the ipsilateral paw to the 
lesioned CeA (i.e., good/unaffected paw) was contacted first and the dot on the ipsilateral 
paw was removed first were calculated.  
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In the cylinder test (as described in Schallert et al., 2000), a plastic cylinder (20 
cm in diameter and 30 cm in height) was stood up on one end.  Rats were placed into the 
cylinder and spontaneous forepaw touches to the cylinder during rears/exploration of the 
vertical wall were recorded. If only one paw was placed on the cylinder, it was recorded 
as independent use of that limb. If both paws were placed on the cylinder simultaneously, 
or if one paw was placed on the wall and then the other was immediately placed on the 
wall and alternated with the other limb during stepping, it was recorded as simultaneous 
use of both limbs.  A total of 20 instances of left, right, and simultaneous (both) forelimb 
use were recorded during exploration of the cylinder wall in either horizontal or vertical 
planes. Preference for the limb use ipsilateral to the lesioned side was calculated by using 
the following equation previously established by Schallert et al. (2000): Ipsilateral paw 
touches + (.5) both paw touches divided by Total number of touches (ipsi + contra+ both)  
For the rotation test, each rat was given an intraperitoneal injection of 
amphetamine (Sigma Aldrich) at a dose of 1mg/kg. Twenty minutes afterwards, the rat 
was placed into a plastic bowl (60 cm in diameter, 43 cm in height) with tape delineating 
four quadrants. The rat was allowed to move about the bowl for five minutes and each 
quarter turn was recorded for the ipsilateral and contralateral sides in relation to the CeA 
lesion. 
2.3.2.3 Histology.   
Rats received an overdose of pentobarbital (86 mg/kg) and phenytoin (11 mg/kg) 
mix (Euthasol® by Virbac Animal Health, Fort Worth, TX) and then were perfused 
transcardially with 0.9% saline followed by 4% Paraformaldehyde (PFA) in 0.1 M 
phosphate buffer (PB). The brains were extracted and placed into a 20% sucrose PFA 
solution overnight.  The next day brains were rapidly frozen using powdered dry ice and 
stored at -80ºC.  Brains were sliced at 30 µm using a sliding microtome and sections 
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containing the striatum, the amygdala and the midbrain dopamine regions were collected 
in four series.   
One series was used for tyrosine hydroxylase (TH) staining and an adjacent series 
was used for Nissl staining.  For the TH staining, the tissue was first treated with 0.3% 
hydrogen peroxide in PBS. Then the tissue was placed into a 6% normal goat serum 
(NGS) in PBS with 0.3% Triton (PBST) for one hour after rinsing in PBS.  Immediately 
afterwards the tissue was incubated in 0.15% PBST solution containing 3% NGS and 
mouse TH antibody (1:5000, ImmunoStar, Hudson, WI) for 72 hours at 4 ºC.  After 
rinsing, the tissue was incubated with biotinylated goat anti-mouse (1:250, Vector 
Laboratories, Burlingame, CA) for 1 hour and then with avidin-biotin conjugate (PK-
6100, Vector Laboratories) for 1 hour, and reacted using 3,3-diaminobenzidine (DAB; 
Sigma Aldrich).   
TH density was assessed after the TH-stained tissue had been mounted and cover-
slipped. Sections were imaged using a microscope (Olympus BX61) at a magnification of 
10x. The Nissl stained sections were used for anatomical orientation and for 
determination of the size and shape of the central amygdala. Using the Nissl section, a 
border was created around the CeA and then transferred to the appropriate TH-stained 
section and the density measure was taken within that border.  Two samplings were also 
taken from the CeA at levels 25-28 (in accordance with Swanson Rat Atlas, 2003), using 
a circle with a radius of 100 µm (Fig 1). For the striatal reading, two dorsal and two 
ventral measurements (140 µm length square) were taken from the caudate putamen (CP) 
at levels 11, 15, and 18 and one dorsal and one ventral measurements were taken at level 
22.  In addition, CP area immediately adjacent to the CeA was sampled at levels 25-28 
for possible spread of 6-OHDA. TH density in the SNc and ventral tegmental area (VTA) 
was assessed by placing a circle with a radius of 100 µm over the SNc and VTA.  Two 
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samplings of each structure were taken at levels 36-39. Furthermore, two samplings in 
the midbrain reticular nucleus (MRN) area dorsal to the SNc were taken at levels 38 and 
39 for baseline readings of non-dopaminergic area.  Mean gray value measurement in 
Image J was used to calculate the brightness of image pixels (Rasband, 1997-2001, NIH).   
 
2.3.3 Experiment 2 
2.3.3.1 Surgery.  
For the second experiment, a separate group of rats (N= 51) was used.  All of the 
animals had bilateral cannula (26 gauge, PlasticsOne, Roanoke, VA) implants targeting 
the CeA (AP = -2.0, ML = ±3.6, DV = -7.2). These animals were previously used in a 
different task that measured attentional processing (i.e., 5-choice serial reaction time task) 
and had received a total of 4 bilateral infusions of saline, D1 antagonist SCH 23390, or 
D2 antagonist Raclopride.  For the current study, animals’ prior behavioral and drug 
experience were balanced and equally represented in each group.  Even though animals 
had bilateral cannula implants, they only received unilateral manipulations for the current 
study.  
2.3.3.2 Behavioral Measures.  
The disengagement, adhesive dot, and limb use in cylinder exploration tests were 
conducted twice in the same manner as described for Experiment 1. The first set of tests 
was a baseline measure with unilateral saline infusion and the second set of tests involved 
an infusion of either a D1 antagonist SCH 23390 or D2 antagonist Raclopride (Sigma) to 
the same unilateral side where saline was infused. The interval between the saline and 
drug infusions was 24-48 hrs, and all the infusions were given in 0.2 µl over 2-min via 
33-gauge infusion needle that extended 1 mm beyond the guide cannula. Two doses of 
SCH 23390, 0.5 µg and 1.0 µg, and two doses of Raclopride, 0.25 µg and 0.75 µg were 
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tested.  In total, there were four groups of rats in which a given rat only received a total of 
two infusions, one saline infusion to serve as its own control and one drug infusion.  For 
each group, the infusion site was counterbalanced so that half of the animals received 
infusion on the right CeA and the other half received it on the left CeA. Fifteen minutes 
after the saline/drug infusions, each rat was tested on all three tests, which took an 
average of 15 minutes to complete.   
2.3.3.3 Histology.  
 Rats were perfused transcardially with 0.9% saline and 10% formalin. The brains 
were extracted, placed into 20% sucrose formalin solution overnight, and then frozen the 
following day.  Brains were sliced using a sliding microtome at a thickness of 40 µm and 
sections containing the CeA were saved. Mounted sections were Nissl-stained to verify 
cannula placements. Cannulas were considered to have good placements if the guide 
cannula track was visualized within 1 mm above the CeA or if the injection needle track 
was seen within the CeA. 
 
2.4 RESULTS 
 
2.4.1 Experiment 1 
2.4.1.1 TH Density.  
TH density measurements were taken in the CeA, CP, SNc, and VTA.  The 
sampled areas are illustrated in Fig 2.1 and representative pictures of the sampled areas 
from a single animal are shown in Fig 2.2. The density measures seen in Figure 2.3 
correspond to the mean grey value in Image J, which reports brightness value of the 
sampled areas, thus higher numbers represent areas with low/reduced TH density.  The 
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measurements of the MRN area (used for baseline reading of non-TH stained area) just 
dorsal to the SNc averaged 50 x 103.  The measurements in the interested regions 
revealed decreased TH density in the lesioned CeA (i.e., the side that received 6-OHDA 
infusion) and the SNc ipsilateral to the lesioned CeA.  However, there were no 
differences in the CP and the VTA between the two hemispheres. Paired sample t-tests 
comparing the structure ipsilateral and contralateral to the lesioned side were conducted 
for each brain region.  In the CeA and the SNc, there was a significant difference between 
the lesioned and intact sides, t(5) = 2.87, p < 0.05 and t(5) = 3.05, p < 0.05, respectively.  
For the CP and VTA, there were no statistically significant differences between the lesion 
and intact sides, t(5) = 1.08,  p> 0.3 and t(5) = 0.27, p > 0.5, respectively. Additional 
analyses only on the caudal CP areas dorsal to the CeA showed that TH density was still 
not significantly between the two hemispheres (p>0.2).   
2.4.1.2 Disengagement Test.  
Animals with 6-OHDA infusion in the CeA showed deficits in disengagement 
behavior.  When the perioral stimulation was given on the side contralateral to the 
lesioned CeA, they failed to disengage from drinking and did not orient towards the 
stimulation (Fig 2.4A).  In contrast, when the rats were tested while not in the act of 
drinking they always oriented when touched on either side. When they were periorally 
stimulated on the ipsilateral side to the lesion, they readily disengaged from drinking and 
oriented towards the stimulation.  A paired sample t-test was conducted on 
disengagement behavior (i.e., percentage of trials when the animals disengaged from 
drinking) between the sides ipsilateral and contralateral to the CeA lesion. All rats 
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disengaged significantly more to ipsilateral perioral stimulation than to contralateral 
perioral stimulation, t(5)=7.51, p = 0.01.  
 
2.4.1.3 Adhesive Dot Test.  
When the adhesive dots were placed on the forepaw pads, animals readily 
contacted and removed the dots using their teeth.  However, they showed ipsilateral paw 
bias in which they first contacted and removed the dot placed on the paw ipsilateral to the 
lesioned CeA before contacting and removing the dot placed on the contralateral paw. 
Two one-sample t-tests were conducted, one on ipsilateral dot contact and one on 
ipsilateral dot removal to determine if either of these behaviors occurred more than would 
be expected by chance (i.e. 50%). The rats contacted the ipsilateral dot first more 
frequently than would be expected due to chance, t(5)=8.56, p < 0.001; Fig 4B, and they 
also removed the ipsilateral dot first more than would be expected due to chance, t(5) = 
6.27, p < 0.01; Fig 2.4B. 
2.4.1.4 Cylinder Test.   
Rats showed no motor impairment as measured by bias in the forepaws use to 
touch the cylinder wall when rearing/exploring.  Animals used both forepaws equally 
whether it was independent or simultaneous use of the paws.  Bias for the ipsilateral limb 
was calculated using the equation denoted in the methods section. A one-sample t-test 
confirmed that ipsilateral paw use was not different from the 50% chance level, t(5) = 
0.38, p > 0.5; Fig 2.4C. 
2.4.1.5 Amphetamine-Induced Rotation Test.   
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Typically, animals with nigrostriatal dopamine depletion show ipsilateral rotation 
bias when injected with amphetamine (Choi-Lundberg et al., 1998).  However, rats with 
the CeA dopamine depletion showed no preference in their rotational behavior towards 
the ipsilateral side (Fig 2.4D). A paired sample t-test confirmed that there was no bias in 
the direction of the rotations, t(5)= 0.74, p > 0.1.   
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Figure 2.1 Sampling areas used to measure density in TH-stained tissue 
 
 
 
 
 
Diagrams are adapted from Swanson (2003) to represent the sampled areas to measure 
density in tyrosine hydroxylase (TH)-stained tissue. In the diagrams of the top row, black 
and open circles represent sampled areas in the central amygdala (CeA) and in the 
adjacent caudate putamen (CP) area, respectively. Diagrams in the middle row show 
sampled striatal areas as black squares. Diagrams at the bottom row show sampled areas 
of the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) as black 
circles and sampled midbrain reticular nucleus (MRN) as open circles. ACB, nucleus 
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accumbens; BLA, basolateral amygdala nucleus; CeAl, central amygdala nucleus lateral 
part; CeAm, central amygdala nucleus medial part; GP, globus pallidus; SI, substantia 
innominate. Adapted with permission from Brain Maps: Structure of the Rat Brain (3rd 
ed., pp. 39, 47, 53, 61, 67, 69, 71, 73, 89, 91, 93, 95), by L. W. Swanson, 2003, San 
Diego, California: 
Academic Press. Copyright (2003) by Elsevier.  
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Figure 2.2 Photomicrographs of TH-stained sections 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Photomicrographs of the tyrosine hydroxylase (TH)-stained brain sections taken from an 
animal that received 6-hydroxydopamine (6-OHDA) infusions into the right central 
amygdala (CeA). The right CeA as well as the right substantia nigra pars compacta (SNc) 
are visibly lighter compared with ones on the left whereas the caudate putamen (CP) 
regions do not show obvious differences between two hemispheres. Horizontal bars on 
the upper right corner in each row indicate 100 µm.  
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Figure 2.3 TH density quantification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean (± SEM) gray value measure in the tyrosine hydroxylase (TH)-stained tissue. The 
sampled areas are the central amygdala (CeA), substantia nigra pars compacta (SNc), 
caudate putamen (CP), and ventral tegmental area (VTA). TH density measures are 
compared between the ipsilateral (i.e. the same side in which the CeA was infused with 
6-hydroxydopamine [6-OHDA]) and contralateral (i.e. the side with intact CeA) regions. 
As indicated by higher brightness value, TH density was significantly lighter in the 
lesioned CeA and the SNc ipsilateral to the lesioned CeA in comparison to their own 
contralateral regions. *p ˂ .05.  
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Figure 2.4 Performance in motor, sensorimotor, and disengagement tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Mean (± SEM) percentage of disengagement from drinking to perioral stimulation on 
ipsilateral and contralateral sides in relation to lesioned central amygdala (CeA). (B) 
Mean (± SEM) percentage of trials with first contact and removal of the adhesive dot 
placed on the ipsilateral paw. (C) Mean (± SEM) bias of ipsilateral paw use in the 
cylinder test. (D) Mean (± SEM) quarter turns induced by amphetamine. * p ≤ 0.01 
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2.4.2 Experiment 2 
 
2.4.2.1 Cannula placement.  
Cannulae were judged as being acceptable if the center of the cannula placement 
was between AP -1.53 and 2.00 mm and at the most 1 mm above the CeA. Nineteen rats 
were excluded from the experiment for inaccurate cannula placement leaving 32 rats with 
good placement with the breakdown between the groups being n = 7 in the 0.5 µg SCH 
23390 group, n = 10 in the 1.0 µg SCH 23390 group, n = 7 in the 0.25 µg Raclopride 
group, and n = 8 in the 0.75 µg Raclopride group.  Figure 2.5 depicts each cannula 
placement in relation to the CeA.  Each point represents the cannula tip at its centermost 
point with the grey ovals representing animals in the 0.5 µg SCH 23390 group, the black 
ovals representing animals in the 1.0 µg SCH 23390 group, the grey diamonds 
representing animals in the 0.25 µg Raclopride group, and the black diamonds 
representing animals in the 0.75 µg Raclopride group. 
2.4.2.2 Disengagement Test.  
When the animals were tested for disengagement behavior after unilateral 
infusion of saline, they all readily disengaged from drinking with perioral stimulation 
(white bars in Fig 2.6A and 2.6B).  When the animals were tested again after 24-48 hrs 
with D1 or D2 antagonists, only the rats that received unilateral infusion of 1.0 µg D1 
antagonist, SCH 23390, showed impaired disengagement (Fig 2.6A).  Orienting was not 
diminished at all if the rats were not drinking. Interestingly, even though the 
disengagement deficits were substantial in the contralateral side of the infusion, some 
deficits were observed in the ipsilateral side as well.  Animals that received the lower 
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dose of D1 antagonist SCH23390 or either doses of D2 antagonist Raclopride did not 
show any impairment in disengagement behavior (Fig 2.6A and 2.6B). Paired t-tests 
comparing baseline to test performance confirmed these observations. With the larger 
dose of SCH 23390, there was a significant difference between the baseline and test 
performance ipsilaterally, t(9)= 2.34, p = 0.04, and contralaterally, t(9)= 3.85 , p < 0.01. 
There was no difference between baseline and test performance at the lower dose of SCH 
23390 on the ipsilateral side, t(6)= 1.00, p > 0.1, and the contralateral side, t(6)= 1.55, p > 
0.1. There was no difference within the 0.25 µg Raclopride group in disengagement 
between saline and infusion days on the side ipsilateral to the infusion, or on the side 
contralateral to the infusion, t(6) = 1.00, p > 0.1. There was no t-test conducted between 
saline and infusion day on the ipsilateral side because the means were identical.  
Additionally, there was also no difference in disengagement seen in the 0.75 µg 
Raclopride group between saline and infusion day on the side ipsilateral to the infusion, 
t(7) = 1.24, p > 0.1, or the side contralateral to the infusion, t(7) = 1.43 p > 0.1.  
We also ran additional analyses to confirm that animals’ prior drug experiences 
(as mentioned in the methods) did not influence the current results.  There were no 
differences in disengagement behavior as well as dot and cylinder tests among the rats 
that had received saline, D1, and D2 antagonists prior to the current study.  Furthermore, 
there was no interaction effect between their prior drug exposure and the current drug 
exposure. 
 
2.4.2.3 Adhesive Dot Test.  
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When animals had adhesive dots placed on their forepaws after saline infusion, 
both dots were readily removed across all 5 trials. There was no preference for one paw 
as shown with 53% preference for the ipsilateral dot touched, suggesting no sensorimotor 
deficits and no dominant paw use as a result of saline infusion.  Additionally, 24-48 hrs 
later when the animals were given an infusion of D1 antagonist, SCH 23390, there was 
no paw preference in which of the dots were first touched, at the 0.5 or 1.0 µg doses (all 
ps > 0.1). When given an infusion of the D2 antagonist, Raclopride, there was again no 
preference at the 0.25 or 0.75 µg doses for which of the dots was first touched or 
removed, all ps > 0.05.  The ipsilateral bias for dot touched was at a chance level ranging 
50-58% among the drugs and doses tested.   
2.4.2.4 Cylinder Test.   
After the saline infusion, all animals showed no bias or preference for one limb 
use over another when contacting the sides of the cylinder. When tested 24-48 hrs with a 
D1 antagonist SCH 23390 or D2 antagonist Raclopride infusion, neither drug caused a 
preference for which forepaw was used to contact the cylinder when rearing, all ps > 0.1.  
Ipsilateral preference was at a chance level ranging 46-52% among the drugs and doses 
tested. 
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Figure 2.5 Cannula placements within the central amygdala (CeA) between AP -1.53 and 
-2.00. 
 
 
 
Cannulations were judged as acceptable if the tip of the cannula track was at most 1 mm 
above the CeA. Each oval or diamond represents a cannula tip at its most central point for 
each animal. Ovals represent the animals receiving SCH 23390 with the gray 
representing the lower dose (0.5 µg) and the black representing the higher dose (1.0 µg). 
The diamonds represent the animals receiving Raclopride with the gray representing the 
lower dose (0.25 µg) and the black representing the higher dose (0.75 µg). 
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Figure 2.6 Disengagement function after CeA D1 or D2 antagonism 
 
 
 
Mean (± SEM) percentage of disengagement from drinking to perioral stimulation on 
ipsilateral and contralateral sides to the central amygdala (CeA) that received infusions of 
D1 (A) or D2 (B) antagonists. White bar represents disengagement on the day of saline 
infusion and black bar represents disengagement on the day of drug infusion. * p   .05. 
** p   .01. 
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2.5 DISCUSSION 
In the first experiment, animals with 6-OHDA lesions of the CeA failed to 
disengage from drinking in order to orient to perioral stimulation on the contralateral side 
of the lesion, but showed intact disengagement behavior bilaterally when not engaged in 
drinking. All rats also showed normal orienting to ipsilateral stimulation whether or not 
they were engaged in drinking at the time. In the second experiment, rats with infusions 
of the D1 antagonist SCH 23390, but not D2 antagonist Raclopride, directly into the CeA 
showed deficits in disengagement behavior.  In both experiments, animals did not show 
any deficits in the sensorimotor tests with the exception of the adhesive dot test in 
experiment 1.  They contacted and removed dots from the ipsilateral paw to the lesion 
first.  Taken together, the current study suggests that the CeA is necessary for 
disengagement behavior and may mediate this behavior through a D1 mechanism. 
Previous work on rodent models of PD demonstrated that the deficit in 
disengagement behavior was not rescued by treatments that restored sensorimotor 
deficits.  For example, Schallert and Hall (1988) were able to train animals with unilateral 
nigrostriatal dopamine depletion to recover from somatosensory neglect.  However, the 
same animals continued to show complete failure to orient to the contralateral perioral 
stimulation if they were engaged in eating, drinking or grooming behavior.  In other 
studies, rats with grafts of dopamine-rich fetal ventral mesencephalon in the dopamine 
depleted striatum recovered from the earlier sensorimotor deficits, but continued to show 
deficits in disengagement behavior (Mandel et al., 1990; Nikkhah et al., 1993). These 
findings suggest that the striatal dopamine circuitry that is important for sensorimotor 
functions might not mediate the disengagement behavior.  In fact, our current study 
showed that an extra-nigrostriatal circuitry (i.e., the CeA dopamine function) was 
important in mediating disengagement behavior without affecting orienting response to 
 34 
stimulation in the absence of drinking behavior.  It is unlikely that disengagement deficits 
seen in our study are entirely due to the potential damage to the striatum in the course of 
CeA manipulations.  In experiment 1, the overall TH density in the CP area was not 
different between the two hemispheres.  Even though some lighter TH density was 
observed occasionally in the caudoventral CP area near the lesioned CeA, there were no 
obvious differences between the two hemispheres.  In experiment 2, there were intact 
disengagement and sensorimotor functions on the contralateral side of saline or D2 
infusions as well as on the ipsilateral side (i.e., the side being modulated by the 
hemisphere with the cannula implant without infusion).  Thus, potential mechanical 
damage to the striatum could not be responsible for disengagement deficits seen in our 
study.  
 Failure to disengage from an event/task is not limited to drinking behavior.  It can 
occur in the presence of eating or grooming (Schallert and Hall, 1988).  Animals may 
also show disengagement deficits to a different event other than perioral stimulation. 
Whishaw and Tomie (1988) reported that unilateral nigrostriatal 6-OHDA lesioned 
animals were unable to stop eating in order to dodge when other rats approached them 
from the contralateral side.  It is interesting to note that visual disengagement deficits 
have also been reported in PD patients  (Sacrey, Travis, & Whishaw, 2011; Sacrey & 
Whishaw, 2012).  In a reach-to-eat task, in which subjects are required to reach for a 
small food item (e.g., Cheerio) in order to eat it, visual attention is usually engaged as the 
subject reaches for food.  However, once the subject reaches the target and begins to 
grasp the food, visual attention is quickly disengaged, possibly in order to engage 
somatosensory attention to finish the task.  Unlike typical subjects, PD patients were not 
able to disengage visual attention at the point of grasping the food and took much longer 
to finally disengage.  Thus, it is likely that disengagement deficits seen in our study are 
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not due to impaired mechanisms for processing drinking behavior and perioral 
stimulation per se. As originally suggested by Schallert and Hall (1988), the 
disengagement deficit may reflect impaired capacity to simultaneously monitor multiple 
sensory events and to direct attention appropriately.   
The current study suggests that intact CeA dopamine function is important for 
disengagement behavior. It is likely that the CeA influences disengagement behavior in 
conjunction with or by modulating other areas such as the striatum and cortex.  
Anatomical connections suggest possible information flow among these areas via limbic-
cortical-striatal “spiral loops” (Fudge & Haber, 2000; Haber, Fudge, & McFarland, 
2000).  Several studies demonstrated that CeA’s interaction with nigrostriatal function 
was important for behaviors reflecting different aspects of attention, including attentional 
shifting (Lee et al., 2008; Lee et al., 2005, 2006).  In particular, the role of the CeA-
nigrostriatal circuitry in conditioned orienting behavior is notable (Han et al., 1997; Lee 
et al., 2005).  In an appetitive conditioning, animals often acquire conditioned orienting 
response to the conditioned stimulus such as light.  This behavior is interpreted as 
reflecting acquired/enhanced attention to the stimulus via conditioning (Holland, 1977).  
Compromise in the CeA-nigrostriatal function impairs conditioned orienting behavior 
without affecting unconditioned orienting displayed in the absence of conditioning.  
Thus, it is plausible that the CeA-nigrostriatal projection might be important in 
attentional allocation in situations that require more complex information integration 
whether it is orienting to perioral stimulation while drinking or orienting to light during 
conditioning. CeA may also influence prefrontal and parietal cortical functions via its 
connections to cortical projecting cholinergic cells in the substantia innominata (Holland, 
2007; Maddux, Kerfoot, Chatterjee et al, 2007).  It is notable that attentional 
disengagement during covert orientation was impaired among people with parietal 
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cortical damage (Posner et al., 1984).  In addition, rats with posterior parietal cortical 
damage were impaired in attentional set-shifting (Fox et al., 2003).  Thus, it is possible 
that the CeA might interact with the parietal cortex to mediate disengagement behavior.   
Even though the SNc is best known for its dopaminergic projections to the striatal 
area that is involved in motor and related functions, some studies showed that the SNc is 
involved in other information processing. In particular, it has been suggested that a key 
function of dopamine neurons in the midbrain area is to direct or enhance attention to 
biologically significant events or cues that predict significant events (Redgrave, Prescott, 
& Gurney, 1999; Wolfram Schultz & Dickinson, 2000).  Dopamine neurons in the SNc 
and VTA respond to stimuli that signal biologically significant events such as food (W 
Schultz, Dayan, & Montague, 1997) or aversive airpuffs to the eye (Matsumoto & 
Hikosaka, 2009) and to salient and arousing events independent of reward value (Horvitz, 
2000).  Thus, the nigral dopamine input to the CeA may be important for disengagement 
behavior in our current study. In addition, the dopamine input from the VTA to the CeA, 
even though it is sparse, should also be considered (Pitkänen, Pikkarainen, Nurminen, & 
Ylinen, 2000; L. W. Swanson, 1982).  Our histological analyses of TH density in 
experiment 1, however, showed that depleting dopamine input in the CeA via 6-OHDA 
infusion only reduced TH density in the SNc, but not in the VTA. Therefore, the SNc 
dopaminergic input to the CeA seems to be the main source in regulating CeA dopamine 
function important for disengagement behavior.  
Our second experiment suggested that a D1, but not D2, mechanism in the CeA 
was important for disengagement behavior.  This finding is in line with what is typically 
known about the D1 and D2 functions.  In the striatum, D1 and D2 receptors generally 
have opposite/different effects on neural mechanisms such as adenylate cyclase, synaptic 
plasticity, and learning.  For example, D1 is reported to enhance adenylate cyclase, long-
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term potentiation, and appetitive conditioning while D2 either impairs or has no effects 
on these (Calabresi, Pisani, Centonze, & Bernardi, 1997; Eyny & Horvitz, 2003; Kerr & 
Wickens, 2014; Yamamoto et al., 1999). Striatal D1 and D2 receptors also have 
opposite/different responses to dopamine depletion or L-DOPA treatment. D1 receptor 
density and mRNA levels are generally reduced after the loss of nigrostriatal dopamine 
input, while D2 receptor density and mRNA levels tend to increase (Gerfen et al., 1990; 
Joyce, 1991; Marshall, 1979). Chronic L-DOPA treatment seems to enhance D1 signaling 
or binding whereas the effects on D2 are minimal with some reporting down regulation 
(Aubert et al., 2005; Darmopil, Martín, De Diego, Ares, & Moratalla, 2009; Xu, Zhang, 
Qin, Papa, & Cao, 2009).  However, some evidence suggests that CeA D1 and D2 
mechanisms might differ from those in the striatal or cortical areas. For example, D1 and 
D2 receptors in the amygdala, including the CeA, are not linked to adenylate cyclase 
activity (Kilts, Anderson, Ely, & Mailman, 1988; Leonard et al., 2003). Some studies 
showed that CeA D1 and D2 influence learning in the same way: intra-CeA infusions of 
D1 or D2 antagonists impaired fear conditioning and conditioned place preference while 
D1 and D2 agonists improved both learning tasks (Guarraci, Frohardt, Falls, & Kapp, 
2000; Guarraci, Frohardt, & Kapp, 1999; Rezayof, Zarrindast, Sahraei, & Haeri-Rohani, 
2002; Zarrindast et al., 2003).  It is possible that the effects of D1 and D2 mechanisms in 
the CeA are more cognitive domain specific. In addition to the disengagement behavior, 
we also found that D1, but not D2, mechanisms were important for the five choice 
attentional task (Smith et al., 2011).  
In both experiments, animals generally did not show some typical sensorimotor 
deficits linked to extensive striatal DA neuron loss as measured by several behavioral 
tasks.  During the adhesive dot test in the first experiment, however, the rats consistently 
made contact with and removed the ipsilateral dot first, even though the contact and 
 38 
removal of the ipsilateral dot were followed by the contact/removal of the contralateral 
dot.  The latencies to remove the dots in the ipsilateral vs. contralateral paws were 32-sec 
and 39-secs, respectively, and were not statistically different (p>0.1). Unlike the temporal 
D1 inactivation in the CeA, which resulted in no ipsilateral bias in the dot test, depletion 
of CeA dopamine resulted in reduced TH density in the SNc, presumably reflecting 
reduced dopamine function in the SNc.  This could have potentially influenced the 
nigrostriatal dopamine activity, which is suggested to be important for the adhesive dot 
test.  Even though our data suggested that there was no difference in striatum TH density 
between the ipsilateral and contralateral sides, subtle changes in nigrostriatal activity 
undetected by TH density might have been enough to cause ipsilateral bias.  However, it 
is not known whether the nigral dopamine cells send collateral projections to the CeA and 
striatum.  Based on our TH density data, retrograde-depletion of nigral dopamine input to 
the CeA did not seem to affect nigral dopamine input to the striatum, possibly suggesting 
separate SNc projections to the CeA and the striatum.  We are currently conducting an 
anatomical study to address this issue. 
Together, our current study shows that the nigral-CeA dopamine circuitry may be 
involved in disengagement behavior.  This finding may have significant implications for 
understanding one of the most consistent characteristics in PD: inability to engage in (or 
shift attention between) two tasks (Filoteo et al., 1997; Naismith et al., 2010; Ravizza & 
Ciranni, 2002; Yamaguchi & Kobayashi, 1998).  Accumulating evidence suggests that 
failure in attentional allocation in PD patients cannot be simply explained by 
deterioration of cortical functions (Heiko Braak et al., 2004; Lewis et al., 2005; 
Woodward et al., 2002).  Interestingly, the CeA shows the most consistent pathological 
changes among the amygdala subnuclei in PD patients (H. Braak et al., 1994; Heiko 
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Braak et al., 2004; Harding, Stimson, Henderson, & Halliday, 2002).  Furthermore, the 
pathological changes in the CeA occur as the SNc shows the first sign of pathogenesis, 
prior to cortical changes.  Thus, CeA dopamine dysfunction may contribute to attentional 
disengagement problems seen in PD patients.  
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Chapter 3: The roles of central amygdala D1 and D2 receptors on 
attentional performance in a five choice task 
3.1 ABSTRACT 
The central amygdala (CeA) has been shown to play an important role in 
mediating several attentional processes including selective and sustained attention. 
Emerging evidence suggests that the connections between the CeA and the midbrain 
dopamine areas are important for attentional processing. However, little is known about 
the role of dopaminergic input into the CeA in mediating attentional processes. To 
investigate how dopamine activity in the CeA modulates attentional processing, CeA D1 
and D2 receptors were temporarily inactivated during testing in a five choice task. In this 
task, rats were trained to detect one of five recessed ports that briefly illuminated in order 
to receive a food reward, therefore requiring the rats to successfully sustain their attention 
to monitor all five ports and selectively attend to the lit port. Then, rats were tested in 
several altered versions of the task to increase attentional load (e.g. variable ready 
period).  In two experiments, the D1 antagonist, SCH 23390, or the D2 antagonist, 
raclopride, were infused into the bilateral CeA preceding the test sessions. D1 but not D2 
inactivation reduced performance in the more demanding versions of the five choice task. 
Therefore, CeA D1 receptors might mediate attentio2nal functions important for visual 
cue detection in a five choice task.  
                                                
This work was published as: Smith, ES,  Fabian, P, Rosenthal, A, Kaddour-Djebbar, A., & Lee, HJ. The 
roles of central amygdala D1 and D2 receptors on attentional performance in a five choice task (accepted to 
Behavioral Neuroscience). Authors Fabian, Rosenthal, and Kaddour-Djebbar contributed to the 
experimentation while authors Smith and Lee equally contributed to the design, execution, analyses, and 
writing of this work.  
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3.2 INTRODUCTION 
The central nucleus of the amygdala (CeA) plays an important role in appetitive 
learning and attentional processing (Peter C. Holland & Gallagher, 1999). The CeA is 
necessary for several forms of attention such as enhanced orienting to a conditioned 
stimulus (e.g., rearing towards an appetitively conditioned light stimulus; Gallagher et al., 
1990; McDannald, Kerfoot, Gallagher, & Holland, 2004) and enhanced attention to a 
conditioned stimulus as a result of an unexpected outcome contingency (P C Holland & 
Gallagher, 1993). Further, the connections between CeA and midbrain dopamine areas 
have been implicated in these attentional processes (El-Amamy & Holland, 2006; Han et 
al., 1997; Lee et al., 2008; Lee, Wheeler, & Holland, 2011; Lee et al., 2005, 2006).  
The CeA also modulates selective and sustained attention as measured by the 
ability to attend to a specific visual cue in the presence of multiple cues. Holland and 
colleagues found that bilateral CeA lesions impaired performance in an operant multiple-
choice reaction time task (Holland et al., 2000). In this task, rats were trained to nose 
poke into a port that was briefly illuminated (500msec) among 3 ports to receive a food 
reward. The impending port illumination was signaled by the house-light for 5 sec. When 
the attentional load was increased by shortening the port illumination to 100 msec or by 
varying the duration of the house-light signal, rats with CeA lesions showed reduced 
accuracy and response time. In subsequent studies, Holland and colleagues also showed 
that the CeA’s connections to the cholinergic substantia innominata/nucleus basalis 
magnocellularis (SI/nBM) and the cholinergic input to the medial prefrontal cortex 
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(mPFC) were important for mediating the attentional performance in a similar multiple-
choice reaction task (Holland, 2007; Maddux et al., 2007).   
However, it is currently unknown whether the midbrain dopamine connections 
with the CeA, previously implicated in enhanced attentional processing of conditioned 
cues ( Lee et al., 2005, 2006) also play an important role in mediating attentional 
performance during the multiple-choice reaction task. Anatomically, the CeA and the 
midbrain dopamine cells have reciprocal connections (Asan, 1997; Cheung et al., 1998; 
Fudge & Haber, 2000; Haber et al., 2000; Hongjoo J. Lee et al., 2011; Hongjoo J Lee et 
al., 2005; L. W. Swanson, 1982), suggesting that dopamine can have a direct influence on 
CeA function. In fact, several studies showed that manipulations of dopamine receptors 
in the CeA altered learning and memory such as fear conditioning and conditioned place 
preference (Guarraci et al., 2000, 1999; Rezayof et al., 2002; Zarrindast et al., 2003).  
Our recent study also suggests that dopamine function in the CeA is critical for a 
particular type of attentional processing (Smith, Geissler, Schallert, & Lee, 2013). Either 
permanent dopamine depletion or temporary blockage of D1 receptors in the CeA 
produced deficits in the rat’s ability to disengage from an ongoing activity and attend to 
an incoming stimulus. Therefore, we examined whether dopamine functions in the CeA 
are important for attentional performance during a five choice task by temporally 
inactivating CeA D1 receptors (Experiment 1) or CeA D2 receptors (Experiment 2). 
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3.3 METHOD 
3.3.1 Subjects 
One hundred and three male Long-Evans rats (Charles River) weighing 250-275 g 
upon arrival were housed in a vivarium with a reversed 14 hour light: 10 hour dark cycle 
with lights off at 10 AM. One week after arrival, rats were food restricted to maintain 
90% of their free-feeding body weight but had constant access to water. Rats were 
allowed ad libitum access to food and water during the one-week recovery period after 
surgery. All behavioral training and testing occurred during the dark phase. All 
experiments were conducted according to the National Institutes of Health’s Guide for 
the Care and Use of Laboratory Animals and all protocols were approved by the 
Institutional Animal Care and Use Committee at The University of Texas at Austin. 
3.3.2 Surgery 
Rats were anesthetized using 2-5% isoflurane gas (Abbott Laboratories) and were 
placed into the stereotaxic frame (Kopf Instruments, Tujunga, CA). All the rats were 
implanted with bilateral guide cannulae (26 gauge, PlasticsOne) to target the CeA (AP = -
2.0, ML = ±3.6, DV = -7.2). Once the cannulae were in place, dental acrylic (Lang Dental 
Manufacturing Co., Wheeling, IL) was poured onto the skull to create a head cap with 4 
jewel-screws anchored to the skull. After the dental acrylic had completely dried, dummy 
cannulae were inserted into the guide cannulae. The rats received a subcutaneous 
injection of buprenorphine hydrochloride (0.01 mg/kg; TW Medical, Denver, CO) and 
were given one week to recover from surgery.  
3.3.3 Apparatus 
Five choice training and testing was conducted in 8 operant boxes with aluminum 
side walls and ceiling, and clear acrylic front and back walls (30.5 cm W × 25.4 cm D × 
30.5 cm H; Coulbourn Instruments, Whitehall, PA). One of these side walls was concave 
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and contained five recessed ports (each 2.5 cm in diameter) with each of the recessed 
ports 3 cm from the grid floor (stainless steel rods 0.5 cm in diameter, parallel, spaced 1.0 
cm apart) and had 3 red LED lights inside to illuminate the port at the appropriate time. 
Additionally, the ports were equipped with infrared beams that detected nose pokes. 
Opposite the concave wall was a 2-watt house light (centered on the wall, 26 cm from the 
floor) and a recessed food cup (centered, 2 cm from the floor) equipped with an infrared 
beam to detect entries. On the top of the box was an activity monitor (Coulbourn 
Instruments) that measured activity through infrared beam breaks. Each box was housed 
in a light- and sound-attenuating chamber (58.4 cm × 61 cm × 45.7 cm; Coulbourn 
Instruments) and interfaced with a computer using GraphicState 3.1 (Coulbourn 
Instruments).  
3.3.4 Five choice task 
3.3.4.1 Shaping  
In order to train the rats on the five choice task, two shaping procedures were 
conducted. First, rats underwent a magazine-shaping session in which they were trained 
to eat a single grain pellet (45 mg grain tablet, Test Diet, Richmond IN) delivered to a 
food cup located within the conditioning chamber.  A total of 30 pellets were delivered at 
a variable interval (averaging 60 sec) over a 30 min session. After this session, all rats 
reliably retrieved grain pellets from the food cup.	  Second, the rats went through a nose 
poke-shaping session in which they were trained to make a nose poke response to the 
ports.  All five ports were illuminated for 30 sec and a nose poke to any port during this 
time resulted in the delivery of a grain pellet in the food cup. This daily session was 
continued until the rats met criterion of 80% or more responses over 30 trials with a 
variable intertrial interval (ITI) of 30 sec. After completing the shaping sessions, the rats 
began training in the five choice task.  
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3.3.4.2 Training  
Rats were trained to the baseline task gradually. The beginning of a trial was 
signaled by the house light. After 5 sec of constant illumination (i.e., ready period), one 
of the five target ports was illuminated. Rats first had to detect (i.e., nose poke) a port that 
was illuminated for 30 sec. Once the rats reached the criterion (80% trials with correct 
responses), the port light duration was shortened successively to 20 sec, 10 sec, 5 sec, 3 
sec, 1 sec, and then finally to 500 msec once they met the criterion at each stage. 
Regardless of the port light duration the session time was 30 min, but as port light 
duration decreased, the number of trials increased to accommodate the 30 min training 
window. Therefore, the total trials for each stage ranged from 30 trials (for 30 sec port 
light) to 60 trials (for 500 msec port light). The rats had a total of 5 sec (i.e., response 
period) from the time the port light was illuminated to make a nose poke response to the 
target port unless the port light duration was longer than 5 sec, in which case the rats 
were allowed to make a nose poke for the entire duration the port was illuminated. A 
correct nose poke resulted in an immediate delivery of a grain pellet and darkening of the 
house light (and the port if still illuminated). If no correct response was made during the 
5 sec response period, the house light was darkened. Responses to the non-target ports 
(i.e., the other 4 that were not illuminated) during the 5 sec response period were 
recorded as errors but resulted in no consequences.  In addition, nose poke responses to 
any of the 5 ports during the 5 sec ready period were recorded as premature responses but 
did not have any consequences. The baseline task consisted of 60 trials in a 30 min 
session (variable ITI of 30 sec) and each port was illuminated equally (i.e., 12 times per 
session) on a semi-random schedule (i.e., no port was lit more than two times 
consecutively). This procedure was adapted from Holland and colleagues (Holland, 2007; 
Holland et al., 2000; Maddux et al., 2007), which differ from the typical 5 choice serial 
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reaction time task (5CSRTT) procedure (Robbins, 2002). The initiation and termination 
of the trials are independent of the rats’ response in our procedure. Therefore, premature 
response during the ready period does not delay or cancel port illumination. In addition, 
an incorrect response during the response period does not terminate the trial allowing the 
rats an opportunity to correct their mistakes and make a correct response. Nevertheless, 
this modified version of the five choice task was sensitive to attentional challenges and 
manipulations of the CeA and its connections to the cortico-cholinergic system (Holland, 
2007; Holland et al., 2000; Maddux et al., 2007)  
In order to finish training on the 500 msec baseline task, the rats had to reach the 
criterion twice during 3 consecutive training days. Then, the rats received bilateral 
cannulae implantation, were given a week to recover, and were retrained on the 500 msec 
task to the same criterion as before (See Table 3.1). 
3.3.4.2 Testing 
 Once rats reached criterion on the 500 msec task post-surgery, they received a 
handling procedure for two days before testing.  The handling procedure consisted of a 
mock drug infusion process in which the dummy cannulae were removed, the rats were 
gently held for a couple of minutes, and the dummy cannulae were replaced. The testing 
phase was 7 days long with 4 infusion/test days. These infusion tests consisted of one 
baseline test and three challenge tests (all 60 trials each).  In the first challenge, the port 
light duration was shortened from 500 msec to 100 msec for all trials.  In the second 
challenge, the typically constant 5 sec ready period varied to 1, 5, or 9 sec. The third 
challenge was a blink condition in which the house light blinked during the 5-sec ready 
period. Half of the rats were run in the order of 500 msec baseline task, shortened port 
light challenge, variable ready period challenge, blink challenge. The other half were run 
in the reverse order (blink, variable ready period, shortened port light, baseline). In 
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between these four test days, the rats underwent the baseline task with no infusion to 
ensure that there were no lasting effects of the drugs (See Table 3.2). 
3.3.5 Infusions 
Rats were assigned to receive 0.9% saline (Experiments 1 and 2), a D1 antagonist 
SCH23390 (Sigma Aldrich, St Louis, MO; Experiment 1), or a D2 antagonist raclopride 
(Sigma Aldrich; Experiment 2). All the infusions were given fifteen minutes before the 
start of testing. Bilateral infusions (0.2 µl each) were delivered over 2-min via 33-gauge 
infusion needle (PlasticsOne) that extended 1 mm beyond the guide cannula using an 
infusion pump (Harvard Apparatus, Holliston, MA) and a Hamilton syringe (Hamilton, 
Reno, NV). Two doses of SCH 23390 (0.5 µg and 1.0 µg given bilaterally) and two doses 
of raclopride (0.25 µg and 0.75 µg given bilaterally) were used. Therefore, there were 
three groups per experiment; (1) Saline, SCH 23390 0.5 µg, SCH23390 1.0 µg; (2) 
Saline, raclopride 0.25 µg, and raclopride 0.75 µg. 
3.3.6 Histology 
After behavioral testing was complete, rats were perfused transcardially with 
0.9% saline and 10% formalin. The brains were extracted, placed into 20% sucrose 
formalin solution overnight, and then frozen the following day. Brains were sliced using 
a sliding microtome at a thickness of 40 µm and sections containing the CeA were saved. 
Every fourth section was mounted and Nissl-stained to verify cannula placements. 
Cannulae were considered to have good placements if the guide cannula track was 
visualized within 1 mm above the CeA (as defined by Swanson, 2004) as the infusion 
cannula extended 1 mm past the tip of the guide cannula or if the injection needle track 
was seen within the CeA.  
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3.3.7 Statistical Analyses 
All statistical analyses were conducted in PASW version 18. All measures of 
performance in the task were assessed using a repeated measures 3x4 analysis of variance 
(ANOVA) with the between group factors of drug assignment (control and two different 
doses of drugs) and the within factors of testing sessions (baseline and three different 
attentional challenges). Four post-hoc One-Way ANOVAs were conducted (when 
appropriate) on each testing session.  
3.4 RESULTS 
3.4.1 Experiment 1: CeA D1 Antagonism 
3.4.1.1 Cannula placement verification 
Cannula placements were considered acceptable if the guide cannula track was 
visualized within the CeA or up to 1 mm above the CeA (as defined by Swanson, 2003). 
The number of rats with acceptable cannula placements was 10 in the saline control 
condition, 8 in the SCH 23390 1.0 µg group and 6 in the SCH 23390 0.5 µg group 
(Figure 3.1). Six rats in the saline group included in the analyses only had acceptable 
unilateral cannula placements. However, their performance levels were not different from 
the ones with acceptable bilateral placements at all 4 tests with saline infusions (all ps > 
0.1). Unacceptable placements were either too dorsal or too rostral in relation to the CeA 
and located in the striatum, substantia innominata or the intercalated nucleus. 
Additionally, one of the rats in the saline group with acceptable unilateral placements 
received a mock infusion prior to testing (due to blocked cannula), in which the rat was 
just gently held on the experimenter’s lap for the duration of the actual infusion. 
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3.4.1.2 Post-surgery training 
Rats were re-trained daily on the baseline 500 msec task post-surgery until they 
met the criterion of 80% correct performance (i.e., trials with correct nose poke to the 
target port) twice within 3 consecutive days of training. To determine if there were any 
pre-existing differences between the groups prior to drug infusions, two measures were 
examined: (1) the average percent correct trials on the days the rats met criterion and (2) 
the number of days necessary to meet criterion. When a One-Way ANOVA was run on 
average percent correct trials, there was a main effect of group, F(2,21) = 4.34, p = 0.026. 
Post-hoc Tukey’s HSD revealed that the average percent correct trials for the SCH 23390 
1.0 µg group (M = 88.85 SEM = 1.03) was significantly higher than the control group (M 
= 84.16, SEM = 0.97). However, when a one-way ANOVA was run on the amount of 
training days needed to reach criterion, there was no difference between groups, F(2,21) 
= 1.15, p = 0.34.  
3.4.1.3. Infusion tests 
Accuracy.  Accuracy in each test was measured as percentage of trials with 
correct responses out of a total 60 trials (Figure 3.2A). The results show an overall main 
effect of drug, F(2,21) = 6.598, p = 0.006, and an interaction of the drug and testing, 
F(6,63)= 3.389, p = 0.006 while the overall testing effect was marginally significant, 
F(3,63) = 2.537 p = 0.065. To further examine the interaction, separate One-Way 
ANOVAs were conducted for each testing session. These revealed that the D1 antagonist, 
SCH 23390 had no effect on performance in the 500 msec baseline test [F(2,21) = 0.645, 
p = 0.54] or in the 100 msec test [F(2,21) = 1.087 p = 0.36]. However, D1 receptor 
antagonism did impact performance at the variable ready period test [F(2,21) =  4.539, p 
= 0.02)] in which the higher dose of SCH 23390 (1.0 µg) significantly lowered accuracy 
in comparison to the control group (Tukey’s HSD). In the blink challenge test, there was 
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also a significant effect of group assignment [F(2,21) = 9.661, p = 0.001] with the rats 
receiving the higher dose of SCH 23390 displaying reduced accuracy in comparison to 
control rats and to rats receiving the lower dose of SCH 23390.  
Correct Response Latency. Performance in the five choice task was also assessed 
using latency to respond correctly (Figure 3.2B). The overall results show a main effect 
of testing, [F(3,63) =4.354 p = 0.008], a trend of a main effect of drug [F(2,21) = 3.325, p 
= 0.056], and a significant interaction of testing and drug [F(6,63) = 2.84, p = 0.016].  
Further analyses revealed that SCH 23390 had no effect on response latency in the 500 
msec test [F(2,21) = 0.175, p = 0.84], the 100 msec test [F(2,21) = 0.177, p = 0.84], or 
the variable ready period test [ F(2,21) = 1.771, p = 0.20] . However, the D1 antagonist 
did have an effect on response latency in the blink challenges, F(2,21) = 11.673 p < 0.001 
in which the rats receiving the higher dose of SCH 23390 were slower to respond 
correctly than the rats receiving the lower dose or saline.  
Omissions. Omissions were defined as trials in which no nose poke response 
(correct or incorrect) to the ports was made during the 5-sec response period (Figure 
3.2C). The data show a main effect of testing [F(3, 63) = 3.128, p = 0.032], a main effect 
of drug [F(2,21)= 12.516, p < 0.001], and an interaction of testing and drug  [F (6, 63) = 
2.904, p = 0.015]. One-way ANOVAs revealed that there was a main effect of drug in all 
three attentional challenges  [100 msec: F(2,21) =6.81, p = 0.005; variable ready period: 
F (2,21) = 4.782, p = 0.019; blink: F(2,21) = 8.373, p = 0.002 ] but not in the 500 msec 
task [ F(2,21) = 0.692, p = 0.512, Figure 2C]. Tukey’s post hoc tests demonstrated that at 
all attentional challenges, rats receiving the higher dose of SCH 23390 had a higher rate 
of omissions than the other two groups.  
Premature Responses. Premature responses were defined as nose poke responses 
to the ports during the ready period prior to the illumination of a port (Figure 3.2D). 
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There was a main effect of testing, [F(3, 63) = 19.832, p < 0.001], a main effect of drug, 
[F(2,21) = 6.302, p = 0.007] and an interaction of testing and drug [F (6, 63) = 3.741, p = 
0.003]. Further analyses elucidated that there was a main effect of drug at all attentional 
challenges [100 msec: F(2,21) = 4.414, p  = 0.025; variable: F(2,21) = 6.757, p = 0.005; 
blink: F(2,21) = 8.487, p = 0.002] but not at the 500 msec task [ F(2,21) = 2.436, p = 
0.112]. Rats receiving the higher dose of SCH 23390 committed fewer premature 
responses in comparison to control rats at all three attentional challenges as well as fewer 
premature responses compared to rats receiving lower dose of SCH 23390 in the blink 
condition.  
Locomotor Activity. To quantify locomotor activity during testing sessions, beam 
breaks from an infrared activity monitor were recorded for the duration the rats were in 
the operant boxes. Locomotor activity (seen in Table 3.3) was not affected by the 
application of a D1 antagonist as demonstrated by a lack of significant main effect of 
drug [F(2, 21) = 0.893, p = 0.424] as well as no main effect of testing [ F(3,63) = 0.861 p 
= 0.466] or interaction of the two factors [F(6,63) = 1.45, p = 0.21].  The results eliminate 
the possibility of motor impairment as an explanation for the decrements in performance 
seen in the attentional challenges.  Furthermore, we analyzed the latency to retrieve the 
food pellets once the rats made the correct nose poke response (Table 3). There were no 
differences among the groups at any testing point: drug [F(2, 21) = 0.53, p = 0.535], 
testing [ F(3,63) = 0.454 p = 0.715], and interaction [F(6,63) = 0.905, p = 0.497]. These 
results further rule out motor as well as motivational factors for the decreased 
performance seen in the attentional challenges.    
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Table 3.1 Timeline of experiment progression 
 
  
Event  Number of Days       Criterion TO PROGRESS  
Pre-surgery training 10-14 ≥80% correct trials 2 out of 3 
consecutive days 
Surgery and Recovery 7 n/a 
Post-surgery training 2-10 ≥80% correct trials 2 out of 3 
consecutive days 
Testing  7 No criterion – rats moved through 
testing schedule regardless of 
performance 
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Table 3.2 Testing orders for attentional challenges 
 
 
 
 
 
Note: Rats received infusions every other day starting day 1 (gray shading) and received 
no infusion on three baseline days interspersed between infusion days (no shading). 
  
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Order 1 500 msec Baseline 
100 
msec Baseline Variable Baseline Blink 
Order 2 Blink Baseline Variable Baseline 
100 
msec Baseline 
500 
msec 
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Figure 3.1 Cannula placements within the CeA between AP -1.53 and -2.00. 
 
 
Each oval represents a guide cannula tip at its most central point for each animal. Filled 
ovals represent the animals receiving SCH 23390 with the grey representing the lower 
dose (0.5 µg) and the black representing the higher dose (1.0 µg) while open (white) 
ovals represent animals in the control group. Dotted ovals represent the placements of 
rats with unilaterally acceptable placements. 
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Figure 3.2 Five choice task performance after CeA D1 antagonism 
 
 
 
A. Mean (± SEM) percent trials with correct responses across all tests.  B. Mean (± SEM) 
latency to make the first correct response. C. Mean (± SEM) numbers of trials with 
omissions (no nose pokes during the response time) across all tests. D. Mean (± SEM) 
numbers of premature responses across all tests. Premature responses were defined as 
nose pokes to any ports during the ready period directly prior to the port light 
illumination. *p < 0.05, ** p < 0.01, *** p < 0.001. 
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Table 3.3. Locomotor activity and food cup latency after CeA D1 antagonism  
 
 
Group 500 msec 100 msec Variable Blink 
 
Activity 
(# of beam 
breaks) 
 
Food Cup 
Latency 
(sec) 
Saline 491 ± 91.60 525.3 ± 73.75 419 ± 84.14 467.7 ± 70.04 
SCH 0.5µg 446 ± 96.43 525.33 ± 94.54 544.67 ± 125.28 676.67 ± 135.67 
SCH 1.0 µg 393.5 ± 52.15 416.75 ± 94.14 462.42 ± 60.74 377.63 ± 54.66 
     Saline 1.55 ± 0.24 1.28 ± 0.07 1.40 ± 0.18 1.45 ± 0.245 
SCH 0.5µg 1.67 ± 0.12 1.74 ± 0.24 1.67 ± 0.19 1.67 ± 0.14 
SCH 1.0 µg 1.52 ± 0.11 1.49 ± 0.12 1.55 ± 0.10 1.52 ± 0.11 
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3.4.2 Experiment 2: CeA D2 Antagonism 
3.4.2.1 Cannula placement verification 
 Cannula placements were again considered acceptable if the cannula track was 
visualized within the CeA or up to 1 mm above the CeA (see Figure 3.3).  In Experiment 
2, the number of rats with acceptable placements were six in the control condition, seven 
in the raclopride 0.25 µg group, and six in the raclopride 0.75 µg group. Four of the rats 
in the saline group only had acceptable unilateral cannula placements. Unacceptable 
cannula placements were located dorsal to the CeA in the striatum or rostral to the CeA in 
the striatum or substantia innominata.  Additionally, two of these four rats only received a 
mock infusion due to blocked guide cannulae. 
3.4.2.2 Post-surgery training 
Rats were re-trained daily on the baseline 500 msec task after cannula placement 
surgery until they met the criterion of 80% correct performance twice within 3 
consecutive days of training. To determine if there were any preexisting differences 
between the groups prior to drug infusions, two measures were examined: (1) the average 
percent correct trials on the days the rats met criterion and (2) the number of days 
necessary to meet criterion. One-way ANOVAs were conducted for each variable with 
drug group assignment as the between subjects factor. There were no differences in 
average percent correct trials [F(2,16) = 0.332, p = 0.722] and in number of training days 
needed to meet criterion [F(2,16) = 2.32, p = 0.13].  
3.4.2.3 Infusion Tests 
Accuracy.  Performance on the infusion tests was first measured by accuracy (i.e., 
percentage of trials with correct response). The results (Figure 3.4A) suggest that D2 
antagonist, raclopride, did not influence accuracy as seen by no effects of drug [F(2,16) = 
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1.643, p = 0.224], or testing [F(3,48) = 1.302, p = 0.29] or an interaction of those two 
[F(6, 48) = 0.52, p = 0.79]. 
Correct Response Latency.  Performance in each of the infusion day tests was also 
assessed using response latency to nose poke the correct port. There was only a main 
effect of testing [F(3,48) = 3.244, p = 0.03], but no main effect of drug [ F(2,16) = 1.311, 
p = 0.28] and no interaction of drug and testing [ F(6,48) = 0.559, p = 0.76, Figure 3.4B]. 
Upon conducting six paired samples t-tests comparing performance at the different 
infusion tests with a bonferroni-adjusted significance level of p = 0.008, no significant 
differences emerged (all ps > 0.02). While there were no significant differences across t-
tests, it is likely that the original main effect of testing is due to overall slightly longer 
latencies in the three challenge versions of the task in comparison to the 500 msec 
baseline task. 
Omissions. The overall omission rates were low across all the testing sessions and 
did not differ among the drug groups (Figure 3.4C): testing [F(3, 48) = 0.972, p = 0.414], 
drug [F(2,16) = 0.802, p = 0.466] , an interaction [F(6,48) = 0.519, p = 0.791].  
Premature Responses. Raclopride also did not influence the nose pokes to the 
ports made during the ready period  (Figure 3.4D). There was only a significant main 
effect of testing, F (3,48) = 24.018, p ˂0.001, but no drug [F(2,16) = 0.417, p = 0.67] or 
an interaction [ F(6,48) = 0.985, p = 0.446]. Post hoc paired samples t-tests were 
conducted with a bonferroni-adjusted significance level of p = 0.008, and revealed greater 
levels of premature responses made in the variable ready period test compared to all other 
tests: 500 msec [t(18) = -5.164, p < 0.001], 100 msec [t(18) = -6.174, p , 0.001], and blink 
[t(18) = 9.279, p < 0.001].  
Locomotor Activity. Regardless of test or drug assignment, activity levels were 
comparable across all rats (Table 3.4). There were no effects of drug [F(2, 16) = 0.751, p 
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= 0.488], testing [F(3,48) = 1.684, p = 0.183] or interaction of these two variables 
[F(6,48) = 0.57, p = 0.752].  
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Figure 3.3 Cannula placements within the CeA between AP -1.53 and -2.00. 
 
 
Each oval represents a guide cannula tip at its most central point for each animal. Open 
ovals represent animals receiving saline and filled ovals represent the animals 
receiving  Raclopride with the grey representing the lower dose (0.25 µg) and the black 
representing the higher dose (0.75 µg). Dotted ovals represent the placement for animals 
with unilaterally acceptable placements. 
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Figure 3.4 Five choice task performance after CeA D2 antagonism. 
 
 
A. Mean (± SEM) percent trials with correct responses across all tests.  B. Mean (± SEM) 
latency to make the first correct response. C. Mean (± SEM) numbers of trials with 
omissions (no nose pokes during the response time) across all tests. D. Mean (± SEM) 
numbers of premature responses (nose pokes to any ports during the ready period) across 
all tests. No significant differences were detected. 
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Table 3.4. Locomotor activity (beam breaks) after CeA D2 antagonism  
 
 
  
Group 500 msec 100 msec Variable Blink 
Saline 470 ± 67.32 637.5 ± 70.58 581 ± 97.12 559.67 ± 64.28 
Raclopride 0.25 µg 533.43 ± 62.28 578 ± 86.64 570 ± 93.03 552.57 ± 88.04 
Raclopride 0.75 µg 617.67 ± 64.53 652.83 ± 80.42 666 ± 88.33 716.5 ± 78.08 
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3.5 DISCUSSION 
Here we have demonstrated that CeA D1 but not D2 receptors are important for 
maintaining adequate performance in this five choice task. When D1 receptors in the CeA 
were temporarily inactivated using SCH 23390, response accuracy decreased when the 
ready period became variable from trial-to-trial or when the house light blinked during 
the ready period. Furthermore, D1 receptor antagonism in the CeA resulted in more 
omissions and fewer premature responses in all three attentional challenges as well as 
increased correct response latency when the house light blinked during the ready period. 
This impairment in performance was significant in the group that received a higher dose 
of D1 antagonist SCH 23390 even though this group showed better performance during 
the baseline training prior to the infusion. Thus, the pre-existing differences were not 
likely to confound the subsequent results showing impairing effects of SCH 23390.  
Therefore, taken together, these data suggest that CeA D1 receptors play an important 
role in modulating performance during the five choice task.  
The increased omission rates observed in the current study falls within the range 
of what others have seen in cases when accuracy has been impaired as well as when 
accuracy has been relatively unaltered (e.g., Baunez & Robbins, 1999; Passetti, Dalley, & 
Robbins, 2003).  Increased omission is generally interpreted as reflecting impaired 
attention when other measures such as food cup latency are not affected (as was the case 
in our study). However, it can also reflect non-attentional aspects such as ‘response 
vigor’ described by Robbins (2002) as reflected by response latencies and rates of 
omissions. In addition, a premature response in our study is likely to reflect the overall 
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response vigor more than impulsive behavior because in this procedure, premature 
responses do not result in any consequences (i.e. termination of the trial). Generally, in 
other versions of this task, the rat must withhold responding during the ready period in 
order to avoid a ‘time-out’ period, therefore premature responses are used to gauge 
inhibitory control over impulsivity (T. W. Robbins, 2002).  However, in our version of 
the task, responses made during the ready period were not followed by time-out and 
therefore premature responses are not necessarily due to a failure to inhibit responding 
and cannot be interpreted strictly as a measure of impulsivity. And as a consequence of 
this modification, the number of premature responses tends to be higher in our procedure 
but comparable to other data sets using this same protocol (Olshavsky et al., 2014).  
It is likely that the CeA D1 receptors are important for modulating other aspects 
of five choice task in addition to attentional processing. Studies have demonstrated 
dissociation between accuracy and response vigor.  For example, systemic inactivation of 
DA receptors can result not in deficits in accuracy but in response vigor (Harrison, 
Everitt, & Robbins, 1997; Weed & Gold, 1998). At the local level, D1 receptors within 
the medial prefrontal cortex (mPFC) and striatum are necessary for task accuracy while 
D2 receptor roles differ depending on the area under examination. In the mPFC, D2 
receptor inactivation has little-to-no impact on performance in the 5-CSRTT (Granon et 
al., 2000) while striatal D2 receptors impact response latency (Agnoli & Mainolfi, 2012).  
Within the nucleus of accumbens, D1 receptors appear to be important for performance 
during the 5-CSRTT (Pezze, Dalley, & Robbins, 2007): D1 receptor partial agonist SKF 
38393 improved the accuracy and reduced omission, whereas D1 receptor antagonist 
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SCH 23390 decreased accuracy, and increased both omissions and correct response 
latencies. In contrast, D2 receptors in the nucleus of accumbens do not seem to directly 
modulate attentional function but influence the general performance including 
perseverative responses and food cup latency. Our findings align with existing work 
showing the importance of D1 receptors in attentional performance and more ambiguous 
role of D2 receptors.  
Reduced performance by D1 receptor blockade in the CeA is not likely due to 
motor impairment or a simple inability/unwillingness to perform the basic task. The 
activity levels examined during the sessions were comparable across all three groups. The 
Coulbourn activity monitor used in the current study is commonly used to measure 
activity levels in the conditioning chamber. For example, freezing behaviors are recorded 
using the same kind of monitors (Lee, Choi, Brown, & Kim, 2001; Lee & Kim, 1998). 
We have also detected enhanced activity levels in the same set up. Systemic injection of 
D1 agonist, SKF 829580 (0.25 mg/kg), significantly increased activity levels during a 
classical appetitive conditioning (unpublished data): Saline group (514±59 beam breaks), 
D1 agonist group (831±54 beam breaks), p<0.005. Therefore, we believe our activity 
monitoring system is sensitive enough to record potential differences in activity levels. 
Further, the overall response latency of the rats was under 2 seconds and 2-3 seconds 
when the performance was impaired even though the allotted response time was 5 
seconds demonstrating that the rats had enough time to complete the task.  The range of 
the response latency seen in the current study is very similar to the ones reported by 
Holland et al. (2000) who initially used the modified version of the five choice task. 
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Their reported response latency was generally just below 2 seconds for control and CeA-
lesioned groups and was within 2-4 seconds for CeA-lesioned group when performance 
was impaired. In addition, the rats infused with D1 antagonist in the current study were 
not any slower in collecting the food pellet once it was dispensed into the food cup. This 
suggests that the overall motivational levels were similar in terms of their willingness to 
retrieve the food reward. While an effect of multiple infusions cannot be completely ruled 
out given that each rat received a total of 4 infusions of the same drug and dose, this 
experiment was designed to minimize any possible multiple infusion effects. Firstly, we 
used two different orders of the attentional challenges as seen in Table 2 and confirmed 
that order of attentional challenge tests did not result in differences in performance levels. 
Furthermore, in addition to having two testing orders, we spaced infusions 48 hours apart 
with the intent of minimizing any potential effect of repeated infusions.   
 It has been previously demonstrated that D1 and D2 receptors are important for 
learning. Rats with systemic injections of D1 and D2 antagonists during a Pavlovian 
learning paradigm showed respective impairment and enhancement of conditioned food 
cup approach when tested 24-hours later drug-free (Eyny & Horvitz, 2003).  However, 
other work has shown that within the CeA, D1 and D2 receptors operate similarly to 
affect fear conditioning and conditioned place preference (CPP). Intra-amygdala (mostly 
targeting CeA) infusions of 2 µg SCH 23390 (D1 antagonist) and 1 µg ecticlopride (D2 
antagonist) prior to fear conditioning and/or prior to a retention test 24-hours post-
conditioning resulted in reduced freezing at the retention test (Guarraci et al., 2000, 
1999). Similarly, intra-CeA infusions of 1.0 µg SCH 23390 or 0.5 µg sulpiride (D2 
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antagonist) resulted in decreased acquisition of morphine-induced CPP (Rezayof et al., 
2002; Zarrindast et al., 2003). Instead of having opposing roles on Pavlovian appetitive 
learning as is the case at the systemic level, D1 and D2 receptors within the CeA have 
similar roles in modulating fear and reward learning. Comparatively, we find that a 1.0 
µg dose of SCH 23390 in the CeA causes a decrement in attentional function while 
neither dose (0.25 or 0.75 µg) of the D2 antagonist, raclopride had an impact on 
attentional functioning as measured by the five choice task. The findings of our current 
study also align with our recent work examining CeA D1 and D2 receptor functions in 
another behavioral process called disengagement behavior (Smith et al., 2013). 
Disengagement behavior is the ability to stop or disengage from an ongoing behavior (i.e. 
drinking) to attend to an incoming stimulus such as perioral stimulation (Schallert & Hall, 
1988). Depletion of dopamine input in the CeA caused a disruption in disengagement but 
not simple spontaneous orienting to perioral stimulation in the absence of ongoing 
activity, suggesting that CeA dopamine function is important for an attentional 
component of this behavior without affecting sensory information processing (Smith et 
al., 2013). In addition, using the same doses and antagonists used in the current study, we 
demonstrated that CeA D1 receptor antagonism impaired disengagement behavior while 
D2 antagonism within the CeA had little-to-no impact on disengagement behavior. It 
cannot be completely ruled out that higher doses of D2 antagonist, raclopride might 
influence the performance during the five choice task. However, in a study that examined 
the role of CeA D2 receptors in fear and anxiety, intra-CeA infusions of 0.75 µg 
raclopride (the same dose used in the current study) yielded the same results as higher 
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doses (de la Mora, Gallegos-Cari, Arizmendi-García, Marcellino, & Fuxe, 2010). For 
example, intra-CeA infusions of either 0.75 µg or 2 µg raclopride increased the latency 
for the rats to bury an electrified probe while the same two doses and a higher dose (4 µg) 
had no effect on the rats’ behavior on elevated plus maze. Thus, the maximal effect of 
raclopride in the CeA D2 receptors seems to have been achieved with 0.75 µg.         
 The midbrain dopamine inputs to the CeA arise from both the SNc and the ventral 
tegmental area (Oades & Halliday, 1987; L. W. Swanson, 1982). However, our previous 
study suggests that the nigral dopamine input might be more important for modulating 
CeA’s function. Injection of 6-hydroxydopamine into the CeA, which caused 
disengagement deficits, resulted a decrease in dopaminergic cells in the SNc but not in 
the VTA suggesting that dopaminergic input from the SNc is important for successful 
disengagement behavior (Smith et al., 2013). We have also shown that intact nigral 
dopamine and CeA connections are crucial in processing enhanced attention driven by 
prediction error (Lee et al., 2006; Lee et al., 2008). Furthermore, blocking the 
communication between the VTA and the CeA does not result in the same deficits in 
enhanced orienting to a visual conditioned stimulus as when the SNc-CeA 
communication is blocked (Lee et al., 2005; Lee, et al., 2011). Others have also shown 
that MPTP injections that caused significant reduction in the nigrostriatal dopamine 
fibers in mice also resulted in significant reduction of dopamine fibers in the CeA 
(Schober, Herfel, & Unsicker, 2005). While the VTA’s input to the CeA cannot be ruled 
out, it is likely that the SNc dopaminergic input into the CeA plays an important role in 
attentional processing.  
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Among the many neural circuits that are involved in regulating attention, the CeA 
might modulate attention through the basal forebrain cholinergic system, known to play a 
crucial role in attentional function (Harati, Barbelivien, Cosquer, Majchrzak, & Cassel, 
2008; McGaughy, Dalley, Morrison, Everitt, & Robbins, 2002; Risbrough, Bontempi, & 
Menzaghi, 2002).  The CeA can influence the basal forebrain cholinergic system via its 
direct projections to the SI/nBM  (Fritz, Yilmazer-Hanke, Roskoden, Schwegler, & 
Linke, 2005) which, as a part of the basal forebrain system, in turn sends cholinergic 
projections to cortex, including the PFC (Mesulam, Mufson, Wainer, & Levey, 1983). 
The SI/nBM and its projections to the PFC are known to play a crucial role in visual 
attention during the 5CSRTT (McGaughy et al., 2002). Further, it has been shown that 
the connections between the CeA and SI/nBM are also necessary for maintaining 
accuracy in a similar task (Holland, 2007) and the elimination of cholinergic inputs to the 
PFC as well as lesions of the CeA produce similar deficits in the multiple choice reaction 
task (Maddux, et al., 2007). Similarly, cholinergic cells in the SI/nBM and their 
projections to the posterior parietal cortex as well as the CeA play an important role for 
enhanced attentional processing driven by prediction error (Bucci, Holland, & Gallagher, 
1998; Chiba, Bucci, Holland, & Gallagher, 1995; Maddux et al., 2007), the same 
attentional processing modulated by the SNc-CeA connections (Lee et al., 2006; Lee et 
al., 2008). Therefore, the CeA might modulate attentional function via its connections to 
the cortical-cholinergic system.  
However, the role of CeA’s substantial reciprocal connections to the SNc cannot 
be ruled out (Fudge & Haber, 2000; Gonzales & Chesselet, 1990). It is possible that the 
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CeA could be modulating attentional function through the nigrostriatal dopaminergic 
system, which in concert with the PFC is also crucial for maintaining adequate 
performance in the 5-CSRTT (Christakou, Robbins, & Everitt, 2001; Rogers et al., 2001).  
Nigrostriatal dopamine depletion (Baunez & Robbins, 1999), but not necessarily ventral 
striatal dopamine depletion (Cole & Robbins, 1989) impairs accuracy when the 
presentation of the port light becomes unpredictable. In the current study, the higher dose 
of D1 antagonist SCH 23390 also significantly impaired accuracy when the ready period 
varied. Reducing temporal predictability of the visual targets is likely to require higher 
levels of readiness or alertness to respond. Therefore, CeA D1 receptors might be 
important for modulating this aspect of attentional processing. In addition to the 
modulation of attentional function, the CeA’s connections to the nigro-striatal pathway 
can also influence other factors influencing performance during the five choice task. 
Bilateral lesions of the medial part of the striatum significantly affected all aspects of 
performance during 5CSRTT including ‘response vigor’ (Rogers et al., 2001). In the 
same study, lateral striatal lesions resulted in severe performance deficits (i.e., increased 
omission) that precluded them from completing the task. More specific nigro-striatal 
dopamine depletion also increased omission and correct response latency with a minor 
impact on accuracy (Baunez & Robbins, 1999). Therefore, the CeA might also play a role 
in modulating response vigor via its connections to the nigro-striatal pathway.  
The current experimental preparation used to study the roles of CeA dopamine 
receptors in attention may give insight into diseases that are characterized by aberrant 
dopaminergic function. Specifically, Parkinson’s disease (PD), primarily known as a 
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motor disorder due to the hallmark nigrostriatal dopamine loss, also features attentional 
dysfunction even in the early stages of disease (Filoteo et al., 1997; Swainson, Rogers, 
Sahakian, Summers, & Polkey, 2000; Woodward et al., 2002; Yamaguchi & Kobayashi, 
1998; Zhou et al., 2012). Dysfunction of the mesocortical system is suggested to be 
responsible for PD-related cognitive problems; however, cortical areas typically are 
among the last regions to show pathological changes in PD (Alafuzoff et al., 2009; Braak 
et al., 2004), and a drug therapy targeted to restore prefrontal function is not always 
effective at improving attentional deficits in PD patients  (Lewis et al., 2005; Owen et al., 
1993). Thus, extra-cortical regions are likely to contribute to attentional deficits, 
especially in the early stages of disease. Therefore, the loss of SNc dopaminergic input 
into the CeA might contribute to the attentional dysfunctions associated with PD.  This 
work also has implications for other disorders beyond PD. Dysfunction of dopamine 
system is often seen in disorders accompanied by attentional issues, such as ADHD, 
depression, and schizophrenia (Abi-Dargham, 2004; Aleman & Kahn, 2005; Braak et al., 
1994; Di Michele, Prichep, John, & Chabot, 2005; Laurens, Kiehl, Ngan, & Liddle, 2005; 
Swanson et al., 2000). Thus, examining dopamine functions in the CeA will broaden our 
understanding of the neural mechanisms responsible for attentional deficits associated 
with PD and various other mental disorders. 
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Chapter 4: The impact of L-dopa on attentional impairments in a rat 
model of Parkinson’s disease 
4.1 ABSTRACT 
Deficits in attention including difficulty switching attention between tasks or 
rules, sustaining attention, and selectively attending to specific stimuli are commonly 
seen in patients with Parkinson’s disease (PD). Further, while these deficits are frequently 
reported, it is unclear how traditional dopamine replacement therapy such as L-dopa 
affects these deficits. Therefore, in rat model of PD in which dopamine is unilaterally 
depleted using 6-hydroxydopamine, we first examined the impact of acute and chronic L-
dopa treatments on attentional switching as modeled by disengagement behavior (i.e. the 
ability to disengage from an on-going behavior such as eating or drinking to attend to 
perioral stimulation). Then, in a separate experiment, we evaluated the use of L-dopa for 
treating selective and sustained attention deficits using a five choice task. Our data 
suggest that the L-dopa dose necessary to recover motor function can also successfully 
restore attention switching behavior (i.e. disengagement behavior) in the short term. 
However, the dose of L-dopa useful for recovering disengagement behavior and motor 
function further worsened performance in the selective and sustained attention task. 
Furthermore, this same dose was responsible for inducing dyskinesias in rats given 
chronic daily injections. Taken together, these findings demonstrate that simple dopamine 
replacement therapy may not be sufficient for treating all types of attentional dysfunction 
occurring in PD.   
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4.2 INTRODUCTION 
While Parkinson’s disease (PD) is primarily characterized by the cardinal motor 
dysfunction, cognitive and attentional deficits are also commonly present (Pfeiffer, 
Løkkegaard, Zoetmulder, Friberg, & Werdelin, 2014b; Weintraub et al., 2015). Patients 
with PD demonstrate difficulty with executive function, working memory, as well as 
several types of attention. For example, PD patients have difficulty dividing attention 
between multiple stimuli, sustaining attention for a prolonged period of time, and 
selectively attending to relevant stimuli and ignoring irrelevant stimuli (Filoteo et al., 
1997; Yamaguchi & Kobayashi, 1998; Zhou et al., 2012a). Furthermore, PD has also 
been shown to result in difficulty switching behavioral rules or tasks (Cools, Barker, 
Sahakian, & Robbins, 2003; Cools, Clark, Hornykiewicz, 1974; Owen, & Robbins, 2002; 
Ravizza & Ciranni, 2002).  
However, the ability of traditional dopamine replacement therapy (i.e. levodopa; 
L-dopa) in recovering these attentional difficulties in PD is not well understood. In a 
review by Hornykiewicz (1974), L-dopa is said to improve attentional switching behavior 
in cases of mild PD, however no study has been conducted in severe PD to study the 
ability of L-dopa to improve attention switching. In the case of set-shifting, L-dopa 
recovers the ability to shift response rules (i.e. Wisconsin card sorting task) but causes 
new impairments in reversal rules (i.e. reversal of reward probability; Cools et al., 2002, 
2003; Dujardin et al., 2013). Further, there are conflicting reports on whether selective 
and sustained attention can be improved with L-dopa.  For example, Dujardin et al. 
(2013) demonstrated that PD patients on L-dopa continue to show impairments in choice 
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reaction time tasks in comparison to healthy controls (Dujardin et al., 2013) while Zhou 
et al. (2012) showed no improvements in selective or sustained attention with L-dopa and 
Moustafa, Sherman, and Frank (2008) demonstrated persistent selective attention deficits 
(but not worsened) with L-dopa administration. These varied results may be partly due to 
the nature of clinical research. Patients with PD are commonly on other dopaminergic 
and non-dopaminergic medications in addition to L-dopa. The disease severity also varies 
between studies and L-dopa may be differentially effective depending on disease 
severity.  
Therefore, it is pertinent to study the effects of dopamine replacement therapy on 
attentional impairments in animal models of PD. While attentional dysfunction in PD-
modeled animals is not well characterized, there is some work demonstrating in both non-
human primate and rat models of PD that attentional deficits do exist (Schallert & Hall, 
1988; Decamp and Schneider, 2004). Specifically, rats with unilateral dopaminergic 
depletion of the nigrostriatal pathway fail to disengage from an on-going behavior (e.g., 
eating, drinking, grooming) to attend to perioral stimulation even though they have intact 
sensory ability to detect the perioral stimulation (Schallert & Hall, 1988). This behavior 
is thought to be analogous to basic attention switching behavior in humans (Posner et al., 
1984). Non-human primates exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) also show impairments in sustained attention and attentional shifting behavior 
(Decamp & Schneider, 2004).  
While the therapeutic value of L-dopa has been extensively characterized, little 
work has been done to assess the efficacy of L-dopa in the treatment of attentional 
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dysfunction in models of PD. Recently, work by Schneider, Pioli, Jianzhong, Li and 
Bezard (2012) found that the dose necessary to improve motor function in the MPTP-
exposed primates further impaired sustained attention. That is, when asked to sustain 
attention and indicate which of 3 cues was lit, macaques that received a dose of L-dopa 
optimized for improving motor impairments, decreased the rate of correct responses. 
Beyond this, no other work to date has assessed the impact of L-dopa on a spectrum of 
attentional processes in animal models of PD. Therefore, we designed two experiments to 
determine the impact of L-dopa treatment on attentional switching behavior (Experiment 
1) and selective and sustained attention (Experiment 2) in a rat model of PD.   
4.3 EXPERIMENT 1: ACUTE AND CHRONIC EFFECTS OF DAILY L-DOPA ADMINISTRATION 
ON DISENGAGEMENT BEHAVIOR 
In this experiment, all rats were given unilateral infusions of 6-hydroxydopamine 
(6-OHDA) into the medial forebrain bundle. After post-surgery recovery, rats received 
daily L-dopa or vehicle (saline) injections for 4 weeks and were tested for disengagement 
behavior along with motor function at Day 1, Week 1, Week 2, and Week 4 (Figure 4.1).  
4.3.1 Method 
4.3.1.1 Subjects 
Male Sprague-Dawley rats (300-400g, Harlan) were triple-housed in a vivarium 
with a reversed 14 hour light: 10 hour dark cycle with lights off at 10 AM. Rats had ad 
libitum access to food for the duration of the experiment and water access was only 
restricted 24 hours prior to disengagement testing. All behavioral training and testing 
occurred during the dark phase. All experiments were conducted according to the 
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National Institutes of Health’s Guide for the Care and Use of Laboratory Animals and all 
protocols were approved by the Institutional Animal Care and Use Committee at The 
University of Texas at Austin. 
4.3.1.2 Surgery 
Rats were anesthetized using 2-5% isoflurane gas (Abbott Laboratories) and were 
placed into the stereotaxic frame (Kopf Instruments, Tujunga, CA). All rats were given 
unilateral infusion of 6-Hydroxydopamine (6-OHDA) into the medial forebrain bundle 
(AP = -3.3, ML = ±1.7, DV = -8.5). A concentration of 7µg/µl 6-OHDA was prepared in 
PBS with 0.1% ascorbic acid (Sigma Aldrich, Milwaukee, WI) and 1.0 µl was infused at 
a rate of 0.1 µl per minute (Hamilton syringe; Harvard Apparatus infusion pump). After 
the infusion was finished, the skull incision was sutured shut and rats received a 
subcutaneous injection of buprenorphine hydrochloride (0.01 mg/kg; TW Medical, 
Denver, CO). Rats were then placed on a heating pad and once awake and mobile, they 
were returned to their home cage and given a two week recovery period.  
4.3.1.3 L-dopa injections 
There were three separate groups of injection conditions. For two groups of rats, 
L-dopa methyl ester hydrochloride (Sigma Aldrich, Milwaukee, WI) was given either at 5 
mg/kg or 10 mg/kg. For both groups, benserazide (10 mg/kg; Sigma Aldrich, Milwaukee, 
WI) was given 15 minutes prior to L-dopa injection to block decarboxylation of L-dopa 
peripherally. The third group was a vehicle group that was further divided into two 
subgroups: one group received two saline injections spaced 15 minutes while the other 
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group received an injection of benserazide (10 mg/kg) and then saline injection 15 
minutes apart. However, no difference between these two subgroups existed so they were 
collapsed to form the vehicle group. The attentional disengagement test followed by a 
motor (cylinder) test was conducted 15 minutes after the second injection (i.e., either 
saline or L-dopa). 
4.3.1.4 Behavioral testing 
Disengagement Test. For the 24 hours immediately prior the disengagement test, 
all rats were water deprived so that they would be motivated to drink when the testing 
began.  For testing, each animal was allowed to drink from the water spigot at the back of 
the home cage.  While engaged in drinking, each rat was stimulated periorally using a 
cotton swab. Five trials were conducted on each side, in which the order of stimulation 
was randomized.  The number of times the animal disengaged from drinking after the 
perioral stimulation was recorded for each side and percentages were calculated.  Rats 
were also periorally stimulated when they were not engaged in drinking to measure 
baseline reaction to sensory stimulation. Rats were first tested prior to L-dopa injection to 
assess baseline deficits and additionally tested at 4 different time points over the course 
of 4 week injection period (Fig 1).     
Cylinder Test. In the cylinder test to measure forelimb use (as described by 
Schallert, Fleming, Leasure, Tillerson, & Bland, 2000), a plastic cylinder (20 cm in 
diameter and 30 cm in height) was stood up on one end.  Rats were placed into the 
cylinder and spontaneous forepaw touches to the cylinder during rears/exploration of the 
vertical wall were recorded. If only one paw was placed on the cylinder, it was recorded 
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as independent use of that limb. If both paws were placed on the cylinder simultaneously, 
or if one paw was placed on the wall and then the other was immediately placed on the 
wall, it was recorded as simultaneous use of both limbs.  A total of 20 instances of left, 
right, and simultaneous (both) forelimb use was recorded during exploration of the 
cylinder wall in either horizontal or vertical planes. The rat was removed from the 
cylinder either after 20 instances of forelimb use or 5 minutes has passed. The cylinder 
test was conducted immediately after the disengagement test. Preference for the limb use 
contralateral to the lesioned side (i.e., affected limb by the dopamine lesion) was 
calculated by using the following equation previously established by Schallert et al. 
(2000): 
Contralateral paw touches + (.5) both paw touches 
Total number of touches (ipsi + contra+ both) 
L-dopa induced dyskinesias. Rats were assessed at each testing session for L-dopa 
induced dyskinesias (LIDs), using a modified abnormal involuntary movement (AIM) 
rating system adapted from Cenci & Lundblad (2007). Rats were scored on a scale from 
0-4 in four different AIM categories: limb (i.e. hyperkinetic movement of usually the 
forepaws), axial (i.e. torsion or flexion of the trunk), motor (i.e. increased 
locomotion/turning towards the side contralateral to the lesion, and oral (i.e. chewing 
motions, twitching of facial muscles). A score of 0 indicated no presence of the AIM 
while scores 1-4 indicated presence of dyskinesia to varying degrees. A score of 1 
signified a present but infrequent movement and a score of 2 indicated a movement 
present for more than half of the observed time. A score of 3 was given for a 
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continuously present dyskinesia that was suppressible by external stimulation such as a 
tap on the cage. If the movement was continuous and unable to be suppressed by external 
stimulation, it was given a score of 4. Ratings were given for all four AIM categories and 
then added together for a total AIM score. If LIDs were severe enough to impair or 
prevent performance in the behavioral tasks, the rat was not tested for the remainder of 
the experiment. 
4.3.1.5 Immunohistochemistry 
At the conclusion of the experiment, rats received an overdose of pentobarbital 
(86 mg/kg) and phenytoin (11 mg/kg) mix (Euthasol® by Virbac Animal Health) and then 
were perfused transcardially with 0.9% saline followed by 4% Paraformaldehyde (PFA) 
in 0.1 M phosphate buffer (PB). The brains were extracted and placed into a 20% sucrose 
PFA solution overnight.  The next day brains were rapidly frozen using powdered dry ice 
and stored at -80ºC.  Brains were sliced at 30 µm using a sliding microtome and sections 
containing the midbrain dopamine regions were collected in four series.   
For the tyrosine hydroxylase (TH) staining, the tissue was first treated with 0.3% 
hydrogen peroxide in PBS. Then the tissue was placed into a 6% normal horse serum 
(NHS) in PBS with 0.3% Triton (PBST) for one hour after rinsing in PBS.  Immediately 
afterwards the tissue was incubated in 0.15% PBST solution containing 3% NHS and 
mouse TH antibody (1:5000; ImmunoStar, Hudson, WI) for 72 hours at 4 ºC.  After 
rinsing, the tissue was incubated with biotinylated horse anti-mouse IgG (1:250, Vector 
Laboratories) for 1 hour and then with avidin-biotin conjugate (PK-6100, Vector 
Laboratories) for 1 hour, and reacted using 3,3-diaminobenzidine (DAB; Sigma Aldrich).   
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Once the TH-stained tissue was mounted and cover slipped, sections were imaged 
using a microscope (Olympus BX61) at a magnification of 10x.  In order to determine the 
extent of dopamine depletion, basic 2-D stereology was conducted. The number of TH+ 
cells in the SNc was counted across four sections of tissue (levels 36-39; Swanson, 2003). 
These numbers were averaged and compared lesion to intact side. In addition to TH+ 
count in the SNc, integrated optical density in the SNc and ventral tegmental area (VTA) 
was also measured using ImageJ (Rodbardt function; Rasband, 1997-2001; NIH). Optical 
density was measured by sampling two locations (radius 100µm) for each structure at 
four levels (SNc: 36-39; VTA: 37-40; Swanson, 2003). 
4.3.2 Results 
4.3.2.1 Dopamine depletion and lesion verification 
Quantification of dopamine depletion for lesion verification purposes was 
calculated two ways (Figure 4.2A). First, TH immunoreactive (ir) cells were counted in 
the entire SNc across four sections. These numbers were averaged and overall dopamine 
depletion was calculated by obtaining the percent difference score between the intact and 
lesioned sides. Secondly, optical density measures were taken across the same sections, 
averaged and the same percent difference score was calculated.  For this study, only rats 
with 50% or greater DA depletion were included in the statistical analyses. Using either 
measure resulted in the exclusion of (the same) five rats. Of the rats included in analyses 
(VEH: n=7; L-dopa 5 mg/kg: n=7; L-dopa 10 mg/kg: n=7), there was an 77% reduction 
in TH-ir positive cells in the SNc with no significant group differences [F(2,18) = 1.45 p 
> 0.2]. Using the optical density measurement, overall lesion severity was lower (86%), 
however no differences between these groups were detected [F(2,18) = 1.85, p > 0.15]. 
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TH optical density was also quantified in the VTA and on average there was 65% 
dopamine depletion with no group differences in optical density between groups [F(2,18) 
= 0.18, p > 0.5]. 
4.3.2.2 Dyskinesia development 
As a consequence of daily L-dopa injections, some rats developed L-dopa induced 
dyskinesias (Table 4.1) and were unable to be tested thus changing the n values as the 
experiment progressed (Table 4.2). For the rats that developed dyskinesia, most were first 
observed to have dyskinesia at the Week 1 testing time point.  Most commonly, rats 
displayed a forelimb dyskinesia precluding them from being tested in either behavioral 
test. While the maximum possible score was a 16 (4 sub-ratings all 0-4), no rat scored 
above an 8 at onset. While all sub-categories of dyskinesias were observed, typically only 
one or two of the subcategories were observed in each rat. Forelimb dyskiniesias were 
most commonly seen and present in the majority of rats. On average, forelimb dyskinesia 
at onset was rated at 2 and 2.25 (4 max) for the L-dopa 5 mg/kg group and L-dopa 10 
mg/kg group respectively. The overall LID scores at the onset for both treatment groups 
were relatively similar (L-dopa 10 mg/kg: 2.8 ± 0.6; L-dopa 5 mg/kg: 2.4 ± 0.8).   
4.3.2.3 Disengagement behavior 
To determine if L-dopa administration had an impact on disengagement behavior 
on the affected side (contralateral side), one-way ANOVAs were conducted among three 
groups at each testing time point.  At baseline (prior to L-dopa injection), all rats showed 
low or non-existent levels of disengagement behavior on the affected side and these 
severe deficits in disengagement were not different among three groups as expected [F 
(2, 21) = 0.41, p = 0.67; Figure 4.2B]. On the first day of injection, rats in the saline 
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group and 5 mg/kg L-dopa group continued to show severe disengagement deficits. 
However, the rats that received 10 mg/kg L-dopa showed significant improvement in 
disengagement behavior [F(2,18) = 17.92, p < 0.001]. At Week 1, no differences in the 
rate of disengagement are seen amongst the groups [F(2,12) = 1.25, p = 0.32] even 
though both L-dopa groups show more disengagement than the saline group. It is likely 
to be caused by the overall increase in variability of the disengagement behaviors in rats 
across all groups. Only one rat in the L-dopa 10 mg/kg group was able to be tested at 
Week 2 and no differences between the L-dopa 5 mg/kg group and the saline group were 
observed [F(2,8) = 2.5 p = 0.14].  At Week 4, only one rat in the L-dopa 10 mg/kg group 
and two in the L-dopa 5 mg/kg group had not developed dyskinesias and therefore no 
analyses were conducted.  
4.3.2.4 Motor function 
The cylinder test was conducted to assess motor function in all rats. In order to 
determine if there was any preference in paw usage in the cylinder, one-way t-tests with a 
test value of 50% (chance usage of one paw) were conducted for each group at each time 
point. To allow for group comparisons, one-way ANOVAs at each time point were also 
conducted.  No analyses were conducted for the week 4 time point due to the majority of 
L-dopa treated rats having developed dyskinesias by that point. Across all time points, 
rats receiving vehicle showed either a significant decrease in bad paw usage or a trend of 
decreased bad paw usage [Baseline: t(6) = 5.21, p ˂ 0.001; Day 1: t(6) = 7.12, p ˂ 0.001, 
Week 1: t(5) = 2.30, p = 0.07; Week 2: t(5) = 2.40, p = 0.06; Figure 4.2C].  L-dopa 5 
mg/kg did not improve the use of bad paw as they continued to display impaired usage of 
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the bad paw across all time points as well [Baseline: t(6) = 12.466; Day 1: t(6) = 22.36, p 
˂0.001; Week 1:  t(5) = 3.06, p = 0.028; Week 2: t(4) = 6.14, p < 0.01]. However, the L-
dopa 10mg/kg group was able to recover initially impaired bad paw usage [Baseline: t(6) 
= 20.221, p ˂ 0.001] after a single injection of 10 mg/kg L-dopa [Day 1:  t(6) = 0.63, p > 
0.5]. This improvement was still observed after a week of injections [Week 1: t(4) = -
0.42, p > 0.5]. No statistic was calculated at Week 2 as only 2 rats could be tested due to 
dyskinesia development. Furthermore, when comparing across groups, no differences in 
bad paw usage were seen at baseline [F(2, 18) = 0.83, p > 0.4] but at Day 1 
administration of L-dopa 10 mg/kg resulted in increased bad paw usage compared to 
vehicle treatment [Day 1: F(2,18) = 3.53, p = 0.05]. However, this effect went away at 
Week 1 [F(2,14) = 2.27, p = 0.1]. 
4.3.3 Experiment 1 Discussion 
Acutely, L-dopa 10 mg/kg, but not 5 mg/kg, is effective in restoring 
disengagement and motor function of the affected side. However, rats receiving either 
dose of L-dopa readily develop dyskinesias thus precluding any potential chronic benefits 
of L-dopa. While it appears that L-dopa 10 mg/kg becomes less effective at Week 1, the 
rats remaining at Week 1 show similar motor and disengagement performance from Day 
1 to Week1 suggesting no decrease in efficacy. 
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Figure 4.1 Experiment 1 design: Acute and chronic effects of L-dopa on disengagement 
behavior and motor function 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Rate and severity of dyskinesia in L-dopa-treated rats 
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Figure 4.2 Dopamine depletion, disengagement behavior, and motor function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean (± SEM) dopamine depletion in the SNc as measured by counting of TH+ 
cells and sampling of optical density.  B. Mean (± SEM) disengagement behavior on the 
side contralateral to 6-OHDA lesion. C. Mean (± SEM) usage of the bad (contralateral) 
paw in the cylinder test, chance usage = 50%. ** p < 0.01, *** p < 0.001 
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4.4 EXPERIMENT 2: THE IMPACT OF L-DOPA ADMINISTRATION ON FIVE CHOICE TASK 
PERFORMANCE 
In experiment 1, many rats developed dyskinesias within 1-2 weeks of L-dopa 
injections preventing further testing to examine the chronic effects. Therefore, only the 
acute effects of L-dopa on selective and sustained attention were examined using a five 
choice task (Figure 3A). The rats were trained on this task prior to surgery (unilateral 6-
OHDA infusion into the MFB), and then re-trained after recovering from the surgery 
(Figure 4.3). Performance in the five choice task of these rats on and off L-dopa were 
then compared.  
4.4.1 Method 
4.4.1.1 Subjects 
Male Sprague-Dawley rats (300-400g, Harlan) were triple-housed in the same 
condition as in Experiment 1 with a reversed 14 h light: 10 h dark cycle with lights off at 
10 AM. Rats were food restricted to maintain 90% of free-feeding weight except during 
the post-operative recovery period and had ad libitium access to water during the 
experiment. All behavioral training and testing occurred during the dark phase. All 
experiments were conducted according to the National Institutes of Health’s Guide for 
the Care and Use of Laboratory Animals and all protocols were approved by the 
Institutional Animal Care and Use Committee at The University of Texas at Austin. 
4.4.1.2 Surgery 
Rats were anesthetized using 2-5% isoflurane gas (Abbott Laboratories) and were 
placed into the stereotaxic frame (Kopf Instruments, Tujunga, CA). All rats were given 
 87 
the same unilateral infusion of 6-OHDA into the medial forebrain bundle as done in 
Experiment 1 except a range of 0.6-1.0µl of the 7µg/µl 6-OHDA solution was given. 
Also unlike Experiment 1, rats were given 25 mg/kg dose of desipramine (Sigma Aldrich, 
Milwaukee, WI) prior to surgery to protect noradrenergic cells from 6-OHDA. They also 
received the same post-operative care as in Experiment 1. 
4.4.1.3 L-dopa injections 
The rats were divided into three injection groups and received identical injection 
procedures as in Experiment 1. Briefly, there were L-dopa 5 mg/kg and L-dopa 10 mg/kg 
groups, and vehicle group. Benserazide (10 mg/kg) was given 15 minutes prior to L-dopa 
injections or some saline injections. Unlike Experiment 1, the rats received the injection 
procedures only over three days during the final days of behavioral testing. 
4.4.1.4 Five choice task 
Apparatus. Five choice task training and testing was conducted in 8 operant boxes 
with aluminum side walls and ceiling, and clear acrylic front and back walls (30.5 cm W 
× 25.4 cm D × 30.5 cm H; Coulbourn Instruments, Whitehall, PA). One of these side 
walls was concave and contained five recessed ports (each 2.5 cm in diameter) that were 
located 3 cm from the grid floor (stainless steel rods 0.5 cm in diameter, parallel, spaced 
1.0 cm apart) and had 3 red LED lights inside to illuminate the port at the appropriate 
time. Additionally, the ports were equipped with infrared beams that detected nose pokes. 
Opposite the concave wall was a 2-watt house light (centered on the wall, 26 cm from the 
floor) and a recessed food cup (centered, 2 cm from the floor) equipped with an infrared 
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beam to detect entries. Each box was housed in a light- and sound-attenuating chamber 
(58.4 cm × 61 cm × 45.7 cm; Coulbourn Instruments) and interfaced with a computer 
using GraphicState 3.1 (Coulbourn Instruments).  
Shaping. In order to train the rats on the five choice task, two shaping procedures 
were conducted. First, rats underwent a magazine-shaping session in which they were 
trained to eat a single grain pellet (45 mg grain tablet, Test Diet, Richmond IN) delivered 
to a food cup located within the conditioning chamber.  A total of 30 pellets were 
delivered at a variable interval (averaging 60 sec) over a 30 min session. After this 
session, all rats reliably retrieved grain pellets from the food cup.	  Second, the rats went 
through a nose poke-shaping session in which they were trained to make a nose poke 
response to port.  All five ports were illuminated and a nose poke to any port resulted in 
the delivery of a grain pellet in the food cup. This daily session was continued until the 
rats met criterion of 80% or more responses over 30 trials with a variable intertrial 
interval (ITI) with an average of 30 sec. After completing the shaping sessions, the rats 
began the baseline training in the five choice task.  
Training. In the baseline task, the beginning of a trial was signaled by the 
illumination of the house light. After 5 sec of constant illumination (i.e., ready period), 
one of the five target ports was illuminated for 500 msec. The rats had a total of 5 sec 
(i.e., response period) from the time the port light was illuminated to make a nose poke 
response to the target port. A correct nose poke resulted in an immediate delivery of a 
grain pellet and darkening of the house light (and the port if still illuminated). Responses 
to the non-target ports (i.e., the other 4 that were not illuminated) during the 5 sec 
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response period were recorded as errors but resulted in no consequences.  In addition, 
nose poke responses to any of the 5 ports during the 5 sec ready period were recorded as 
premature responses but did not have any consequences. The baseline task consisted of 
60 trials in a 30 min session (variable ITI of 30 sec) and each port was illuminated 
equally (i.e., 12 times per session) on a semi-random schedule (i.e. no port was lit more 
than two times consecutively). This procedure was adapted from Holland et al., (2000) 
and Maddux et al., (2007), in which the initiation and termination of the trials were 
independent of the rats’ response.   
Rats were trained to the baseline task gradually. Rats first started on a task where 
the port light was illuminated for 30 sec which allowed the rats 30-sec response period.  
Once the rats reached the criterion (80% trials with correct responses), the port light 
duration was shortened successively to 20 sec, 15 sec, 10 sec, 5 sec, 3 sec, 1 sec, and then 
finally to 500 msec. Regardless of the port light duration, the session time was 30 min 
resulting the number of trials for each program to change. Therefore, total trials started at 
35 (for 30 sec port light) and increased to 60 as the port light duration shortened to 500 
msec. In order to finish training on the 500 msec baseline task, the rats had to reach the 
criterion (80% correct response) twice during 3 consecutive training days. Then, the rats 
received unilateral 6-OHDA MFB lesions, were given two weeks to recover, and then 
retrained on the task to the same criterion as before. 
Re-training and Testing.  In our typical five choice task procedure, rats are briefly 
re-trained on the 500 msec protocol after a given surgery, and are further tested in more 
challenging protocols with higher attentional demands.  However, rats with unilateral 
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dopamine depletion show significant behavioral deficits at 500 msec protocol. Thus, rats 
were re-trained on the task starting from the 30s stimulus duration and subsequent 
protocols as criterion was met. The majority of animals with acceptable lesions was 
unable to complete re-training to perform at 500 msec protocol. Therefore, these rats 
were discontinued from re-training after seven days of sub-criterion (< 80%) performance 
in the same training protocol (e.g., 5 sec port light protocol). Once this occurred, the rats 
were injected with saline or L-dopa and run again in the same training protocol that the 
rats stagnated on to test the possibility that L-dopa could improve the impaired 
performance levels. Rats were tested across three days with an injection of L-dopa or 
saline occurring prior to each session. Performance on these three days was compared to 
the last three days of training prior to the injections. 
4.4.1.5 Immunohistochemistry 
Brain tissue was collected and preserved, processed for TH in an identical manner 
as Experiment 1. The immunohistological staining process was the same except that a 
higher concentration of primary antibody (mouse anti-TH) was used (1:2500).  
4.4.2 Results 
4.4.2.1 Dopamine depletion and lesion verification 
There were 32 rats with 50% or greater dopamine depletion. However, as there 
were so few rats with ≥50% dopamine depletion completing five choice training (n=7; 
mean dopamine depletion: 63%), we chose to focus on the rats unable to complete 
training. Therefore from here on, only data from the rats unable to complete five choice 
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training is presented. All groups showed comparable dopamine depletion of the SNc as 
measured by the optical density method described above [F(2,22) = 0.54, p = 0.59 ; Table 
2]. Furthermore, all groups showed greater than 50% dopamine depletion of the VTA but 
no differences in the level of dopaminergic depletion among these groups [F(2,22) = 
1.44, p = 0.26; Table 4.2]. 
4.4.2.2 Five choice task 
After completing training in the five choice task, rats were given 6-OHDA 
infusions unilaterally into the MFB. Once two-weeks of recovery were complete, rats 
were re-trained using the same pre-surgery training method. The majority of rats were 
unable to re-train down to 500 msec port light protocol in the five choice task post-
surgery (Fig 4.4A). Rats were considered to have failed re-training after 7 days of sub-
criterion performance (< 80%) on the same training protocol. The median protocol they 
remained was at 5 sec port light duration. As these rats showed severe deficits in this 
task, we continued to train the rats for three more days and gave L-dopa (or saline) 
injections 15 minutes prior to training on those three days. Within the vehicle group, half 
of the rats were treated with benserazide and saline while the other half were treated with 
two injections of saline. No differences between these two subgroups existed so they 
were collapsed to form one vehicle group. Performance of these rats on L-dopa (or 
saline) for those three days (on) were then compared to their performance on the last 
three days prior to the injections (off).  
 Performance on and off L-dopa was examined across treatment groups using 
percentage of correct trials. The rate of correct responses when comparing pre-injection 
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vs injection days was differentially affected by the dose of L-dopa injected [F(2,22) = 
4.395, p = 0.025; Figure 4.4B]. While there were no differences in performance between 
groups on the training sessions prior to injection,  [F(2,22) = 0.56, p = 0.58] there was a 
difference in the rate of trials completed correctly in the testing sessions in which L-dopa 
injections were give directly prior [F(2,22)= 13.77, p < 0.001]. Additionally, rats 
receiving L-dopa 10 mg/kg performed significantly fewer correct trials in comparison to 
both rats receiving L-dopa 5 mg/kg and vehicle.  
Because the rats received dopamine depletion unilaterally, we investigated the 
possibility that performance in the five choice task varied by port location. To do this, 
percentage of correct responses were calculated for the extreme left and right ports then 
were renamed the ipsilateral and contralateral ports in reference to the lesion location in 
the rat (Figure 4.4C & 4.4D). If the rat had a left hemisphere lesion, the right-most port 
was considered the bad-side (contralateral) port and the left-most port was considered the 
good-side (ipsilateral) port and vice versa for a right side lesion. A repeated measures 
ANOVA looking at performance pre- and post-infusion in both the good and bad side 
ports was conducted (between-subjects variable: time point; within-subjects variable: port 
location in reference to the lesion). L-dopa did not impair performance across the board 
[F(2,22) = 1.00, p = 0.4], but did impair performance depending on port location [F(1,22) 
= 32.01, p < 0.001] demonstrating that all lesioned rats show a lower correct response 
rate in the port contralateral to the lesion compared to the port ipsilateral to the lesion. 
There was also a trend of an interaction of port location and treatment assignment 
[F(1,22) = 3.46, p = 0.07]. Paired samples t-tests assessing performance with and without 
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injection treatment at each group level demonstrates that saline injection nor low dose of 
L-dopa injection does not change performance in either ports (all ts < 1, all ps> 0.4). 
However, while the high dose of L-dopa does not alter the rate of correct responses in the 
port contralateral to the lesion [t(8) = 0.479, p = 0.65] it does decrease the rate of correct 
responses in the port ipsilateral to the lesion [ t(8) = 3.64, p = 0.007; Figure 4.4D].   
4.4.3 Experiment 2 Discussion 
As the majority of rats were unable to complete re-training in the five choice task, 
rats were assessed in the protocol they were unable to meet criterion on (80% correct 
trials) after seven training sessions. Acute L-dopa injections prior to training in this 
protocol resulted in a dose dependent decrease in the rate of correct responses. This 
overall decrease in correct responses is specifically due to decreased performance on the 
port most ipsilateral to the lesion (i.e., unaffected/good side). The compromised 
performance on the contralateral (i.e., affected/bad side) port was unaffected by L-dopa 
administration. 
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Figure 4.3 Experiment 2 design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Schematic representation of the five choice task with a cue (port light) duration of 500 
msec. B. Experiment 2 design. Rats were trained on a series of task in which the port 
light was successively shortened as the rats showed proficiency in each cue duration 
protocol. After rats were trained on the task and recovered from surgery, the rats were 
retrained on the task. Rats were unable to re-train on the task, and after stagnating on the 
same training protocol for 7 days, rats were given L-dopa injections and then run through 
the same training protocol for three days and performance as assessed.  
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Table 4.2 Dopamine (DA) depletion in the SNc and VTA after 6-OHDA infusion  
  
DA depletion (%) 
  n SNc VTA 
Saline 8 88.88 ± 1.60 72.83 ± 2.80 
L-dopa 5 
mg/kg 8 85.13 ± 1.20 64.95 ± 4.48 
L-dopa 
10mg/kg 9 88.71 ± 4.71 71.07 ± 2.69 
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Figure 4.4 Five choice task performance in 6-OHDA-lesioned rats  
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Figure 4.4 continued 
A. Training progress for all rats. Each bar represents one rate. Bar terminates at the 
training protocol the rat was unable to complete to criterion (i.e. ≥80% correct). B. Mean 
(± SEM) percentage of trials completed correctly. C. Schematic demonstrating the 
contralateral port is the port opposite the lesioned hemisphere and the ipsilateral port 
refers to the port on the same side as the lesioned hemisphere. D. Mean (± SEM) 
percentage of correct trial for the ipsilateral and contralateral port pre-treatment and with 
L-dopa injection.  E. Mean (± SEM) percentage of trials omitted. D. Mean (± SEM)  
premature responses (i.e. responses made during ready period). * p < 0.05, ** p< 0.01 
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4.5 GENERAL DISCUSSION 
These experiments are the first to extensively characterize deficits in attention in a 
rodent 6-OHDA model of PD. While disengagement deficits have been studied 
previously in the 6-OHDA model of PD (Mandel et al., 1990; Schallert & Hall, 1988), 
deficits in selective and sustained attention have not. Here we have demonstrated that 
80% or greater unilateral dopamine depletion leads to profound difficulty in selective and 
sustained attention. While rats were unable to complete re-training to reach baseline 
performance (with 500 msec port light duration) that was achieved prior to 6-OHDA 
lesions, most made it at least half-way through re-training and stagnated with sub-
criterion performance in the training protocol with a 5s port light duration. Furthermore, 
this decrement in performance was lateralized such that performance was specifically 
impaired in trials in which the lit port was contralateral to the lesion. 
The findings from both experiments demonstrate that L-dopa can be acutely 
effective at returning some but not all attentional functions disrupted in this rat model of 
PD. After one injection, disengagement behavior was readily recovered with the same 
dose of L-dopa that recovered motor function of the affected paw. However, as time 
progressed rats receiving this 10 mg/kg dose developed dyskinesias readily. As a result, 
some of the rats treated successfully at Day 1 were unable to be tested at Week 1. But 
when comparing performance from Day 1 to Week 1 solely for the rats still able to be 
tested at Week 1, there is no decreased in efficacy.  Further, the lower dose of 5 mg/kg 
was not successful in returning motor function but does show moderate improvement in 
disengagement behavior at Week 1.  
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Disengagement behavior has previously been shown to be dependent on 
nigrostriatal dopamine as well as SNc dopaminergic projections to the central amygdala 
(Mandel et al., 1990; Schallert & Hall, 1988; Smith, Geissler, Schallert, & Lee, 2013). 
Thus, it was anticipated that L-dopa administration would improve disengagement 
behavior. Because disengagement behavior was improved with the same dose of L-dopa 
as motor function, this adds further evidence that L-dopa use in humans may efficacious 
in improving both attention switching behavior and motor function at the same dosage.   
While 10 mg/kg L-dopa was effective at improving disengagement deficits 
acutely after the first injection, the same dosage resulted in further impairment in already 
sub-optimal performance during the five choice task. This parallels similar research done 
in a non-human primate model of PD. Decamp & Schneider (2004) demonstrated that 
deficits in sustained attention do exist in monkeys exposed to MPTP and that these 
deficits can be exacerbated (Jay S. Schneider, Pioli, Jianzhong, Li, & Bezard, 2013) with 
L-dopa administration.  However it is reasonable to expect that L-dopa would improve 
these functions as dopamine has also been shown to play an integral role in selective and 
sustained attention.  Specifically, dopaminergic input into the medial PFC is integral for 
these aspects of attention (Granon et al., 2000; Winstanley et al., 2010). Further, it seems 
that striatal dopamine and it’s input to the PFC is necessary for proficiency in a selective 
and sustained attention task as shown by profound deficits in accuracy after striatal 
lesions (Belinda J. Cole & Robbins, 1989; Rogers et al., 2001), impaired ability to 
reacquire the task after the lesion has been created (Rodgers et al., 2001), and even 
greater deficits when the striatum and PFC are disconnected ( a Christakou et al., 2001). 
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We see a similarly profound difficulty in reacquiring the task after 6-OHDA infusion. 
Therefore, it was expected that L-dopa would enhance dopamine levels and restore 
functionality of the striatum which would then allow the striatum to successfully mediate 
attention through its cortico-striatal loops ( a Christakou et al., 2001). However L-dopa 
does not improve selective and sustained attention deficits and instead further exacerbates 
these impairments.  
There are several possible reasons for this lack of improvement in five choice task 
performance in unilateral nigrostriatal dopamine depleted rats after L-dopa 
administration. Firstly, L-dopa administration significantly increases extracellular 
dopamine in both hemispheres in a unilateral rat model of PD and increases D1 receptor 
occupancy (Orosz & Bennett, 1992; Robertson & Robertson, 1989). Previously, D1 
receptor have been shown to contribute to attentional function and excessive D1 
stimulation may lead to interference in attentional function. Furthermore, tonic and 
phasic signaling are known to play specific roles in dopaminergic modulation of several 
behavioral functions including reward processing. L-dopa has been shown to increase 
tonic firing, and in mild PD phasic signaling has been shown to be altered (Mouradian et 
al., 1988). Secondly, in addition to dopamine, norepinephrine also mediates attentional 
processes feeding into the prefrontal cortex (Carli, Robbins, Evenden, & Everitt, 1983; 
Newman, Darling, & McGaughy, 2008). Lesions of the dorsal noradrenergic bundle 
result in deficits in a five choice serial reaction time task designed to assess multiple 
aspects of selective, sustained, and divided attention (Carli et al., 1983). In PD, there is 
also a decrease in the presence of norepinephrine due to degradation of the locus 
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coeruleus (Chan-Palay & Asan, 1989) that occurs early in the progression of PD. 
However in our experimental preparation for Experiment 2 that examined five choice 
task performance, a noradrenergic blocker, desipramine was given prior to surgery to 
protect noradrenergic fibers. Further, it has been shown that the administration of L-dopa 
(the precursor to both dopamine and norepinephrine) not only increases dopamine levels 
but also norepinephrine levels albeit at a lower rate (Wiegand & Perry, 1961). Dopamine 
and norepinephrine levels show an inverted U-shaped relationship with attentional 
performance. Atomoxetine enhances the availability of both dopamine and 
norepinephrine in the PFC (Bymaster et al., 2002) and at moderate doses improves PFC-
mediated attentional processes but causes impairments in these attentional processes at 
higher doses (Gamo, Wang, & Arnsten, 2010; Newman et al., 2008; Robinson et al., 
2008). Therefore, it is plausible that the systemic administration of L-dopa in this model 
in which noradrenergic fibers were protected (via desipramine) that systemic L-dopa 
administration increased norepinephrine to an undesirable level which further disrupted 
lesion-induced selective and sustained attention deficits. 
To further address the possibility that this experiment may have simply utilized L-
dopa doses that were too high, we injected an even lower dose of L-dopa (2.5 mg/kg) to a 
separate group of rats with unilateral dopamine lesions and observed their performance 
on the five choice task. If it were the case that L-dopa could be useful for improving five 
choice performance and we were simply giving too much, a lower dose would have been 
effective.  However, this low dose of L-dopa (2.5mg/kg) neither improved nor worsened 
 102 
performance in this five choice task. Thus, this demonstrates that it is not the case that the 
negative impact of L-dopa was due to the dose being higher than necessary. 
Due to the inability of a range of doses of L-dopa to improve performance and the 
pattern of deficits seen in the five choice task, it may be that the enhancement of 
dopamine (and possibly norepinephrine) in the intact hemisphere is causing these 
increased attentional deficits with L-dopa administration. While there is a decrement in 
performance from baseline with L-dopa injection, this decrement does not occur 
uniformly across all five ports in the five choice task. Specifically, accuracy data from the 
left-most and right-most ports (converted to ipsilateral and contralateral ports in relation 
to lesioned hemisphere) revealed that the impairment in performance on L-dopa is due to 
decreased accuracy in trials in which the port ipsilateral the lesion hemisphere were lit. 
Performance in the port ipsilateral to the lesioned hemisphere was significantly decreased 
while leaving contralateral port performance unchanged with L-dopa. And as dopamine’s 
effect on attention and other cognitive tasks often show an inverted-U relationship (Gamo 
et al., 2010; Robinson et al., 2008; Vijayraghavan, Wang, Birnbaum, Williams, & 
Arnsten, 2007), this deficit suggests that a high dose L-dopa may be specifically 
impairing the ability of the intact hemisphere to mediate attentional function in the five 
choice task by enhancing dopamine to a detrimental level. 
However, these deficits in selective and sustained attention may not simply be due 
to an increase in the neurotransmitters and brain areas directly related to L-dopa. 
Selective and sustained attentional is dependent on many neurotransmitters  (e.g. 
dopamine, acetylcholine, norepinephrine, serotonin) and many brain areas which 
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commonly receive dopaminergic input from the SNc or striatum (T. W. Robbins, 2002). 
For example, in addition to dopamine and norepinephrine, the basal forebrain cholinergic 
system is highly important for selective and sustained attention and receives 
dopaminergic input from the SNc (McGaughy et al., 2002; Muir, Page, Sirinathsinghji, 
Robbins, & Everitt, 1993; Risbrough et al., 2002).  Thus repairing such complex 
attentional function governed by such a large network may be unachievable simply by 
enhancing dopaminergic tone with L-dopa.    
Because giving infusions of 6-OHDA into the MFB results in dopaminergic cell 
loss in the VTA in addition to the SNc, it should be considered whether these deficits are 
not solely attentional deficits but are partly due to reduced motivation. Previously, 
dopaminergic lesions of the VTA and nucleus accumbens have led to marked decreases 
in reward-seeking or motivated behavior (Adamantidis et al., 2011; Fields, Hjelmstad, 
Margolis, & Nicola, 2007; Weinberg, Nicholson, & Currie, 2011). Further, lesions of the 
SNc alone can decrease the number operant responses to obtain sucrose solutions, but in 
a sucrose preference test SNc-lesioned rats show no decrease in sucrose preference 
(Favier et al., 2014) . This suggests that while these rats show no impairments in reward 
processing, they do show impairments in motivation to pursue the reward. Therefore it is 
possible the deficits seen in the five choice task could be due in part to decreases in 
motivation as food rewards are used as motivation for performing the task. However, it is 
unlikely that these difficulties in re-training in the five choice task are due to decreased 
motivation. Most rats unable to complete training in the five choice task were able to 
complete at least half of the training protocols with 80% correct trials or better and 
 104 
collected the food rewards for these trials. Furthermore, while these rats may have had 
decreases in motivation levels, motivation to work for a food reward may have been 
enhanced to a non-deficit level due to the mild food restriction all rats were maintained 
on during the experiment. 
One major difference between Experiment 1 and Experiment 2 is the use of 
desipramine to protect noradrenergic fibers in Experiment 2 but not Experiment 1. As 
noradrenergic fibers neighbor dopaminergic fibers of the MFB (Jones & Moore, 1977), it 
is plausible that in Experiment 1 (in which desipramine was not used), there was 
norepinephrine depletion as a consequence of 6-OHDA infusion into the MFB. 
Therefore, it cannot be ruled out that the differences in L-dopa efficacy seen from 
Experiment 1 to Experiment 2 are due to norepinephrine. However, while it is a plausible 
argument, it seems unlikely that disengagement behavior would respond differently to L-
dopa in a preparation that preserved norepinephrine. Previously, we have demonstrated 
that D1 receptors within the central amygdala are necessary for modulating the 
attentional component of disengagement behavior (Smith et al., 2013). Furthermore while 
norepinephrine has been implicated in attention, attention switching in humans has been 
shown to be mainly supported by dopamine and dopaminergic areas such as the striatum 
(Dove, Pollmann, Schubert, Wiggins, & Yves von Cramon, 2000; Luna et al., 2001; 
Sohn, Ursu, Anderson, Stenger, & Carter, 2000; Vaidya et al., 1998; Volkow, Fowler, 
Wang, Ding, & Gatley, 2002). Therefore, this gives us reason to conclude that 
norepinephrine is less crucial for attention switching compared to other more complex 
attentional functions. 
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 These findings demonstrate that L-dopa is not sufficient for treating multiple 
types of attentional deficits in a rat model of PD. While the same dose of L-dopa is able 
to restore basic attentional switching function and motor function in a unilateral 
dopamine depletion model of PD, L-dopa administration was not able to restore more 
complex attentional function (i.e. selective and sustained attention). In addition to 
continuing to study the use of L-dopa to treat  other cognitive and attentional deficits, 
more studies must be conducted to understand how dopamine transmission facilitates 
attention, and how L-dopa affects dopamine transmission in the context of attention. 
Furthermore, future work should also assess the possibility that attentional or cognitive 
functions such as selective and sustained attention that are reliant on many systems and 
neurotransmitters may be better treated with non-dopaminergic drugs that either target 
different neurotransmitter systems or enhance global neural function. 
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Chapter 5: An assessment of the ability of methylene blue to reduce 
behavioral and dopamine deficits in a 6-OHDA model of Parkinson’s 
disease 
5.1 ABSTRACT 
Recently, alternative drug therapies for Parkinson’s disease (PD) have been 
investigated because of several shortcomings of traditional dopamine-based therapies 
including difficulty treating cognitive and attentional dysfunction in PD. A promising 
therapeutic avenue is to target mitochondrial dysfunction in PD. One way to improve 
mitochondrial function is with the application of USP methylene blue (MB), an 
antioxidant and metabolic enhancer. MB has been shown to improve cognitive function 
in both intact rodents and rodent disease models. Therefore, we have investigated the 
ability of MB to treat attentional deficits as well as motor deficits in a rat 6-
hydroxydopamine (6-OHDA) model of PD. MB also has neuroprotective capabilities that 
have specifically been demonstrated after neurotoxic insult so we also assessed the ability 
of MB to provide neuroprotection in this model. Through these experiments we have 
shown that daily administration of MB (4mg/kg) does not improve attentional processes 
such as attention switching (i.e. disengagement behavior) and selective and sustained 
attention (assessed using a five choice task; Experiment 2). Furthermore, MB was able to 
provide moderate neuroprotection in the SNc but this neuroprotection is dependent on the 
amount of 6-OHDA infused into the medial forebrain bundle. In conclusion, MB is not 
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dopaminergic fibers in this model. Future work should continue to study and optimize the 
abilities of MB for the treatment of PD.  
5.2 INTRODUCTION 
Currently, Parkinson’s disease (PD) is most commonly treated pharmaceutically 
with levodopa (L-dopa), which while very effective at alleviating motor symptoms, has 
its shortcomings. For example, levodopa has been shown to be ineffective in restoring 
certain cognitive functions affected in PD (Cools et al., 2003; Dujardin, Degreef, Rogelet, 
Defebvre, & Destee, 1999; Lewis et al., 2005; Robbins & Cools, 2014; Schneider et al., 
2013). Specifically, attentional processes such as attentional shifting (both task or rule/set 
shifting) and selective and sustained attention are common in PD and show varied 
responses to L-dopa. For example, the reduced ability to shift attention to a new rule or 
task in PD patients is improved with L-dopa (Cools et al., 2003, 2002). Among patients 
with mild PD, L-dopa has no impact on selective and sustained attention (Lewis et al., 
2005; Moustafa et al., 2008). In addition to the conflicting effects of L-dopa on 
attentional functions, chronic L-dopa administration in patients and in animal models of 
PD can result in the development of L-dopa induced dyskinesias and impulse control 
disorders (Leeman & Potenza, 2011; Poletti & Bonuccelli, 2013; Rajput et al., 2002; 
Weintraub, 2008). For these reasons it is pertinent to investigate alternative treatments for 
PD.  
Here we have investigated the possibility of using methylene blue (MB) to treat 
behavioral and neuronal deficits in a rat model of PD. MB is an antioxidant compound 
that also increases cell metabolism through the enhancement of mitochondrial activity at 
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the cytochrome oxidase complex (Lindahl & Öberg, 1961; Scott & Hunter, 1966; 
Visarius et al., 1997). MB has been shown to enhance cognitive function in both intact 
and disease-modeled rodents. A low dose of MB can facilitate learning and memory of 
intact rats in both appetitive and aversive contexts by increasing mitochondrial 
respiration (Callaway, Riha, Bruchey, Munshi, & Gonzalez-Lima, 2004; Callaway, Riha, 
Wrubel, McCollum, & Gonzalez-Lima, 2002; Martinez, Jensen, Vasquez, McGuinness, 
& McGaugh, 2013). Additionally, chronic MB administration enhanced spatial learning 
in a mouse model of Alzheimer’s disease that exhibited mitochondrial dysfunction 
(Medina, Caccamo, & Oddo, 2011). Within the context of PD, MB was shown to restore 
motor function and preserve striatal cellular function in a rotenone model of PD (Wen et 
al., 2011), but MB’s effects on cognitive functions in PD models are unknown.  
Mitochondrial dysfunction is a common property of neurodegeneration seen in 
humans as well as animal models of neurodegenerative diseases including PD (Fukae et 
al., 2007; Janetzky et al., 1994; Kupsch et al., 2014; Mizuno et al., 1998). Therefore, MB 
also has the potential to be an effective neuroprotective agent by (1) enhancing cell 
metabolism and hence boosting the health of the cell and (2) reducing reactive oxidative 
species within and around the cell (Poteet et al., 2012). Oxidative stress is the primary 
cause of dopaminergic apoptosis in PD (Kanthsamy et al., 1994; Pallanck & Greenamyre, 
2006; Schapira, 2008) thus potentially making MB a viable route of neuroprotection in 
PD. As proof of concept, infusion of MB into the striatum directly after an infusion of the 
neurotoxin rotenone to the same site significantly attenuated cell loss at the lesion site 
(Rojas et al., 2009) 
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 However, as of yet, the ability of MB to restore cognitive and motor deficits and 
simultaneously provide neuroprotection in an animal model of PD has not been shown in 
the same experimental preparation. Therefore we have devised two experiments to 
examine the behavioral and neuronal effects of MB in a unilaterally dopamine depleted 
rat model of PD.  In the first experiment, rats were tested for motor function and one type 
of attentional function (i.e., attentional disengagement) after MB treatment. In the second 
experiment, the impact of MB administration was assessed on more complex attentional 
function in a five choice task used to assess several aspects of attention including 
selective, sustained, and divided attention. In both experiments, the effects of MB on 
dopamine cell loss were measured. 
5.3 METHOD 
5.3.1 Subjects 
Ninety-nine Sprague Dawley rats (350-450g; Experiment 1: N = 24; Experiment 
2: N = 75; Harlan) were housed on a reversed 14 hour on: 10 hour off light cycle with 
lights turning off at 10 AM.  In experiment 1, rats had ad libitium access to food for the 
duration of the experiment however, water access was periodically restricted for the 24 
hours prior to disengagement testing only.  In experiment 2, rats were food restricted to 
90% of free-feeding weight for the duration of training and testing during the five choice 
task, and water access was also periodically restricted for 24 hours prior to 
disengagement testing. All behavioral training and testing occurred during the dark phase 
of the light cycle.  All experiments were conducted according to the National Institutes of 
Health’s Guide for the Care and Use of Laboratory Animals and all protocols were 
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approved by the Institutional Animal Care and Use Committee at The University of 
Texas at Austin.  
5.3.2 Surgery 
All rats underwent surgery to induce unilateral dopaminergic depletion or sham 
surgery. First, the rats were anesthetized using 2-5% isoflurane gas (Abbott Laboratories) 
and were placed into a stereotaxic frame (Kopf Instruments, Tujunga, CA). After a burr 
hole was created, 1.0µl (Experiment 1) or 0.6 µl (Experiment 2) of 7µg/µl 6-
hydroxydopamine (6-OHDA; Sigma Aldrich, Minneapolis, MN) in 0.1 M phosphate 
buffered saline with 0.1% ascorbic acid was delivered into the medial forebrain bundle 
(AP= -3.3, ML = ±1.7, DV = -8.6) at a rate of 0.1µl per minute via 2 µl Hamilton syringe 
connected to Harvard apparatus infusion pump. Once the infusion was finished, the 
needle was slowly removed, the skull was cleaned, and the skin was sutured closed. Rats 
in Experiment 2 (but not Experiment 1) were also given 25 mg/kg dose of desipramine 
(Sigma Aldrich, Milwaukee, WI) prior to surgery to protect noradrenergic cells from 6-
OHDA. At the completion of surgery, all rats received a subcutaneous injection of 
buprenorphine hydrochloride (0.01 mg/kg; TW Medical, Denver, CO) and were placed 
on a heating pad and returned to their home cage once awake. 
5.3.3 Daily methylene blue feedings 
Four mg/kg methylene blue (Faulding Pharmaceuticals; Aguadilla, PR) was given 
orally between 10 and 11 AM daily. Methylene blue (in 10% sucrose water) was mixed 
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with 2.6 g crushed Nilla® wafers to create a paste. The vehicle solution (10% sucrose 
water) had blue food coloring (Food, Drug, and Cosmetics Blue No.1) added to it.  
5.3.4 Behavioral Tests: Experiment 1 
5.3.4.1 Cylinder test 
This test examines the use of the forelimbs since rats naturally explore the 
cylinder by rearing and contacting the cylinder wall with the forepaws. So, rats were 
placed into a Plexiglas cylinder stood on its side (20 cm in diameter and 30 cm in height). 
Rats were placed into the cylinder and spontaneous forepaw touches to the cylinder 
during rears/exploration of the vertical wall were recorded. Paw touches were scored in 
accordance with protocol described in Schallert et al., 2000. If only one paw was placed 
on the cylinder, it was recorded as independent use of that limb. If both paws were placed 
on the cylinder simultaneously, or if one paw was placed on the wall and then the other 
was immediately placed on the wall and alternated with the other limb during stepping, it 
was recorded as simultaneous use of both limbs.  A total of 20 instances of left, right, and 
simultaneous (both) forelimb use was recorded during exploration of the cylinder wall in 
either horizontal or vertical planes. The rat was removed from the cylinder either after 20 
instances of forelimb use or 5 minutes has passed. As the rat contacted the cylinder, the 
use of forepaws was recorded (left, right, or both) in accordance with previous 
methodology (Schallert, et al., 2000). Rats with unilateral dopamine depletion of the 
nigrostriatal pathway typically demonstrate a preference for using the paw ipsilateral to 
the lesion and use the paw contralateral very little when contacting the cylinder (Tillerson 
et al., 2001). Therefore, preference for the contralateral paw was calculated thusly: 
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Contralateral paw touches + (.5) both paw touches 
Total number of touches (ipsi + contra+ both) 
5.3.4.2 Disengagement test 
Disengagement refers to the ability to discontinue an ongoing behavior to attend 
to perioral stimulation. Disengagement testing was conducted by restricting access to 
water for the twenty-four hours prior to testing. Rats were first tested for basic orienting 
behavior by stimulating on both sides of the face with a cotton swab out of the rats’ sight 
to ensure no somatosensory deficits existed. During disengagement testing, rats were 
allowed to drink from a water spigot through a hole in the back wall of the home cage.  
As rats drank, an experimenter stimulated both sides of the face and whiskers using a 
cotton swab. If the rat stopped drinking to attend to the stimulation, this was recorded as a 
successful disengagement. If the rat continued to drink and did not stop to attend to the 
stimulation, it was recorded as an unsuccessful disengagement trial. Both sides were 
stimulated a total of 5 times with varying order. Disengagement was quantified by 
recording the percentage of the 5 trials in which disengagement occurred (5/5 = 100).   
5.3.5 Behavioral Tests: Experiment 2 
In addition to conducting the cylinder and disengagement tests, several other tests 
were conducted to assess motor and attentional function. These are described below. 
5.3.4.1 Vermicelli handling test 
The vermicelli handling test originally developed by Allred, et al. (2008) was 
used to assess forepaw function. Rats were trained to eat 7 cm long strands of uncooked 
vermicelli pasta (semolina pasta). Once rats readily ate the pasta, rats were given pasta 
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strands to eat in a testing cage and were filmed for 4 trials. An experimenter blind to the 
conditions scored the rats’ behavior using video playback in half-speed. The 
experimenter recorded the number of paw adjustments made by both paws, the time it 
took to eat the entirety of the pasta, and abnormal behaviors exhibited during the trial 
such as touching the strand of pasta to the cage floor (Allred et al., 2008).   
5.3.4.2 Five choice task 
Apparatus. Five choice training and testing was conducted in 8 operant boxes 
with aluminum side walls and ceiling, and clear acrylic front and back walls (30.5 cm W 
× 25.4 cm D × 30.5 cm H; Coulbourn Instruments, Whitehall, PA). One of these side 
walls was concave and contained five recessed ports (each 2.5 cm in diameter) with each 
of the recessed ports 3 cm from the grid floor (stainless steel rods 0.5 cm in diameter, 
parallel, spaced 1.0 cm apart) and had 3 red LED lights inside to illuminate the port at the 
appropriate time. Additionally, the ports were equipped with infrared beams that detected 
nose pokes. Opposite the concave wall was a 2-watt house light (centered on the wall, 26 
cm from the floor) and a recessed food cup (centered, 2 cm from the floor) equipped with 
an infrared beam to detect entries. Each box was housed in a light- and sound-attenuating 
chamber (58.4 cm × 61 cm × 45.7 cm; Coulbourn Instruments) and interfaced with a 
computer using GraphicState 3.1 (Coulbourn Instruments).  
Shaping. In order to train the rats on the five choice task, two shaping procedures 
were conducted. First, rats underwent a magazine-shaping session in which they were 
trained to eat a single grain pellet (45 mg grain tablet, Test Diet, Richmond IN) delivered 
to a food cup located within the conditioning chamber.  A total of 30 pellets were 
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delivered at a variable interval (averaging 60 sec) over a 30 min session. After this 
session, all rats reliably retrieved grain pellets from the food cup.	  Second, the rats went 
through a nose poke-shaping session in which they were trained to make a nose poke 
response to the ports.  All five ports were illuminated for 30 sec and a nose poke to any 
port during this time resulted in the delivery of a grain pellet in the food cup. This daily 
session was continued until the rats met criterion of 80% or more responses over 30 trials 
with a variable intertrial interval (ITI) of 30 sec. After completing the shaping sessions, 
the rats began training in the five choice task.  
Training and testing. Prior to surgery rats were trained to proficiency on the five 
choice task adapted from Holland, Han, & Gallagher (2000) and Maddux, Kerfoot, 
Chatterjee, et al. (2007) and described in Olshavksy et al., (2014).  Rats were first trained 
on an easier protocol in which the port light duration was 30s. Once rats became 
proficient (80% correct response rate), the rats progressed to the next protocol with a 
shorter port light duration (i.e., 20, 15, 10, 5, 3,1, 500 msec). In the baseline task, a trial 
began with the house light illuminated to signal a 5 sec ready period. At the end of the 
ready period, one of the five recessed ports illuminated for 500 ms. Rats had a five 
second response period beginning with the port light illumination to make a nose poke 
into the correct port in order to receive a grain pellet into the food cup. Rats were allowed 
to nose poke incorrectly during the response period but if a correct response was not 
made within the 5 sec, the trial was ended, signaled with termination of the house light. 
After two training sessions (within a three day period; one training session per day) with 
80% correct or better response rate, rats received surgery.  Two weeks post-surgery, rats 
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began retraining in the same manner as before starting with the port light duration of 30 
sec and successively moving to shorter port light durations exactly as prior to surgery. 
Once criterion was met on the 500 msec protocol again, rats moved onto the testing 
phase. Due to lesion severity, some rats were unable to re-train down to the 500 msec 
protocol. If the rats were unable to reach 80% correct response rate in a particular 
protocol for 7 consecutive days, training was then discontinued 
Rats that completed retraining were tested in three versions of the five choice task 
in which the task was changed to increase attentional load in various manners:  (1) the 
port light duration was shortened from 500 msec to 100msec, (2) the ready period 
between the start of the trial and the port light illumination varied from the previously 
fixed period of 5 sec to 1, 5, and 9 sec, and (3) the previously steady house light now 
blinked during the ready period.  
5.3.6 Immunohistochemistry 
After testing was concluded, rats were given an overdose of pentobarbital (86 
mg/kg) and phenytoin (11 mg/kg) mix (Euthasol by Virbac Animal Health) and then 
were perfused transcardially with 0.9% saline followed by 4% paraformaldehyde (PFA) 
in 0.1 M phosphate buffer (PB). The brains were extracted and placed into 20% sucrose 
PFA solution overnight and were frozen on dry ice and then packaged for storage in the -
80ºC freezer. 
 Brains were sliced at 30µm using a sliding microtome and sections containing the 
midbrain dopamine regions were collected in four series. One series was used for tyrosine 
hydroxylase (TH) staining and an adjacent series was used for Nissl staining. For the TH 
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staining, the tissue was first treated with 0.3% hydrogen peroxide in PBS. Then the tissue 
was placed into a 6% normal horse serum (NHS) in PBS with 0.3% Triton (PBST) for 
one hour after rinsing in PBS.  Immediately afterwards the tissue was incubated in 0.15% 
PBST solution containing 3% NHS and mouse TH antibody (1:5000, ImmunoStar, 
Hudson, WI) for 72 hours at 4 ºC.  After rinsing, the tissue was incubated with 
biotinylated horse anti-mouse IgG (1:250, Vector Laboratories) for 1 hour and then with 
avidin-biotin conjugate (PK-6100, Vector Laboratories) for 1 hour, and color reacted 
using 3,3-diaminobenzidine (DAB; Sigma Aldrich).   
Once the TH-stained tissue was mounted and cover slipped, TH density of the 
substantia nigra (SNc) and ventral tegmental area (VTA) were measured. 
Photomicrographs of sections were taken using a microscope (Olympus BX61) at a 
magnification of 10x. Optical Density was measured (Image J) to assess the density of 
TH staining as a measure of dopaminergic enervation. TH density was assessed by 
placing a circle with a radius of 100 µm over the SNc and VTA. Two samplings of each 
structure using this circle were taken at levels 36-39 in relation to the Swanson Rat Atlas 
(Swanson, 2003).  
5.3.7 Experimental designs 
5.3.7.1 Experiment 1: The impact of daily methylene blue on motor function, 
disengagement behavior, and lesion severity. 
 
All rats received 6-OHDA infusions unilaterally and were assigned to one of three 
treatment groups (see Figure 1a). One group began a daily feeding of MB one week prior 
to surgery and continued for the two weeks post-surgery (n=8). A second group was 
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exposed to MB only for the two weeks post-surgery and was given the vehicle for the 
week prior to surgery (n=8). The third group received the vehicle for the week prior and 
the two weeks after surgery (n=8) to examine the possibility that MB may provide more 
neuroprotective benefit if given prior to neurotoxic insult. All rats were tested for motor 
(cylinder test) and disengagement function two weeks post-surgery and 1 hour after 
MB/vehicle feeding. Then, MB/vehicle were discontinued for two-weeks and rats were 
tested again to assess any potential neuroprotective/long-lasting impact on behavioral 
deficits. Once testing was complete, rats were euthanized, and brains were extracted, 
preserved, and processed for TH immunohistochemistry. 
5.3.7.2 Experiment 2: Assessment of neuroprotection of daily methylene blue after a 
smaller neurotoxic insult and its impact on associated attentional dysfunction  
All rats were first trained on the five choice task (Figure 1b). Once the five choice 
task was mastered, rats had unilateral infusions of 6-OHDA or sham into the MFB.  In 
this experiment, a smaller amount of 6-OHDA was infused with the intent of creating a 
less severe lesion to better model mild-moderate PD in which most attentional 
dysfunctions are reported (Filoteo et al., 1997; Hornykiewicz, 1974; Zhou et al., 2012a). 
Furthermore, a sham lesion group was added as a reference group for the performance 
levels expected in intact rats. Therefore, it was a 2 x 2 design with lesioned and sham 
groups receiving either MB or vehicle treatments (Sham + Vehicle: n = 11; Sham + MB: 
n = 11; Lesion + Vehicle: n = 19;  Lesion + MB: n = 19). MB/Vehicle feedings began the 
day after surgery for all conditions. Two weeks post-surgery, motor and disengagement 
deficits were also assessed in these rats. Motor deficits were assessed using both the 
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cylinder test and the vermicelli handling test. Then, rats began re-training on the five 
choice task. Once training was complete, rats underwent 3 days of testing in 3 different 
attentional challenges. However, not all rats were able to complete post-surgery re-
training. These rats were discontinued from training after 7 days of sub-criterion 
performance (< 80% correct trials) on the same training protocol. Once behavioral testing 
was complete, rats were euthanized, and brains were extracted, preserved, and processed 
for TH immunohistochemistry. 
5.4 EXPERIMENT 1 RESULTS 
5.4.1 Dopamine depletion 
Dopaminergic depletion was determined by quantifying TH staining and 
calculating the percentage of dopamine depletion by comparing the lesion side to the 
intact side for each rat. A value of 100% signifies complete dopamine depletion on the 
lesioned side while a value of 0% indicates no dopamine depletion. Analyses of 
percentage dopamine depletion were conducted on SNc and VTA (Figure 5.2). MB 
treatment either before or after the 6-OHDA lesions did not attenuate dopamine loss in 
the SNc [F(2,21) = 0.33. p = 0.73] and VTA [F(2,21) = 0.003, p = 0.99] as all three 
groups showed comparable dopamine depletion on the lesioned side. 
5.4.2 Cylinder test 
In order to assess paw preference in the cylinder, paw usage was calculated and 
one-sample t-tests were conducted to evaluate if the use of affected paw was at a chance 
level (50%). It was expected that MB administration would recover motor function, 
however this was not the case. At 2 weeks post-surgery, there was no discernable impact 
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of MB (when on board) as rats in all three groups used their contralateral/affected paws 
significantly less (Figure 5.3A, left panel).  All groups showed significantly lower levels 
of contralateral paw use compared to 50% level [Vehicle: t(7) = 5.154, p = 0.001; MB 
Pre & Post: t(7) = 4.467, p = 0.003; MB Post Only: t(7) = 2.830, p = 0.025]. This same 
trend continued when tested 2 weeks after cessation of daily MB feedings. Once again, 
all three groups continued to show a less than chance usage of the bad paw [Vehicle: t(7) 
= 6.222, p < 0.001; MB Pre & Post: t(7) = 3.707, p = 0.008; MB Post Only: t(7) = 4.608, 
p = 0.002; Figure 5.3A, right panel].  
5.4.3 Disengagement test 
As is the case with unilateral dopamine depletion, disengagement behavior was 
only impaired on the side contralateral to the lesion. MB on-board (two weeks post-
surgery) significantly improved disengagement behavior on the side contralateral to the 
lesion (Figure 3B). Planned comparisons of the two treatment groups against the vehicle-
treated group reveal a significant improvement in disengagement behavior in the MB post 
group [t(14) = -2.84, p = 0.026; Figure 5.3B left panel] but not the MB pre+ post group [ 
t(14) = -1.655, p = 0.12].  At wash-out test (2 weeks after the last MB treatment), the 
disengagement levels among MB groups decreased a little and similar analyses revealed 
no significant differences in disengagement differences as a function of MB 
administration (all ps > 0.2; Figure 5.3B, right panel). 
  
 120 
Figure 5.1 Experimental Designs 
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Figure 5.2 Dopamine depletion in the substantia nigra pars compacta (SNc) and ventral 
tegmental area (VTA)  
 
 
Mean (± SEM) dopamine depletion on the hemisphere that received a unilateral 6-OHDA 
MFB infusion in comparison to the intact hemisphere for the substantia nigra pars 
compacta (SNc) and ventral tegmental area (VTA). There were no differences in 
dopamine depletion as a consequence of group assignment. All ps > 0.05.  
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Figure 5.3 Motor and disengagement function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Mean (± SEM) bad (contralateral) paw use in contacting the cylinder walls during 
exploration two weeks post-surgery with MB on board and two weeks after discontinuing 
MB/vehicle treatment. All groups showed decreased usage of the bad paw compared to 
chance level (50%). B. Mean (± SEM) disengagement behavior on the side contralateral 
to the 6-OHDA lesion two weeks post-surgery and two weeks after discontinuing MB or 
vehicle treatment. * p < 0.05, ** p < 0.01  
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5.5 EXPERIMENT 2 RESULTS 
5.5.1 Dopamine depletion 
TH density was measured in both the SNc and the VTA. The optical density was 
measured for both the intact and lesioned sides (averaged across 4 sections, 150 µm apart 
as done in Experiment 1) and then the percentage of dopamine depletion was calculated. 
A value of 100% signifies complete dopamine depletion on the lesioned side while a 
value of 0% indicates no dopamine depletion.  
 Simply by looking at the dopamine depletion measure, it is apparent that there is a 
proportion of rats in both lesion groups (i.e., lesion + vehicle and lesion + MB) with 
minimal dopamine depletion that is within the range of what is seen among sham rats 
(Figure 5.4). This seems to be a common property of 6-OHDA lesions in that either a 
large lesion is created or a small or no lesion is created. And instead of 6-OHDA dose 
having a linear relationship with lesion size, it affects the ‘hit rate’ or the amount of 
successful lesions. Therefore, as we used a moderate/small dose of 6-OHDA compared to 
what was used in Experiment 1, we had rats with severe dopamine depletion and rats with 
little-to-no dopamine depletion. In order to account for the unsuccessful lesions, the 
optical density for the lesioned side was plotted as a function of the intact side optical 
density for the SNc (Figure 5.5A) and the VTA (Figure 5.5C). Then, the distance 
(residuals) of each lesioned rat from the best-fit line for the sham groups (collapsed 
across treatment) was calculated. Rats in the lesion group with a residual no different 
than that of the sham groups (within the 95% confidence intervals for the sham group) 
were considered to have lesion size that was indistinguishable from rats with sham 
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lesions. Six rats from both lesion groups met this exclusion criterion and these rats were 
excluded from further analyses.  
When looking solely at the significantly different residuals for both lesion groups 
in the SNc (Figure 5.5B; shaded area represents 1 standard error), it is apparent that the 
two lesion groups have different residual patterns. When an independent samples t-test is 
conducted on these two samples, the mean residual for the lesion + vehicle group is 
significantly greater than the mean residual for the lesion + MB group [t(24) = 2.20, p = 
0.013]. Thus, while still significantly different from the sham groups, the lesion + MB 
has a significantly smaller mean residual demonstrating that there is a decrease in lesion 
severity with MB administration.  
However, taking the same approach to dopamine depletion in the VTA does not 
reveal the same pattern (Figure 5.5D). After accounting for lesioned rats with the same 
residual to the best-fit line as the sham groups, both groups show overlapping residuals 
suggesting that there is no difference in VTA dopamine depletion as a function of MB.  
5.5.2 Motor function 
Two weeks post-surgery all rats were tested in both the cylinder and vermicelli handling 
tasks for motor impairments. Both tests demonstrate a motor deficit due to lesion and no 
recovery of function with MB. In looking at performance in the cylinder test (Figure 
5.6A) using one sample t-tests, sham groups show normal chance (50%) usage of the 
contralateral paw [sham + veh: t(11) = 0.33; sham + MB: t(10) = 0.32, ps > 0.70] while 
both lesions groups show significantly less than chance usage of the contralateral/affected 
paw [lesion + veh: t(12) = 4.21; lesion + MB: t(12) = 4.58, ps ≤ 0.001]. Furthermore, 
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when examining the relationship of the independent variables (surgery and treatment 
assignment) using a 2 x 2 ANOVA, there is a significant effect of surgery [F(1,45) = 
19.02, p < 0.001] but no significant effect of treatment or an interaction of the two 
variables [treatment: F(1,45) = 0.01, p = 0.92; interaction: F(1,45) = 0.004, p = 0.95]. 
Both lesions groups show decreased paw usage of the affected (contralateral) paw 
compared to both sham groups.  
Examining paw adjustments made by both paws in the vermicelli handling task 
yields similar data. Firstly, while all rats were able to consume pasta in a reasonable 
amount of time, rats that received 6-OHDA were slower at consuming the pasta (M = 
21.0 sec, SEM = 2.1) than sham rats (M =15.1 sec, SEM = 1.16). However, there were no 
differences in pasta consumption as a consequence of MB administration. While 
consumption latency is a useful measure, a more sensitive measure is the quantification 
of paw adjustments made while eating the pasta. Here we saw that lesion rats overall 
regardless of MB treatment exhibited more paw adjustments of the ipsilateral paw that 
sham rats (Figure 5.6B).  A 2 x 2 x 2 mixed-design ANOVA was conducted with the 
between-subjects variables of surgery and MB treatment, and the within-subjects variable 
of paw sides. There was an overall difference in the amount of paw adjustments made 
between two paws [ipsilateral vs. contralateral; F(1, 41) = 13.60, p < 0.001] and also 
between the rats with 6-OHDA and sham lesions [lesion vs. sham; F(1, 41) = 7.31, p = 
0.01]. However, these differences are mainly driven by the increased use of unaffected 
paw among lesioned rats as seen by the interaction effect of paw side and surgery 
condition [F(1,41) = 9.22, p = 0.004]. Looking at solely contralateral/affected paw use in 
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the vermicelli handling test, surgery status does not impact the number of paw 
adjustments made while consuming the dry pasta [F(1,41) = 0.05, p = 0.83]. However 
when only examining use of the paw ipsilateral to the lesion (unaffected paw), there is a 
significant effect of lesion demonstrating that lesioned rats commit more ipsilateral paw 
adjustments than their sham counterparts [F(1,41) = 5.38, p = 0.025]. This suggests that 
in order to facilitate successful pasta consumption, lesioned rats increased the amount of 
paw adjustments made by the unaffected paw. Furthermore, this corroborates findings 
from the cylinder test in which the rats relied more on the unaffected forelimb to contact 
the cylinder wall.  
5.5.3 Disengagement test 
In addition to testing motor function two weeks post-surgery, the impact of 
dopamine depletion and MB treatment on contralateral disengagement behavior was also 
evaluated (Figure 5.6C). A 2 x 2 ANOVA with between-subjects variables of surgery and 
treatment was used to assess disengagement behavior on the side contralateral to the 
lesion. This ANOVA revealed a significant effect of surgery condition [F(1,45) = 7.53, p 
= 0.009], but not an effect of MB treatment [ F(1, 45) = 0.35, p = 0.85; Figure 6C] on 
disengagement behavior.   
5.5.4 Five choice task 
Although all rats received re-training in the five choice task after surgery, not all 
rats were able to complete training and move on to the testing phase. Of the sham 
animals, all but one (sham + veh) were able to move through training and complete 
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testing. However, the majority of the lesioned animals (9 of 13 lesion + veh rats and 6 of 
13 lesion + MB rats) were unable to complete training.  In Figure 5.7A, the top bar in 
each group represents the animals that completed the re-training down to 500 msec 
protocol while the rest of the bars each represent individual rats that did not complete and 
stagnated at a particular protocol. Rats were considered unable to complete training after 
spending 1 week (7 training sessions) on the same training protocol with sub-criterion 
performance. In both lesion groups, most rats stagnated on the 5s port light duration with 
a few advancing to 3s and 1s port light duration. There were no statistical differences in 
the rate of training success between the two lesion groups [Χ2, (1, N = 26) = 1.42, p > 
0.20]. Because of this division, five choice data for the rats that failed to complete 
training was analyzed separately from the rats that successfully completed re-training and 
testing in the 3 attentional challenges. As expected, the lesioned rats that were able to 
reach 500 msec retraining and completed testing (i.e., Lesion+ VEH, n=4, and Lesion + 
MB, n=7) had significantly less severe dopamine depletion within the SNc than rats 
unable to retrain in the five choice task [t(24) = 9.65, p = 0.005].   
Attentional Challenges. In order to assess the impact of dopamine depletion and 
MB treatment on performance in the five choice task, the percent trials with correct 
responses were measured and repeated measures ANOVA was conducted with a within 
variable of 4 levels (baseline task and 3 challenge conditions) and two between factors of 
surgery (lesion vs. sham) and MB treatment (MB vs. vehicle). The overall performance 
levels were reduced with the attentional challenges as seen by the main effect of 
attentional challenge [F(3,90) = 17.97, p < 0.001]. There was also a main effect of 
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surgery [F(1, 30) = 4.29, p = 0.047] suggesting that the lesioned rats generally performed 
worse than sham rats. No other significant effects were observed (all ps > 0.2; Figure 
5.7B).  
Discontinued rats. Rats failing to successfully retrain were discontinued after 
seven days of sub-criterion performance on the same training protocol (lesion + veh: n = 
9; lesion + MB: n = 6). Only one sham animal was discontinued and for that reason, 
excluded from these analyses. Performance (as measured by percent correct trials) on the 
last day of training was assessed (Figure 5.7C). There was no impact of MB treatment as 
both lesioned groups showed similarly low levels of performance [F(1,13) = 0.12, p = 
0.74].   
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Figure 5.4 Dopamine depletion in the SNc and VTA  
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Figure 5.5 Lesion versus intact density in the SNc (top) and VTA (bottom) 
 
 
 
 
 
 
 
 131 
Figure 5.5 continued 
A & C.  Correlation of intact side optical density and infused/lesion side optical density 
in SNc (A) and VTA (C). Best fit line for the sham groups (collapsed) is in black with the 
gray surrounding area representing the 95% confidence interval.  Best fit lines for both 
lesion + veh (red) and lesion + MB (blue) rats with significantly different residuals from 
that of the sham group only. Faded red and blue points represent subjects with lesion 
densities within the 95% confidence interval for the sham animals. These rats were 
considered to have failed lesions. B&D. Lesion density residuals plotted as a function of 
intact density for sham rats (gray; 95% confidence interval), lesion + vehicle (red), and 
lesion  + MB (blue). Within the SNc (B) Mean lesion density residual ± SEM (line + 
shaded area) for both lesion groups are significantly different, p < 0.01.  
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Figure 5.6 Motor and disengagement function  
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Figure 5.6 continued 
A. Mean (± SEM) bad (contralateral) paw usage in contacting the cylinder while 
exploring. Both lesion groups show decreased paw usage than what would be expected 
due to chance (i.e. 50%).  B. Mean (± SEM) ipsilateral and contralateral paw adjustments 
made while eating vermicelli strands. Lesioned rats made significantly more ipsilateral 
paw adjustments compared to sham animals.  C. Mean (± SEM) contralateral 
disengagement behavior. * p < 0.05, ** p < 0.01,*** p < 0.001 
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Figure 5.7  Five choice performance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Subjects able to re-train: 
     attentional challenges 
A. Training progression for all  
 lesioned subjects 
C. Subjects unable to  
     re-train: 
           Last day of training 
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Figure 5.7 continued 
A. The rate of training protocol completion for both lesion groups.  Four lesioned rats 
receiving vehicle and seven lesioned rats receiving MB completed the five choice 
training protocol (represented by the top bar for each group). Rats that did not complete 
are all represented by one bar with the bar terminating at the training protocol unable to 
be mastered. B. Mean (± SEM) correct responses in the baseline five choice task (500 
ms) and three attentional challenges for rats able to successfully re-train on the five 
choice task. C. Mean (± SEM) correct responses on the last day of training for rats that 
were unable to complete the re-training protocol. * p < 0.05 
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5.6 DISCUSSION 
It is established that 6-OHDA administration causes dopamine depletion by 
disrupting mitochondrial function (Glinka, Tipton, & Youdim, 1996; Glinka & Youdim, 
1995; Glinka, Tipton, & Youdim, 1998) and increasing the presence of reactive oxygen 
species (Kupsch, et al., 2014; Permual et al., 1989; Permual et al., 1992; Kumar et al, 
1995). Furthermore, the application of antioxidants either in vitro or in vivo after 6-
OHDA results in decreased presence of reactive oxidative species (Davison, Legault, & 
Steele, 1986; Mayo et al., 1998; Tiffany-Castiglioni, Saneto, Proctor, & Perez-Polo, 
1982; Yamada et al., 1997). MB, not only enhances mitochondrial respiration (Callaway 
et al., 2004) through the electron transport chain but also has antioxidant properties 
(Salaris, Babbs, & Voorhees, 1991). Therefore we anticipated that chronic MB 
administration would lead to neuroprotection of SNc dopamine cells. Our data confirm 
this and demonstrate that an orally administered low-dose of MB can attenuate 
dopaminergic cell loss within the SNc after 6-OHDA infusion. Assessment of 
dopaminergic depletion within the VTA does not demonstrate a neuroprotective effect of 
MB.  It has been demonstrated that the SNc is more susceptible to neurotoxin-induced 
degeneration than the VTA (Liang, Nelson, Yazdani, Pasbakhsh, & German, 2004; 
Speciale, Liang, Sonsalla, Edwards, & German, 1998). Our data also show slightly less 
dopamine depletion in the VTA than the SNc. This resilience may lie in the 
morphological differences of these cells compared to their SNc counterparts. It has been 
demonstrated that mitochondria within dopaminergic SNc and VTA cells differ. 
Specifically, mass of the mitochondria in SNc dopamine cells is smaller than that of VTA 
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dopamine cells mitochondria (Liang, Wang, Luby-Phelps, & German, 2007). While the 
functional significance of these differences in mitochondrial morphology has not been 
elucidated, it is possible that this difference may account for the difference in sensitivity 
to mitochondrial manipulations both good (MB) and bad (6-OHDA). 
However, in comparison to previous work assessing the neuroprotective effect of 
MB, the effect seen in our experiments is rather small.  These differences in effect size 
are likely due to (1) the experimental preparation and (2) the method by which MB was 
delivered/applied.   Previously, MB infused directly into the striatum following a 
rotenone infusion to same location resulted in a markedly smaller lesion size as well as 
significantly greater mitochondrial function as measured by cytochrome oxidase activity 
(Rojas et al., 2009). Others have also show than MB can provide neuroprotection in vitro 
after rotenone application and when given orally in vivo, it can improve motor function in 
a rat neurotoxin model of PD (Wen et al., 2011). However, while Wen et al (2011) 
assessed the presence of reactive oxidative species in vivo, lesion severity and 
dopaminergic depletion were not quantified so the level of cell preservation is unknown.  
Therefore, we suspect that low-dose oral MB administration in combination with an 
acute, large neurotoxic infusion may not demonstrate the full capabilities of MB. The 
differences in the rate of dopamine depletion in our data provide some evidence for this. 
In the first experiment, we gave 7 µg of 6-OHDA to induce dopamine depletion in the 
SNc and saw no reduction in lesion severity with MB administration but in experiment 2, 
we gave a smaller amount of 6-OHDA (4.2µg) and saw MB-dependent neuroprotection. 
Recently, an Alzheimer’s disease model in which transgenic mice showed that starting a 
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MB (20 mg/kg in saccharin water) regimen early was able to slow the rate of protein 
aggregation whereas starting MB treatment after reaching a threshold of protein 
aggregation that resulted in behavioral deficits was not effective (Hochgräfe et al., 2015). 
Therefore, we predict that neuroprotection would be greater in a model in which 
dopamine depletion is induced in a more progressive manner rather than with one acute 
neurotoxic event. Hence, either genetic models that induce protein aggregations leading 
to cellular dysfunction and death or neurotoxic models that gradually induce 
mitochondrial dysfunction and cell loss may be most useful in assessing neuroprotective 
value of MB. 
While we did indeed see a mitigation of dopamine loss with MB, we did not see a 
corresponding mitigation of behavioral dysfunction as a result of this neuroprotection. 
Unilateral 6-OHDA-infused rats regardless of treatment assignment showed comparable 
performance across all motor and attentional tasks. If the neuroprotection due to MB did 
improve behavioral outcomes, we would have expected better performance across all 
measures in lesioned rats receiving MB compared to their vehicle-treated counterparts. It 
has been demonstrated that ~50% dopamine depletion is necessary to see motor 
impairments in both rodent and macaque models of PD as well as in human PD patients 
(Bernheimer, Birkmayer, Hornykiewicz, Jellinger, & Seitelberger, 1973; Riederer & 
Wuketich, 1976; Yuan, Sarre, Ebinger, & Michotte, 2005).  Similarly, lesioned rats 
receiving MB had on average 49 % dopaminergic loss and still exhibited behavioral 
deficits. Therefore, this indicates that a larger preservation of dopaminergic cells is 
necessary to reach a sub-threshold level to see behavioral improvements.  
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Regardless of neuroprotective benefits, we expected that the acute metabolic 
effects of MB would also be able to enhance attention as others have routinely 
demonstrated cognitive enhancement with MB. In intact rats, MB has been shown to 
enhance extinction learning after fear conditioning (Gonzalez-Lima & Bruchey, 2004; 
Wrubel, Barrett, Shumake, Johnson, & Gonzalez-Lima, 2007). As well, performance in 
spatial working memory, discrimination learning, and novel object recognition can also 
be enhanced by MB (Deiana, Harrington, Wischik, & Riedel, 2009; Riha, Bruchey, 
Echevarria, & Gonzalez-Lima, 2005; Wrubel, Riha, Maldonado, McCollum, & 
Gonzalez-Lima, 2007).  However we saw little enhancement of attentional function with 
MB administration. Sham rats receiving MB performed no better in the five choice task 
than their vehicle-treated counterparts. 
 Disregarding sham rats, we also hypothesized that MB would recover attentional 
function in lesioned rats by facilitating compensatory mechanisms/recovering metabolic 
functionality in lesioned rats. MB has been shown to improve behavioral outcomes in 
disease models of both PD and Alzheimer’s disease. Motor function has shown to be 
improved with MB administration in a neurotoxic model of PD (Wen et al., 2011). And 
MB has improved spatial working memory performance in a rat model of Alzheimer’s 
disease (Medina et al., 2011) and discrimination learning in a rat model of cerebral 
hypoperfusion (Auchter, Williams, Barksdale, Monfils, & Gonzalez-Lima, 2014). 
However, our data demonstrate that MB has little impact on attentional function in a 
neurotoxic model of PD. In Experiment 1, MB on-board showed mild enhancement of 
disengagement behavior on the impaired side relative to controls. However, in 
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Experiment 2, this effect was not replicated. It is likely that this effect is a result of 
several differentiating factors between the two experiments. Desipramine was given to 
protect noradrenergic fibers only in Experiment 2. It may be the case that depletion of 
some norepinephrine along with dopamine using 6-OHDA leads to a more profound 
disengagement deficit more susceptible to treatment with MB. Another factor is the 
lesion on average created in the Experiment 2 was smaller than Experiment 1 thus 
making the deficit less severe and possibly less sensitive to improvements as a 
consequence of MB administration. Further, among lesion rats in the five choice task, no 
improvements as a consequence of MB administration were observed either in rats able 
to complete training and the attentional challenges or in those rats that were unable to 
complete training. Taken together, this data suggests that MB is not useful for recovering 
attentional function. 
In this experiment, a low dose of MB (4 mg/kg) was utilized and no behavioral 
improvements as a consequence of MB on board were observed. One cannot rule out that 
a higher dose of MB might be more effective in preserving dopamine cells and/or 
improving behavioral deficits. However, doses within the range of 1-4 mg/kg have been 
shown to improve learning and memory, but by 10 mg/kg, MB becomes ineffective 
(Bruchey & Gonzalez-Lima, 2008). And even higher doses can interfere with metabolic 
processes within the cell which can be more harmful (Bruchey & Gonzalez-Lima, 2008). 
However, higher doses (20 mg/kg) have been used in the treatment of Alzheimer’s 
models with some success in improving behavioral and neural outcomes suggesting that 
the dosing parameters may be different in disease states (Hochgräfe et al., 2015).  
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The reason for which MB on board improves some cognitive tasks but not others 
may also lie in the role of memory. The distinguishing factor between cognitive tasks 
previously shown to be improved with MB administration and the tasks used in these 
current experiments is the necessity of memory. Pavlovian learning, working memory, 
and novel object recognition tasks require learning as the training is conducted over a 
period of days and the variables measured generally assess memory retention. It has also 
been shown that these same low doses of systemic MB as well as applying MB in vitro 
increases the rate of oxygen consumption within the cell (Riha et al., 2005; Callaway et 
al., 2004). Therefore, it is likely that MB exerts its beneficial effect by enhancing 
consolidation processes by increasing mitochondrial respiration necessary for memory 
formation. Here we have studied MB impact on attentional task requiring very little 
memory consolidation. Disengagement behavior is not a trained behavior, and while the 
five choice task requires an initial learning of the reward contingency, performance does 
not rely on the recruitment of short or long term memory processes. Subsequently, it may 
be simply that only cognitive processes relying on consolidation (or reconsolidation) may 
be enhanced with MB. 
As we do not see any amelioration of behavioral deficits with MB alone, MB may 
work better in combination with traditional dopaminergic therapies. While MB can 
restore mitochondrial function, it cannot return dopamine levels to that of a sham 
condition. Therefore, MB in combination with L-dopa or other DA agonists may prove 
useful for more effectively treating both motor and cognitive deficits. It may be possible 
that by giving MB along with L-dopa, the dose of L-dopa necessary to recover behavioral 
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functions could be reduced. And as high doses of L-dopa typically cause unwanted side 
effects, this combination could not only prove useful in the treatment of a wider array of 
symptoms but also in causing fewer side effects.  
Furthermore, it has been demonstrated that L-dopa can be toxic, possibly by 
increasing the rate of 6-OHDA generation (Maharaj, Sukhdev Maharaj, Scheepers, 
Mokokong, & Daya, 2005) and that these toxic effects can be mitigated with the 
application of antioxidants (Pardo, Mena, Casarejos, Paíno, & De Yébenes, 1995). Future 
work should investigate the possibility of this combination in restoring both motor and 
non-motor symptoms including cognitive and attentional dysfunction.  
In sum, this work further validates metabolic enhancement as an effective and viable 
option for neuroprotection. While no data was collected in these experiments to quantify 
metabolic function or reactive oxidative species, we expect that these are the mechanisms 
by which MB is acting. Further, acute metabolic enhancement using MB does not 
enhance behavioral outcomes in this model. While this advances our working knowledge 
of the abilities of MB on board to impact behavior, future work should be aimed to assess 
the impact of MB in models more closely resembling PD neurodegeneration and 
pathology as well as other neurodegenerative disease such as mitochondrial dysfunction 
and oxidative stress are common features of neurodegenerative disorders. 
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Chapter 6: General Discussion 
The goals of this dissertation work were (1) to elucidate the role of dopaminergic 
input into the central amygdala in regards to attention and (2) to understand how 
attentional deficits in a PD model are impacted by dopaminergic and non-dopaminergic 
therapies. In Chapter 2, I demonstrated that dopaminergic input (presumably from the 
SNc) into the CeA is indeed necessary for task switching behavior and specifically, this 
behavior is mediated by D1 receptors. I then found the same role of CeA D1 receptors in 
selective and sustained attention in Chapter 3. In Chapter 4, I assessed the ability of 
traditional dopamine replacement therapy with L-dopa to recover attentional dysfunction 
in a 6-OHDA model of PD and found that different types of attention respond to L-dopa 
administration differently. While attentional switching was able to be remediated in 
unilaterally dopamine depleted rats, more complex selective and sustained attention was 
worsened from the baseline 6-OHDA-induced deficits with the administration of L-dopa. 
Furthermore, chronic administration of L-dopa resulted in the development of 
dyskinesias precluding the rats from being able to perform the attentional tasks. In 
Chapter 5, I observed that methylene blue was able to provide mild neuroprotection to the 
dopamine cells in the 6-OHDA model of PD, but this wasn’t sufficient to result in the 
overall attentional improvements. 
To date, this is the first work to investigate the role of dopamine outside of the 
nigrostriatal pathway on attentional processes impacted in PD. Previously, attentional 
dysfunction has been attributed either directly to innate PFC dysfunction or degraded 
input from the striatum into the PFC (Cools, 2006; Ravizza & Ciranni, 2002). However, 
while the PFC does show pathological changes in PD, these pathological changes do not 
emerge until the last stages of the disease (Braak et al., 2004) whereas attentional 
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dysfunction emerges at the same time as motor dysfunction or prior to the onset of the 
motor deficits (Dubois & Pillon, 1997; Tadaiesky et al., 2008; Wu et al., 2012). Further, 
the striatal-cortical relationship has been widely implicated in attentional function thus 
leading to the hypothesis that PD-related attentional deficits are seen as a result of 
impaired communication of these areas (Agnoli & Mainolfi, 2012; Christakou, Robbins, 
& Everitt, 2001; Christakou, Robbins, & Everitt, 2004). While the degradation of this 
connection certainly contributes to attentional dysfunction seen in PD, this does not fully 
explain how these attentional deficits occur. For example, restoration of striatal function 
with cell graphs after MFB infusion of 6-OHDA does not recover disengagement 
behavior (Mandel et al., 1990). Therefore, it is pertinent to understand the role of other 
dopaminergic structures in attention.  
It has previously been established that the CeA is necessary for several attentional 
processes including conditioned orienting, surprised-induced enhancement of attention, 
and selective and sustained attention, and that the reciprocal relationship of the SNc and 
the CeA must be intact for these attentional processes (El-Amamy & Holland, 2006, 
2007; Lee et al., 2008; Lee, Gallagher, & Holland, 2010; Lee et al., 2006). Furthermore, 
projections emerging from the CeA have been well characterized in the context of these 
attentional processes. Projections from the CeA to the substantia innominata have been 
shown to influence cholinergic pathways regulating attentional function ( Holland, 2007; 
Maddux et al., 2007). However, little work prior to this dissertation has investigated the 
importance of the SNc dopaminergic input into the CeA in these same attentional 
processes. This finding contributes to our understanding of attentional processes and the 
contribution of the nigral dopaminergic influence on CeA function. 
In addition to implicating dopaminergic input into the CeA in attention, I have 
also demonstrated that D1, but not D2, receptors within the CeA are necessary for these 
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attentional functions. This aligns with previous research demonstrating a global need for 
D1 receptors in selective and sustained attention (Agnoli & Mainolfi, 2012; Pezze et al., 
2007). Understanding how dopamine receptors regulate attention allows for the 
formulation of better treatment regimens for PD insofar that L-dopa and dopaminergic 
agonists are commonly used to treat motor and cognitive function in PD. Specifically, as 
the disease becomes severe and most dopamine cells are lost, patients become more 
reliant on dopamine agonist drug therapies. However, the majority of commonly 
prescribed dopamine agonists to treat PD are partial- or full-D2 or D2-like receptors 
agonists (Bonuccelli, Del Dotto, & Rascol, 2009). This could explain why some 
attentional dysfunctions can be treatment-resistant in patients with late-stage PD 
(Chaudhuri & Schapira, 2009; Dujardin et al., 2013). Thus, by understanding the 
contributions of different dopamine receptors to attention, treatments with different 
receptor sensitivities (especially higher D1 affinity) could be utilized to produce maximal 
benefits.  
Because dopamine depletion via the medial forebrain bundle results in decreased 
attentional capacity, I hypothesized that basic dopamine replacement therapy with L-dopa 
would be able to repair attention switching as well as selective and sustained attention in 
the 6-OHDA model of PD. This was not entirely the case as attention switching (i.e. 
disengagement behavior) was easily recovered by L-dopa but selective and sustained 
attention was unable to be recovered. This difference in L-dopa’s ability to recover 
different aspects of attention may be due to the complexity of the attentional processes 
being assessed. Disengagement behavior requires simple attentional orienting to the 
incoming stimulus and has previously been shown to be dependent on nigrostriatal as 
well as nigral-CeA function thus possibly lending itself to be easily repaired with L-dopa 
administration (Schallert & Hall, 1988; Smith et al., 2013). In contrast, while selective 
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and sustained attention is regulated by dopamine and the nigrostriatal pathway, it is also 
modulated by the basal forebrain cholinergic system (McGaughy et al., 2002; Muir et al., 
1993; Risbrough et al., 2002; Robbins et al., 1989) and by dorsal noradrenergic fibers 
(Carli et al., 1983; Cole & Robbins, 1987). As a consequence, this highly intricate system 
may not simply be remediated with the restoration of dopamine levels.  
In addition to demonstrating that L-dopa does not improve selective and sustained 
attention, I also demonstrated that L-dopa further exacerbates these deficits in a rat model 
of PD. It is likely that the exacerbation of attentional function seen with L-dopa 
administration may simply be due to an overdose of dopamine and/or norepinephrine. 
Previously, others have postulated that the incursion of new cognitive deficits with L-
dopa usage may be due to an excess of dopamine in areas that have not yet experienced 
dopamine depletion (Cools, 2006). This may also be the case with selective and sustained 
attention. Within this model, it has been demonstrated that L-dopa enhances dopamine 
levels in both intact and denervated straita albeit at a lower rate in the intact striatum 
(Abercrombie, Bonatz, & Zigmond, 1990). While I did not collect any data in regards to 
dopamine level, the behavioral data suggests that this may be the case. The decreased 
overall accuracy in the selective and sustained attention task was specifically due to 
decreased accuracy in trials in which the port on the side ipsilateral to the lesion was the 
target (i.e. correct) port. This provides evidence for the argument that there is an optimum 
level of dopamine (and possibly norepinephrine) necessary for attentional function and 
that excessive levels cause impairments in attentional function. Thus, the findings in this 
dissertation work demonstrate that even in scenarios of simple dopamine depletion, 
application of L-dopa is detrimental possibly due to the incursion of supra-optimal levels 
of dopamine. 
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Overall, I have demonstrated that simple dopamine replacement therapy is not 
sufficient for restoring attentional function impaired in a rat model of PD. Due to the 
complexity of these cognitive processes as well as widespread pathology outside of the 
SNc in PD, I also assessed the usefulness of moving from a neurotransmitter-focused 
approach to a system-wide enhancement approach to restore cognitive function in this PD 
model. PD results in pathological changes of many areas including the dopamine-rich 
areas such as the SNc but also the locus coeruleus, and in later stages, cortical areas as 
well (Braak et al., 2004). These cells show abnormal mitochondrial function which leads 
to increased oxidative stress and finally, apoptosis (Fukae et al., 2007; Gubellini, Picconi, 
Di Filippo, & Calabresi, 2010; Schapira, 2008). Therefore, one means by which 
symptomology could be improved is by enhancing mitochondrial function of both 
compromised cells (restore function) and non-compromised cells (boost compensatory 
functions). Unilaterally depleting dopamine using 6-OHDA or other neurotoxins results 
in chronic mitochondrial dysfunction in the cells remaining after initial insult thus 
making this avenue feasible to pursue in this model of Parkinson’s disease (Blum et al., 
2001; Glinka & Youdim, 1995).   
I have been the first to attempt to use the mitochondrial enhancer, MB to enhance 
attentional function in intact and PD-modeled rats. While MB has been shown to 
repeatedly improve learning and memory processes (Callaway et al., 2004, 2002; 
Gonzalez-Lima & Bruchey, 2004; Martinez et al., 2013; Riha et al., 2005; Wrubel, Riha, 
et al., 2007), until now it had not been assessed for its ability to improve attentional 
process. My work has demonstrated that MB on-board is only mildly effective at 
enhancing attention in contrast to the marked MB-related enhancements in learning and 
memory repeatedly demonstrated by others in intact and impaired rats. While attention is 
inherently necessary for effective learning and memory formation, these current findings 
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along with other evidence suggest that MB is beneficial for the formation of memories 
after learning but not the ability to initially attend in order to learn. Therefore, it is likely 
that the efficacy of MB lies in its ability to enhance consolidation processes (i.e. synaptic 
plasticity) which require mitochondrial synthesis of energy units such as ATP (Lim & 
Isaac, 2005). While MB (on-board) is marginally useful in restoring reduced attentional 
function, it may serve better as a treatment for mild cognitive impairment (which includes 
short-term memory problems) in PD. 
Further, while MB’s neuroprotective abilities have been assessed previously, it 
has not been assessed in this 6-OHDA model of PD. The neuroprotective effects of MB 
are most commonly studied in vitro ( Nicklas, Vyas, & Heikkila, 1985; Wen et al., 2011).  
This work is the first to look at both behavioral and neuroprotective outcomes of MB 
administration in an in vivo/ex vivo model of PD. I demonstrated that orally-administered 
MB can provide neuroprotection under certain conditions. Only when the amount of 6-
OHDA infused was lowered from 7 µg to 4µg was neuroprotection seen.  
However, while I have demonstrated that oral methylene blue can provide some 
neuroprotection after an acute neurotoxic infusion into the MFB, this does not result in 
less severe behavioral impairments in these animals. Similar to patients diagnosed with 
PD, lesion models of PD only show behavioral deficits once a majority of dopamine cells 
are lost and these behavioral deficits show only a weak correlation with the amount of 
dopamine cell loss (Bernheimer et al., 1973; Riederer & Wuketich, 1976; Yuan et al., 
2005). Even though MB provided mild neuroprotection in my study, it was unable to 
preserve the dopamine cells to levels more than 50% and support intact behavioral 
function. Consequently future endeavors to evaluate the neuroprotective potential of MB 
should utilize models of PD in which neurodegeneration or pathological changes occur 
gradually such as is common in transgenic mouse models or models in which neurotoxin 
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exposure is titrated over time. MB’s neuroprotection might be more effective models 
with slower dopamine cell degeneration. While providing neuroprotection for PD could 
dramatically improve the lifespan as well as quality of life in PD patients, there is an 
inherent shortcoming in any attempt to provide neuroprotection in PD because 
symptomology and the ability to diagnose the disease does not emerge until substantial 
damage has occurred. Therefore the development of neuroprotective measures alone will 
not suffice. In order for any neuroprotective agent to be useful in improving quality of 
life or lifespan, the development of pre-clinical markers for PD is paramount so that cell 
loss can be slowed.  
In the meantime, it would also be prudent to investigate the possibility of using 
MB and L-dopa simultaneously in attempt to better treat patients that have already 
experienced significant dopamine loss. As MB and L-dopa target different aspects of PD, 
it is likely that giving both would have a synergistic effect. Therefore, co-administering 
MB alongside L-dopa may result in better treatment of a wider array of symptoms as well 
as possibly less L-dopa necessary to ameliorate PD symptomology.  
Together, this dissertation work yields substantial information in regards to 
attention impairments in PD. This work highlights the importance of understanding the 
nigral-CeA circuitry in the context of attentional function and suggests a role of this 
mechanism in PD-associated attentional dysfunction. This work also demonstrates that 
attentional dysfunctions in PD do not respond to treatment in the same manner as motor 
dysfunction and further highlight the need for continued study of the nature of cognitive 
dysfunction, the underlying circuitry, and its response to drug treatments. As treatment 
options improve for the motor dysfunction in PD with nuanced drug regimens and deep 
brain stimulation procedures, it is also important to continue to evaluate existing 
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treatments and if necessary, develop new treatment approaches for the non-motor 
symptoms of PD which can be debilitating even after motor function is improved. 
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